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The glucocorticoid receptor (GR) is a ligand-activated transcription factor which, due 
to its central role in anti-inflammatory responses, is a target of many therapeutically 
prescribed drugs. The GR undergoes multiple post-translational modifications, 
including phosphorylation and acetylation; however the role of GR acetylation in 
transactivation is unclear. The functional consequences of GR acetylation at 
K494/495 were investigated at several steps in the hGR pathway, using expressed 
hGR mutants as compared to wild-type GR. Results of reporter transactivation 
assays and immunofluorescence microscopy indicated that acetylation plays a role 
in transactivation and nuclear translocation of the GR. Mutation of acetylation sites 
also differentially affected GR phosphorylation status. Competitive whole cell binding 
assays suggest that GR acetylation at these residues is required for ligand binding 
by the GR. Chromatin immunoprecipitation assays on the endogenous GRE-
containing GILZ gene support a model in which interaction of the immunophillin 
FKBP52 with acetylated hGR plays an important role in GR function by acting as a 
GR coactivator. Taken together, these results suggest that modulation of GR 
acetylation at K494/K495 represents an attractive physiological mechanism for 
regulation of glucocorticoid sensitivity and transactivation efficacy. 
 
GR ligands vary enormously in terms of potency and efficacy for transactivation and 
transrepression. Using an endogenous model system and a panel of 8 different 
ligands differential regulation of five endogenous model genes was investigated, and 
differences in ligand efficacy were observed. In order to investigate the molecular 
mechanism by which ligand-specific differences arise, subcellular fractionation and 
immunofluorescence microscopy were used to examine the extent of GR nuclear 
localisation. It was found that the extent of GR nuclear localisation differed for 
different ligands, and that these values correlated with the maximal transactivation 
efficacy of the GR, and GR phosphorylation at Serine-211. Taken together, these 
results indicate that ligand-selective nuclear import is a key step in modulating 
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The thesis contains the following sections 
1. Chapter 1: Factors affecting ligand- and cell-specific transcriptional 
responses by the GR 
This chapter provides a brief introduction to the GR and its mechanism of action. It 
then gives an overview of the available literature on GR function, with a focus on 
mechanisms eliciting ligand- and cell-selective transcriptional differences. 
 
2. Chapter 2: Aims and hypotheses 
This chapter will cover the aims of the present work, and hypotheses on which the 
direction of the research was based. 
 
3. Chapter 3: Critical role of lysines 494/495 in GR ligand binding and 
function: functional implications of GR acetylation 
This chapter takes the form of a scientific paper. As such, it includes an abstract, an 
introduction covering relevant literature in the field of SR acetylation, materials and 
methods used to generate the data, results and a thorough discussion of the results 
in the context of available literature. All the work presented in this chapter was 
performed by the candidate, except for the site-directed mutagenesis and one 
transactivation experiment performed by another laboratory member and duly 
acknowledged. A modified version of this chapter is in preparation for submission, to 
include data generated by other researchers in the laboratory.  
 
4. Chapter 4: Differential nuclear import of the GR plays a role in ligand-
selective transcriptional responses  
This chapter takes the form of a paper. As such, it includes an abstract, an 
introduction covering relevant literature in the field of GR nuclear import, materials 
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and methods used to generate the data, results and a thorough discussion of the 
results in the context of available literature. All the work presented in this chapter 
was performed by the candidate. Some of these results have been previously 
published in Ronacher et al., 2009. An abridged version of this thesis chapter is in 
preparation for submission.  
 
5. Chapter 5: Future perspectives  
In this chapter possible prospects for further research are discussed.  
 
6. REFERENCES for all the above chapters and addendums to follow 
 
7. Appendix A: Ligands 
This addendum shows the chemical structures of all the ligands used, as well as 
their relative binding affinity as obtained by others in the laboratory, and GR 
fractional occupancy, with a brief discussion of the calculation and relevance of 
these parameters.  
 
8. Appendix B: Dilutions and diluents of primary and secondary antibodies used in 
Western blot 
A table is included summarising the antibody conditions used for Western blotting 
9. Appendix C: Supplementary results pertaining to Chapter 3 
 
10. Appendix D: Supplementary results pertaining to Chapter 4 
 




12. Ronacher, K., Hadley, K., Avenant, C., Stubsrud, E., Simons, S. S., Louw, 
A., and Hapgood, J. (2009) Ligand-selective transactivation and 
transrepression via the glucocorticoid receptor: role of cofactor 
interaction. Molecular and Cellular Endocrinology, 299 (2), 219-31 
This research article includes results from other members of the research group as 
well as some of the results presented in this thesis. The present author also 
contributed to the analysis and interpretation of results, and assisted with writing of 
the paper. It is included here to illustrate the context of this thesis as part of a 
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Factors affecting ligand- and cell-specific transcriptional responses by the GR 
 
The glucocorticoid receptor (GR) is a transcription factor belonging to the nuclear 
receptor superfamily, which also includes the androgen (AR), estrogen (ER), 
mineralocorticoid (MR), and progesterone receptors (PR). These steroid receptors 
(SRs) are all ligand-activated transcription factors, and share a high degree of 
homology (reviewed in Heitzer et al., 2007). This class of receptors makes an 
attractive target for rational drug design due to the central role played by steroid 
receptors in gene regulation and their control of a wide array of physiological 
processes (Adcock, 2000).  
 
Endogenous glucocorticoids (GCs) (cortisol in humans, and corticosterone in rats) 
are synthesised in the adrenal cortex. Release of GCs is pulsatile and follows distinct 
diurnal and ultradian patterns. Physical or emotional stress can also trigger the 
release of GCs via the hypothalamic- pituitary- adrenal (HPA) axis (Lightman et al., 
2008). In response to stress, the hypothalamus releases corticotrophin releasing 
hormone (CRH). CRH acts on the anterior pituitary, stimulating the release of 
adrenocorticotrophic hormone (ACTH), which in turn stimulates the release of 
cortisol from the adrenal cortex into the bloodstream. Cortisol suppresses the activity 
of both CRH and ACTH, providing a negative feedback loop and ensuring tight 
regulation of GC production (reviewed in Papadimitriou & Priftis, 2009). Endogenous 
GCs modulate a wide range of physiological functions by binding to and activating 
the GR, and are essential for homeostasis. Metabolic effects of cortisol include 
increase in blood glucose levels, stimulation of gluconeogenesis by the liver, and 
mobilisation of amino- and fatty acids (Buckingham, 2006). Cortisol is also essential 
for lung development and erythroid cell proliferation. However, the most important 
16 
 
activity of GCs from a pharmacological point of view is their effect on components of 
the immune system regulating inflammation (reviewed in Buckingham, 2006). 
 
GCs have been in use as anti-inflammatory drugs for more than 50 years (Barnes, 
2006). However, while GCs are therapeutically useful, they also cause many side-
effects, including immune suppression, osteoporosis, diabetes, hypertension, 
thinning of the skin and Cushing’s syndrome (Stanbury & Graham, 1998). These 
side-effects limit the usefulness of GCs for long-term treatment of chronic 
inflammatory diseases and are generally due to activation of GR in a non-target 
organ or cell-type, or its activity on non-target genes. Therapeutically administered 
GCs have been observed to exhibit effects that are highly patient-, and cell-specific. 
For instance, in treatment of acute lymphoblastic leukaemia (ALL), the effect of GCs 
is highly cell-specific in promoting apoptosis of lymphocyte cells, while 
simultaneously protecting cells of the endometrium, ovarian follicle, and mammary 
epithelium against apoptosis (reviewed in Gross & Cidlowski, 2008). Thus, a better 
understanding of the molecular mechanisms that govern transcriptional activation by 
the GR is crucial for the design of drugs with greater potency and reduced side-
effects. It would be advantageous for such drugs to be selective for the desired 
target tissue, cell type and gene(s) (Schäcke et al., 2005). 
 
GR ligands can be broadly categorised as agonists (those that increase the 
transcriptional response by GR, either transactivation or transrepression) or 
antagonists (which bind GR but do induce a transcriptional response). It has been 
widely reported that the beneficial effects of GCs are a result of transrepression of 
inflammatory genes, while their transactivation activity is responsible for the negative 
side-effects. Exceptions to this model have been identified, such as transactivation of 
the anti-inflammatory response mediators, mitogen activated protein kinase 
phosphatase 1 (MKP1) (Kassel et al., 2001) and glucocorticoid induced leucine 
zipper (GILZ) (Eddleston et al., 2007). However, this model has stimulated interest in 
the discovery of GCs which cause only transrepression via the GR, without eliciting 
transactivation. GCs with such activity are termed “dissociated GCs” or “selective GR 
agonists” (SEGRAs). The development of drugs with selective anti-inflammatory 
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activity would represent a significant improvement in the treatment of a range of 
inflammatory and autoimmune diseases (reviewed in Adcock, 2000). Furthermore, 
different drugs may elicit the same type of response (e.g. transactivation of a certain 
gene) in the same cell type with differences in potency and efficacy. Understanding 
what causes these differences in drug activity is crucial to the design of drugs that 
are more efficacious in the target tissue, with less activity in non-target tissues 
(reviewed in Simons, 2003). 
 
In this chapter, a brief outline of the structure and mechanism of action of the GR will 
be given, followed by an overview of each of the steps at which ligand-specific 
effects may manifest. The mechanisms by which the same GR ligand can cause 
completely different effects on transcription of the same gene in different cell types 
will be highlighted, as well as possible reasons why different GR ligands can cause 
different transcriptional responses of the same promoter, in the same cell, under the 
same conditions. Although the main focus will be on the human GRα (hGRα), where 
necessary, examples will be drawn from rat GR (rGR) and mouse GR (mGR) and 
other steroid receptors within the class.  
 
1.1 Structure of the GR protein 
 
Although several isoforms of GR have been identified, which will be discussed later 
in the section on ligand and tissue specificity of GR, GRα is the most abundant and 
best-studied isoform. The structure of the GR  protein has been described as 
“modular” because it comprises distinct domains with different functions, as shown in 
figure 1.1 (Revollo & Cidlowski, 2009). At the N-terminus is the variable 
transactivation domain, consisting of activation function-1 (AF-1), which has 
constitutive transcriptional activity and is associated with the basal transcription 
machinery. All the major sites of phosphorylation reside in this domain (reviewed in 
Kumar & Thompson, 2005). The centrally located DNA binding domain (DBD) is 
made up of two highly conserved zinc fingers, which allow the protein to recognise 
and bind to its target motif in DNA. The first zinc finger contains a three amino acid 
18 
 
“P box” motif responsible for specific binding sequence recognition. The second zinc 
finger contains the so-called “D box” which is involved in dimerization of the GR 
monomers (Luisi et al., 1991). A short hinge region adjacent to the DBD gives GR  
flexibility, allowing for changes in conformation on ligand and DNA binding. The C-
terminal domain harbours the ligand-binding domain (LBD). It contains binding sites 
for cofactors and heat shock protein 90 (Hsp90), and the AF-2 domain, which 
confers ligand-dependent transcriptional activity (reviewed in Kumar & Thompson, 
2005). Two nuclear localisation signals (NLSs) are also present, and are exposed on 





Figure 1.1. Graphical representation of the modular structure of 
hGRα. The C-terminal LBD is shown in grey. Nuclear localisation signals 
are represented by black bars. Transcription is carried out by the 
activation function domains AF-1 (constitutive) and AF-2 (ligand-
dependent), represented by ovals. (Modified from Revollo & Cidlowski, 
2009). 
 
1.2 Mechanisms of action of GR 
 
In its unliganded state, the GR resides in the cell cytoplasm in a complex with Hsp 
proteins, and cochaperones (reviewed in Pratt & Toft, 1997). Upon ligand binding, a 
conformational change takes place, and the GR undergoes a number of post-
translational modifications, the best-studied of which is phosphorylation (Faus & 
Haendler, 2006). The GR subsequently translocates to the nucleus, where it can 
bring about an increase (transactivation) or a decrease (transrepression) in 
transcription by binding to the promoter regions of target genes. The mechanisms by 
which GR functions can be divided into two categories for the purposes of simplicity: 
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either direct DNA-binding by the GR or protein-protein interactions of the GR with 
other transcription factors, which is known as “tethering”, as shown in figure 1.2. 
Either of these mechanisms can bring about transactivation or transrepression 
(reviewed in Smoak & Cidlowski, 2004). These mechanisms are discussed below 
with a few examples; however it is important to note that depending on the cellular 
context, different mechanisms may act in concert (reviewed in Newton, 2000).  
 
 
Figure 1.2. Mechanisms of action of GR. In the absence of ligand, GR 
resides in the cytoplasm in a complex with chaperones, including heat 
shock proteins (HSPs). On binding to GCs, GR undergoes post-
translational modifications (P), and translocates to the nucleus, where it 
can facilitate transactivation or transrepression. Transactivation occurs by 
direct DNA binding, and recruitment of cofactors (CoA) and the basal 
transcription machinery (BTM), while transrepression occurs by tethering 
to other transcription factors such as AP-1 and NFκB.  
 
GR transactivation generally involves binding of ligand-activated GR to a 
glucocorticoid response element (GRE) in the promoter region of a target gene. The 
canonical GRE is a palindromic sequence (5’-GGTACAnnnTGTTCT-3’) (Beato et al., 
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1989), to which the activated GR binds as a homodimer (Tsai et al., 1988). 
Dimerization of the GR requires a five amino acid region called the D-loop within the 
DBD (Luisi et al., 1991). The GR homodimer recruits cofactors to the promoter, 
some of which facilitate chromatin remodelling because of their intrinsic histone 
acetyl transferase (HAT) activity. The relaxed chromatin structure allows RNA 
polymerase II and TATA box-binding protein (TBP) access to the promoter to initiate 
transcription (Horwitz et al., 1996). Examples of promoters with GREs include those 
of the metabolic enzymes tyrosine aminotransferase (TAT), and 
phosphoenolpyruvate carboxykinase (PEPCK) (reviewed in Revollo & Cidlowski, 
2009). 
 
Some promoters have a less well-conserved sequence that is also recognised and 
bound by GR homodimers: the negative GRE (nGRE). Binding of GR to an nGRE 
results in transrepression of the gene, usually by exclusion of another transcription 
factor or member of the transcriptional machinery from its response element 
(reviewed in Necela and Cidlowski, 2004). For example, an nGRE is found in the 
promoter of the osteocalcin gene. Binding of ligand-activated GR to this site prevents 
binding of the TATA binding protein (TBP) to its recognition sequence, thereby 
repressing transcription of the gene (Strömstedt et al., 1991; Meyer et al., 1997). 
 
The phenomenon of GR tethering is best illustrated by genes under transcriptional 
control of nuclear factor kappa B (NFĸB) and activator protein-1 (AP-1). The AP-1 
transcription factor consists of a dimer composed of Jun, Fos or Activating 
transcription factor (ATF) subunits. While Jun family members can form homodimers 
or heterodimers with other AP-1 proteins via a leucine zipper motif, the Fos subunit 
is incapable of forming homodimers (Vesely et al., 2009). Genes under the 
transcriptional control of AP-1 encode several tissue-damaging proteins, such as 
collagenase and stromelysin, which contribute to the inflammatory response 
(reviewed in Revollo & Cidlowski, 2009). Ligand-activated GR disrupts this response 
by binding to AP-1, preventing it from recruiting cofactors and initiating transcription, 
and thereby results in transrepression. This tethering mechanism does not require 
GR binding to DNA, but rather occurs via a protein-protein interaction between DNA-




NFĸB is a ubiquitous heterodimeric transcription factor. The predominant 
heterodimer involved in transactivation consists of p65 and p50 subunits (reviewed in 
Simmonds & Foxwell, 2008). Under normal physiological conditions NFĸB exists in 
the cytoplasm bound to and inactivated by inhibitor kappa B (IĸB). Activation of the 
tumour necrosis factor α (TNF ) signalling pathway, by injury or infection, results in 
phosphorylation of IĸB, which allows it to be ubiquitinated and targeted for 
degradation. The liberated NFĸB translocates to the nucleus and binds DNA at 
specific response elements in the promoter region of a range of target genes, 
thereby initiating transcription of these pro-inflammatory genes (Kassel & Herrlich, 
2007). On ligand-activation, GR interacts with the p65 subunit of NFĸB, preventing it 
from activating transcription of inflammatory genes (Nissen & Yamamoto, 2000).  
 
GR tethering can also serve to increase the transcription of genes, such as in the 
case of signal transducer and activator of transcription 5 (Stat5). Stat5 and GR 
interact synergistically to transactivate the -casein gene, in the absence of a GRE 
(Stoecklin et al., 1997). Interactions between GR  and other members of the Stat 
family have been identified, and may result in transactivation or transrepression of 
target genes (reviewed in Rogatsky & Ivashkiv, 2006). GR tethering to AP-1 has also 
recently been found to have a positive effect on gene transcription of certain target 
genes (Maya-Núñez & Conn, 2003; Rani et al., 2009; Kotitschke et al., 2009). 
 
In addition to its well-known genomic effects, the GR is increasingly being implicated 
in alternative, non-genomic effects of GC treatment, and ligand-independent 
transcriptional regulation. These effects are rapid, and insensitive to inhibitors of 
transcription and translation. Although non-genomic effects appear to occur at the 
membrane, it has not been established whether the classical cytosolic GR is 
responsible, or a distinct membrane-bound isoform of the GR. It has been reported 
that GR also takes part in cross-talk with membrane bound receptors such as G-
protein-coupled receptors, resulting in a wide range of intracellular effects. Although 
the subject of non-classical mechanisms of GR activity will not be discussed in detail 
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here, these complex signalling pathways are the subject of a recent review from the 
Hapgood laboratory (Dr A. Kotitschke, PhD thesis, 2009).  
 
1.3 Tissue- and ligand-specificity of GR activity 
 
The cellular activity of GCs involves a complex multistep process, from ligand-
binding to the ultimate biological response, as shown in figure 1.2.1 below, with a 
variety of factors causing differences in responses. Selectivity of action is introduced 
by the different GCs themselves, and also by variation in receptor isoform 
expression. The popular tripartite model of steroid hormone as proposed by 
Katzenellenbogen et al., (1996) includes a third factor: that of the effector site, which 
refers to the tissue or cell type in which the activity takes place. Together these three 
factors (ligand-receptor-effector site) regulate the response to GC, and will be 
discussed in more detail below. 
 
 
Figure 1.2.1. GR transcriptional regulation is a multistep process. (1) 
cytoplasmic GR, held in a ligand-receptive conformation by a complex of 
proteins including heat shock proteins (HSPs), binds GC. (2) GR then 
translocates to the nucleus, (3) dimerizes, and (4) undergoes post-
translational modifications such as phosphorylation and acetylation (P). 
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(5) GR interacts with gene promoters, either directly as depicted here, or 
indirectly via other transcription factors and (6) facilitates recruitment of 
cofactors (CoA) and basal transcription machinery (BTM). (7) Liganded 
GR is rapidly degraded by the proteasome. 
 
1.3.1 Different isoforms of GR allow for GC response to be specific for 
different cell and tissue types, and physiological states  
 
The gene for human GR has been mapped to chromosome 5 (Gehring et al., 1985). 
Unique binding sites for 15 transcription factors have been identified in the promoter 
region of this gene, and their differential activity plays a role in the tight cell- and 
tissue-specific regulation of GR expression (reviewed in Gehring et al., 1985). The 
5’UTR also governs the splicing of the mRNA, which can result in further variation 
through alternative promoter usage (Turner et al., 2006). The two main splice 
variants of human GR are termed  and , which differ in their splicing of exon 9. 
The  isoform is the classical 777 amino acid GR, while the  isoform is a 742 amino 
acid protein with a shorter ligand binding domain, and therefore reduced ligand 
binding and transcriptional activity (reviewed in Nicolaides et al., 2010).  
 
GR  is located in the nucleus and cytoplasm (Kino et al., 2009), and its role there is 
controversial. GR  has been shown to exert a dominant negative effect on 
transactivation by the  isoform on the MMTV promoter in several cell lines, as a 
result of formation of transcriptionally inactive -  heterodimers (Oakley et al., 1999) 
and prevention of coactivator complex formation (Charmandari et al., 2005). The 
physiological relevance of such activity is disputed, as the cellular concentrations of 
the  isoform would appear to be too low to allow a dominant negative effect to occur 
in vivo. However, elevated expression levels of GR  isoform have been reported in 
some GC resistant disorders, which may indicate a role for this isoform in tissue-
specific GC resistance (reviewed in Lu & Cidlowski, 2006). One report has indicated 
that GRβ resides in the cytoplasm in the absence of ligand (Lewis-Tuffin et al., 
2007). Exogenous GRβ was reported to bind the antagonist RU486, and 
subsequently translocate to the nucleus in COS-1 and U2OS cell lines, and to 
regulate gene expression of more than 5000 genes in stably transfected U2OS cells 
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(Lewis-Tuffin et al., 2007). Further experimentation in HCT116 cells failed to confirm 
this observation (Kino et al., 2009). However, GRβ has recently been reported to 
positively and negatively regulate expression of a number of genes in a ligand-
independent, GRE-independent manner in HCT116 cells (Kino et al., 2009). Further 
work therefore needs to be done to clarify the physiological role of GR  (reviewed in 
Kino et al., 2009). 
 
Alternative translation start sites are present in the mRNA for GR . Leaky ribosomal 
scanning results in generation of at least 8 different isoforms which differ at the 
amino terminal. GRαA is translated from Methionine 1, and GRαB is translated from 
Methionine 27, while GRαC1,2,3 and D1,2,3 are several amino acids shorter 
(reviewed in Duma et al., 2006). Both A and B forms have been found endogenously 
in several cell lines, and Yudt and Cidlowski (2001), have demonstrated that while 
GRαA and GRαB have similar transrepression activity, expressed GRαB exhibits a 
two-fold greater transactivation activity than GRαA in COS-1 cells on various 
synthetic promoters. Although the physiological relevance of the A and B isoforms is 
not clear, this may present an additional mechanism determining cell-type specific 
effects of GCs.  
 
Three other isoforms of hGR have been described: GR-P, hGR-A, and hGRγ, which 
are present at much lower concentrations than GR , and most have reduced 
transactivation activity (reviewed in Zhou & Cidlowski, 2005). All the alternative 
isoforms add to the complexity and diversity of GR signalling in different cell and 
tissue types. For instance, differences in expression levels and subcellular 
distribution of GRβ have been implicated in the different GC responses between 
human monocytes and T-cells (Li et al., 2006). However, whether different ligands 
elicit ligand-specific effects via GR isoforms other than GRα has not been 
established.  
 
In addition to the different isoforms identified, variation within the population is further 
increased by a number of different GR polymorphisms which have been shown to 
have an impact on GR function (reviewed in Gross & Cidlowski, 2008). For instance, 
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the ER22/23K polymorphism, found in about 3% of the population (Derijk & de Kloet, 
2008), is associated with decreased transactivation compared to WT GR, and has 
been postulated to be involved in GC resistance (Russcher et al., 2005). The wide 
variety of GR protein isoforms strongly suggests that gene regulation by GR is a 
highly complex process. The variety of possible post-translational modifications, and 
the implications thereof, increases this complexity even further. These will be 
discussed in the section on post translational modifications. However, for the rest of 
the thesis, only the GRα isoform will be examined. 
 
1.3.2 Bioavailability of GR ligand 
 
Under normal conditions, about 80-95% of cortisol in the bloodstream is bound to 
corticosteroid-binding globulin (CBG), and thus is not free to diffuse across cell 
membranes to bind GR (Buckingham, 2006). Only a small percentage of total 
cortisol is thus biologically active. It has also been suggested that CBG plays a role 
in tissue-specific delivery of GCs (Torpy & Ho, 2007). Bioavailability of cortisol is 
further controlled by the activity of 11-β hydroxysteroid hydrogenase enzymes type 1 
and 2. These enzymes regulate intracellular levels of cortisol by catalysing its 
conversion to or from the inactive form, cortisone (Seckl & Walker, 2001). The 
tissue-specific distribution of these two enzymes presents a mechanism to control 
the cellular response to systemic GCs (Gross & Cidlowski, 2008). Whether 
differential bioavailability of ligands is ligand-specific has not been described. 
 
1.3.3 GR concentration and binding affinity of ligand  
 
It is well-established that endogenous GR concentrations vary in different cells and 
tissues of the body (Miller et al., 1998), and this presents an attractive way to 
modulate the transcriptional effects of endogenous GCs. In a thorough analysis of 
the effect of hGR receptor levels in COS-7 cells, Zhao et al., (2003) reported that 
increasing GR levels increased the potency and efficacy of transrepression by dex, 
but interestingly this was not the case for all GR ligands. The authors examined the 
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effect of overexpressing different levels of GR on the transrepressive effect of 
RU486, 6 -methyl-17 hydroxyprogesterone acetate (MPA), budesonide and 
cortisol, and found that, in contrast to budesonide and cortisol, both MPA and RU486 
behaved as agonists at high receptor density, but as antagonists at low receptor 
density. Plausible explanations proposed for this phenomenon include cooperative 
dimerization, which increases with receptor density, or differential recruitment of 
cofactors being more thermodynamically favourable at higher receptor density (Zhao 
et al., 2003). Besides causing tissue-specific effects, differential expression of GR 
could also be responsible for ligand-selective effects, since only a subset of ligands 
exhibited altered biocharacter in response to the variation in GR levels. The 
observation that varying GR levels can shift a GC response curve has been 
corroborated in the Hapgood laboratory (unpublished data).  
 
Different ligands display different binding affinities for the GR depending on their 
particular chemical structure, and their three-dimensional fit into the GR ligand 
binding pocket. The binding affinity of a ligand for the GR determines the fractional 
occupancy, or the ratio of liganded to unliganded GR, at a given concentration (see 
Appendix A for more details). The concentration of GR present does not determine 
the fraction that will be occupied by ligand at a given concentration, since fractional 
occupancy is dependent only on the rate of association and disassociation of 
GR:ligand complexes at a given concentration of ligand. However, Schaaf and 
Cidlowski (2003) reported that ligand affinity correlates with subnuclear mobility of 
liganded GR, and may therefore have important implications for the transcriptional 
effect. For agonists and partial agonists, binding affinity has been shown to correlate 
with potency for transactivation, but not transrepression (Ronacher et al., 2009). 
However the reason for this correlation has not yet been established. 
 
1.3.4 Ligand-binding alters GR conformation 
 
It is generally accepted that ligand-selective maximal responses by steroid receptors 
are due to the induction of ligand-specific conformations of the liganded receptor 
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(Rosen & Miner, 2005). Different conformations of GR LBD bound to different ligands 
have been identified by X-ray crystallography (Kauppi et al., 2003) and hydrogen-
deuterium exchange mass spectroscopy (Frego & Davidson, 2006). Consistent with 
this, full-length GR has been shown to yield different patterns upon partial proteolytic 
digestion when bound to different ligands, indicating differences in protein 
conformation (Vicent et al., 2002). 
 
The rank order of GR transcriptional efficacy has been shown to have a strong 
correlation with the extent of GR phosphorylation at S211 and S226 (Avenant et al., 
manuscript in preparation). In turn, phosphorylation at S211 and S226 has been 
implicated in recruitment of the cofactor GRIP-1 to the GR (Avenant et al., 2010), 
and recruitment of GRIP-1 also correlates strongly with GR transactivational efficacy 
(Ronacher et al., 2009). Thus a central question is what upstream step brings about 
the differential phosphorylation of the GR, as this is likely the basis for ligand-
selectivity at several other steps in the GR transcriptional regulation pathway. One 
possibility is differences in the conformation of liganded GR which cause differential 
exposure of serine target residues to kinases. A second possibility which will be 
discussed shortly is GR nuclear translocation, which indeed could also arise from 
differences in GR conformation.  
 
Differences in GR conformation have not been examined with a large panel of 
ligands. This would allow investigation whether different ligands cause quantifiable 
differences in conformation along a continuum of possible conformations. If so, and 
the rank order of ligands along the continuum matched the rank order of their 
biological activity, this would strongly support the hypothesis that the differences in 







1.3.5 The composition of the Hsp-heterocomplex  
 
In its unliganded state, the GR resides in the cytoplasm and is bound in a complex of 
proteins consisting of Hsps and a variety of cochaperones (Pratt, et al., 2004). 
Formation of the heterocomplex is an ATP-dependent process, involving an initial 
reaction of GR with Hsp70 and the cochaperone Hsp40 (Grad & Picard, 2007). This 
complex is primed for interaction with Hsp90 and the cochaperone Hsp organising 
protein (Hop). The latter complex is stabilised by a dynamic interaction with p23, a 
small ubiquitous cochaperone (reviewed in Pratt et al., 2004). The association of GR 
with this heterocomplex is crucial for its folding, maturation to a ligand-binding 
conformation, trafficking and degradation (reviewed in Grad & Picard, 2007). 
 
Early observations of GR transformation in vitro indicated that dissociation of the GR 
from Hsps on ligand binding was a key step in regulation of GR activity, allowing 
subsequent DNA binding (Mendel et al., 1986; Pratt & Toft, 1997). However, more 
recent reports contest this model, suggesting an interaction between GR and Hsp90 
inside the nucleus (Elbi et al., 2004; Stavreva et al., 2004), and showing an 
interaction between liganded GR and Hsp90 (Fang et al., 2006). Furthermore, Hsp90 
and p23 are ligand-dependently recruited to GRE-containing promoters similarly to 
the GR (Freeman & Yamamoto, 2002). It has recently been shown that upon ligand 
binding, the MR translocates to the nucleus with the Hsp90 heterocomplex intact 
(Galigniana et al., 2010).  
 
Hsp90 contains a tetratricopeptide repeat (TPR) acceptor site at its C-terminal 
domain, to which one of a number of TPR proteins binds (Young et al., 1998). TPR 
sequences are degenerate 34 amino acid repeats which are involved in a number of 
protein-protein interactions. The main TPR proteins found in the GR heterocomplex 
are the immunophilins, so named because they bind to immunosuppressant drugs 
such as FK506 or Cyclosporin A. Immunophilins include FK506 binding protein 51 
(FKBP51), FK506 binding protein 52 (FKBP52) and Cyclophilin 40 (Cyp40). Another 
important TPR protein is the immunophilin homolog protein phosphatase 5 (PP5) 
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(Pratt et al., 2004). Although a subject of some debate, it is now generally accepted 
that Hsp90 dimers contain only one TPR binding site for which the TPR proteins 
compete (Pratt & Toft, 1997). The specific TPR protein occupying this binding site 
has functional implications for the GR heterocomplex. 
 
FKBP52 has been shown to potentiate GR signalling by increasing its hormone 
binding affinity (Riggs et al., 2003), while FKBP51 has been reported to decrease 
GR ligand binding and transactivation (Denny et al., 2000). Furthermore, FKBP52 
has been shown to interact with the motor protein dynein, while FKBP51 does not 
(Wochnik et al., 2005). Hormone binding to the GR has also been observed to 
correlate with a switch from FKBP51 to FKBP52 association on the heterocomplex 
(Davies et al., 2002). This observation lead to the current model of GR nuclear 
import, in which ligand binding induces association of FKBP52 with the 
heterocomplex, allowing association with dynein microtubules, and therefore nuclear 





Figure 1.2. Model for role of immunophilins in nuclear translocation 
of hormone-activated GR (Davies et al., 2002). Immunophilin swop of 
FKBP51 for FKBP52 on ligand binding allows interaction with dynein and 
subsequent nuclear translocation (90= Hsp90, 51= FKBP51; 52= 
FKBP52; D= dynein; Pol= RNA polymerase) 
 
Levels of FKBP51, FKBP52 and PP5 have been shown to vary between different cell 
lines, and this has direct implications for the subcellular localisation of the GR 
(Banerjee et al., 2008). Studies with knockout mice deficient in various TPR proteins 
have lead to the general conclusion that the required TPR protein for appropriate GR 
activity varies between different tissue types (reviewed in Ratajczak et al., 2009). 
Furthermore, high levels of endogenous FKBP51 have been implicated in GC 
resistance of new world primates (Reynolds et al., 1999), indicating that species-
specific differences in TPR expression levels can impact on GR function.  
 
The association of different TPR proteins with the GR heterocomplex has also been 
shown to depend on the nature of the ligand to which GR is bound. Croxtall and co-
workers (Croxtall et al., 2003) used a panel of four different GR ligands to 
demonstrate that the switch of FKBP51 for FKBP52 in association with GR was 
ligand-selective. Interestingly, no correlation between the amount of FKBP52 in the 
complex and GR nuclear translocation was seen. For instance, methyl-prednisolone 
resulted in a strong GR: FKBP52 interaction, but little nuclear translocation, while GR 
liganded to mometasone exhibited a weaker interaction with FKBP52 (predominantly 
remaining complexed to FKBP51), and a greater extent of nuclear translocation. 
Thus, while it is plausible that the different conformations of GR when complexed to 
different ligands are responsible for the differential association with TPR proteins, the 
role of differential TPR association in the resulting GR transcriptional response is still 
unclear. 
 




The palindromic nature of GRE sequences strongly suggests that gene regulation by 
direct DNA binding is to be mediated by dimers, and GR has indeed been shown to 
bind its response element as a homodimer (Tsai et al., 1988). GR molecules 
dimerize through specific contacts on the second zinc finger within the DBD (Luisi et 
al., 1991). GR dimerization has been reported to depend on DNA binding, such that 
DNA binding by one liganded monomer would induce dimerization and DNA binding 
by the second GR molecule to the second half-site of the palindrome (Dahlman-
Wright et al., 1990; Mikuni et al., 2007). However, more recent reports indicate that 
GR dimerization occurs in the cytoplasm (Savory et al., 2001). It has also been 
observed that nuclear translocation deficient mutant GR can be induced to 
translocate when co-expressed with wild-type GR, indicating that translocation of the 
mutant occurs as a dimer with a wild type partner (Savory et al., 1999).  
 
The commonly accepted view is that transactivation requires dimerization, while 
transrepression by protein tethering is mediated by GR monomers (reviewed in 
Nicolaides et al., 2010). This was shown in experiments where mutations to the GR 
D-loop, responsible for dimerization, abrogated transactivation, but did not affect 
transrepression (Tuckermann et al., 1999; Heck, 1994). Dimerization thus presents 
an attractive step for drug targeting, as drugs preventing dimerization could 
potentially have greater transrepressive activity, and reduced transactivation 
(reviewed in Newton, 2000). However, exceptions to this rule of thumb have been 
identified, and the ability of dimerization deficient mutants to transactivate appears to 
depend on the promoter context (reviewed in Newton & Holden, 2007; Meijsing et 
al., 2009). Several endogenous promoters have been identified which contain half 
GRE sites, and are positively regulated by binding of GR monomers (reviewed in 
Schoneveld et al., 2004) 
 
The GR can also function as a heterodimer with other SRs such as MR (Liu et al., 
1995; Savory et al., 2001) and AR (Yu et al., 1997). It has been suggested that 
GR:MR heterodimerization may play a role in mediating tissue-specific effects of 
GCs which activate both receptors (e.g. cortisol and aldosterone) (Savory et al., 
2001), especially in light of the fact that MR and GR are only co-expressed in a 
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subset of tissues (Lu et al., 2006). Furthermore, dimerization of GR appears to be 
ligand-selective as the dissociated GC CpdA abrogates GR dimerization (Dewint et 
al., 2008; Robertson et al., 2009). However, whether the extent of GR dimerization 
elicited by other GR ligands is ligand-selective, and the affect this may have on 
ligand-selective gene regulation by GR, has not been elucidated. The relative 
amount of homo- vs. heterodimers formed may also be ligand-selective.  
 
1.3.7 GR nuclear localisation 
 
In order to elicit its transcriptional effects, the GR must translocate to the nucleus in 
response to ligand. Translocation occurs through a large multiprotein complex called 
the nuclear pore complex (NPC) (reviewed in Kaffman & O'Shea, 1999). This is a 
GTP-dependent process, involving formation of a complex between the cargo protein 
and an importin protein to facilitate docking of the cargo at the NPC (reviewed in 
Kaffman & O'Shea, 1999).  
 
The GR has two NLSs, designated NL1 (in the DBD/hinge region) and NL2 (in the 
LBD) (Picard & Yamamoto, 1987). Although NL1 is required for ligand-dependent 
nuclear import, when incorporated into a fusion protein, this signal caused 
constitutive nuclear localisation. NL2 on the other hand, was found to mediate 
ligand-dependent nuclear import (Picard & Yamamoto, 1987). While NL1 was found 
to facilitate nuclear import through interaction with importin α, NL2-mediated nuclear 
import was independent of importin α (Savory et al., 1999). Subsequently, a variety 
of importin proteins have been implicated in nuclear localisation of the GR in different 
cell systems (Echeverría et al., 2009; Tao et al., 2006; Freedman & Yamamoto, 
2004), suggesting that the precise importin, or combination of importins, involved 
may be cell-type specific.  
 
Few studies have addressed the question of ligand-specific differences in nuclear 
translocation of the GR. While one study identified differences in nuclear 
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translocation between cortisol and RU486, cortisol was used at a sub-saturating 
concentration, so the reduced nuclear GR nuclear translocation in response to 
cortisol could be a due to the reduced fractional occupancy of GR with cortisol 
compared to GR with RU486 (Peeters et al., 2008). Another study which used sub-
saturating concentrations of GR ligand was that of Croxtall et al., (2003) in A549 
cells (e.g. 10nM methyl-prednisolone). Another study showed no significant 
difference in GR nuclear localisation between cells treated with saturating 
concentrations of dex and RU486 in mouse L929 cells (Pariante et al., 2001). These 
studies suffer either the weakness of use of sub-saturating GC concentrations, or 
that of the use of too few ligands (generally only full agonists and antagonists) to 
allow the formulation of robust conclusions about the general effect of different 
ligands on GR nuclear translocation. Many questions thus remain unanswered with 
regard to ligand-selective GR nuclear localisation. 
 
As mentioned in the section on GR conformation, the rank order of GR 
transcriptional efficacy has been shown to have a strong correlation with the extent 
of GR phosphorylation at S211 and S226 (Avenant et al., manuscript in preparation). 
Furthermore, GR phosphorylated at S211 and S226 has been reported to be 
predominantly localised to the nucleus (Wang et al., 2002). This observation could 
indicate that phosphorylation at S211 and S226 is required for nuclear import. 
However this has been shown not to be the case by use of site directed GR mutants 
(Avenant et al., 2010). An alternative explanation is that nuclear import is required for 
phosphorylation at S211 and S226, while yet another possibility is that GR 
phosphorylation and nuclear translocation are mutually independent but both 
modulated by a common upstream event, such as the conformation of ligand-bound 
GR. However the reason for the strong correlation between phosphorylation and 
nuclear localisation presents another unanswered question regarding the molecular 
mechanism of GR activity. Ligand-selective nuclear localisation of the GR definitely 
warrants further investigation with a large panel of ligands used at saturating 
concentrations, to elucidate the impact of nuclear translocation on the biological 




1.3.8 GR mobility within the nucleus  
 
The original model of GR transcriptional regulation involved fairly static promoter 
occupancy by the GR for a period of minutes or hours (Biddie & Hager, 2009). 
However, the currently accepted model portrays a highly dynamic association, either 
by direct DNA binding or protein tethering, between the GR and target promoter, and 
suggests that promoter interactions only last a matter of seconds (reviewed in 
George et al., 2009; Biddie & Hager, 2009). Although the evolutionary benefit 
conferred by the rapid cycling of GR on the chromatin is not understood, it is thought 
that this allows faster responses to changes in ligand concentration than would be 
allowed by a longer-term static GR:chromatin interaction (reviewed in Biddie & 
Hager, 2009). 
 
Fluorescence recovery after photobleaching (FRAP) analysis and the use of tandem 
mouse mammary tumour virus (MMTV) long terminal repeat (LTR) arrays has greatly 
enhanced understanding of the molecular dynamics of nuclear GR (Biddie & Hager, 
2009). When fluorescently tagged GR associated with a chromatin array was 
subjected to FRAP photobleaching, fluorescence was recovered within a matter of 
seconds, indicating that unbleached GR molecules are highly mobile, and swiftly 
replace the photobleached molecules at the promoter (McNally et al., 2000). 
Subsequent reports have confirmed this finding, and in addition, have shown that 
nuclear mobility of the GFP-rGR requires Hsp90 (Elbi et al., 2004) and ATP (Fletcher 
et al., 2002).  
 
The mobility of GR has been shown to vary between different cell types (Schaaf & 
Cidlowski, 2003), and the cell-type specific characteristics responsible for these 
differences in GR nuclear mobility remain to be determined. Furthermore, GR 
nuclear mobility has been found to be ligand-specific, and there is a negative 
correlation between GR mobility and ligand affinity (Schaaf & Cidlowski, 2003). The 
GR has also been found to adopt different distribution patterns within the nucleus 
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when bound to different ligands (Vicent et al., 2002; Schaaf et al., 2005). In COS-1 
cells, the subnuclear distribution of GR ranged from discrete, punctuate foci, to a 
diffuse random distribution depending on the ligand. Using a panel of 13 GR ligands, 
it was found that high affinity (mostly synthetic) ligands caused a more punctuate 
distribution, and a greater reduction in nuclear mobility of GR than lower affinity 
(mostly naturally occurring) ligands. This could suggest that more potent or 
efficacious ligands induce stronger interactions with chromatin, however this 
hypothesis is controversial (Schaaf et al., 2005). Consistent with this finding, 
Stavreva and co-workers (2004) noted a positive correlation between GFP-rGR 
residency at a promoter and transcriptional output (Stavreva et al., 2004). On the 
other hand, Schaaf et al., (2005) reported that GR mobility was lower in the 
subnuclear regions with higher concentrations of GR, and van Steensel et al. (1995) 
showed that subnuclear regions of high GR concentration do not colocalise with 
RNA polymerase or newly synthesised RNA. This would suggest that the reduction 
in GR mobility at concentrated foci is not due to GR transactivation activity, although 
it may relate more to GR transrepression. Thus the role of ligand-specific differential 
nuclear mobility of GR remains to be fully elucidated.  
 
1.3.9 DNA binding  
 
Since the GR is accepted to adopt different conformations on binding to different 
ligands, it makes sense that the extent and kinetics of DNA binding would also be 
affected by the differences in conformation. However, few studies have specifically 
addressed this issue. Wang et al. (2006) examined the transcriptional effect of a 
panel of structurally similar arylpyrazole GR ligands, and further went on to examine 
GR promoter occupancy at several endogenous promoters in A549 human lung 
epithelial cells. Interestingly, promoter- and ligand-specific differences in GR 
recruitment were identified, but recruitment of GR to the promoter did not appear to 
correlate with the fold change in transcription observed for any of the three genes 
and six compounds tested. Thus the precise role of differential DNA binding in 




It has been shown that the sequence of the GRE to which GR binds can have a 
profound influence on its DNA-binding affinity and transactivational activity. This was 
confirmed by X-ray crystallography of the GR DBD complexed with different DNA 
sequences, showing slightly different GR conformations (Meijsing et al., 2009). It has 
also been reported that DNA interactions by the DBD induce conformational changes 
in the AF-1 domain (Kumar et al., 1999). Collectively, this led to the suggestion that 
DNA functions as an allosteric modulator of GR conformation, and can thereby alter 
recruitment of cofactors in a promoter-specific fashion (Meijsing et al., 2009; Lefstin 
et al., 1994). This could have implications for tissue-specific GR activity in certain 
types of cancers, which exhibit a high rate of mutation, as even a single base pair 
mutation in a regulatory region could deregulate GR recruitment and activity.  
 
1.3.10 Protein-protein interactions and cofactor recruitment 
 
GR tethering to other promoter-bound transcription factors has been found to be 
ligand-specific. Garside et al., (2004) noted ligand-induced differences in the 
interaction of GR with the p65 subunit of NFκB, resulting in significantly less GR 
recruitment to the NFκB-regulated interleukin 8 (IL8) promoter in the presence of 
RU486 than in the presence of dex, in HeLa cells. Unfortunately the use of only two 
ligands prevents the formulation of a general conclusion of the role of differential 
interaction with p65 in GR-mediated transrepression, and this remains to be 
investigated with a broader panel of ligands. Moreover, to the best of the present 
author’s knowledge, no reports of ligand-selective differential GR interaction with 
promoter-bound AP-1 subunits or other DNA-binding transcription factors exist in the 
literature.  
 
Once bound to chromatin, or tethered to other transcription factors, steroid receptors 
recruit a range of cofactors to elicit transactivation or transrepression (Horwitz et al., 
1996). These cofactors have traditionally been designated as either “coactivators” or 
“corepressors”, but it is becoming increasingly clear that a single cofactor can elicit 
either an increase or decrease in transcription depending on the promoter context 
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(Rogatsky et al., 2002; Peterson et al., 2007). These definitions have therefore been 
avoided here. The GR interacts with a large number of transcriptional coregulators in 
order to carry out its biological activity, with possibly the best known interaction 
partners being members of the p160 family of transcriptional coregulators: steroid 
receptor coactivator 1 (SRC1), glucocorticoid receptor interacting protein 1 (GRIP1) 
and amplified in breast cancer 1 (AIB1) (reviewed in Xu et al., 2009). These three 
coregulators share a high level of homology and are roughly 160 kDa in size. In 
addition to SRs, the p160s can also potentiate transcriptional responses of other 
transcription factors such as AP-1, NFκB and CREB (reviewed in Xu & Li, 2003). 
Although members of the p160 family can compensate for one another to a certain 
extent, several reports of specific differences in recruitment and activity have been 
reported (Kotitschke et al., 2009; reviewed in Xu et al., 2009). Cofactors which are 
primarily involved in transrepression include silencing mediator of retinoic and thyroid 
hormone receptors (SMRT) and nuclear receptor corepressor (NCoR), which are 
highly homologous (reviewed in Collingwood et al., 1999). 
 
Cofactors mediate their effects by modifying chromatin structure via two main 
mechanisms: either by their own enzymatic activity or by recruitment of other factors 
with enzymatic activity. The intrinsic HAT or HDAC activity of cofactors may play a 
role in modulating acetylation of histones or other proteins to alter the transcriptional 
response. All p160s have been found to possess intrinsic HAT activity (Goel & 
Janknecht, 2004), (Spencer et al., 1997; Chen et al., 1997), while NCoR and SMRT 
have intrinsic histone deacetylase (HDAC) activity that removes acetyl groups from 
histones, causing compaction of the chromatin structure, and reducing transcription 
from the promoter (reviewed in Privalsky, 2004). Cofactors such as the p160 family 
may also act as “scaffolds” for recruitment of secondary coregulators such as 
adenovirus E1A-binding protein p300 (p300), CREB-binding protein (CBP), 
p300/CBP associated factor (pCAF), and coactivator associated arginine 
methyltransferase 1 (CARM1) (reviewed in Rosenfeld & Glass, 2001). These 
secondary coregulators possess chromatin modifying properties, and induce a more 
relaxed chromatin conformation in which the promoter of the target gene is more 
accessible to RNA polymerase or basal transcription machinery (reviewed in Xu & Li, 
2003). NCoR and SMRT, acting in a corepressive context, recruit other HDAC 
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proteins, which cause chromatin compaction and reduce transcription (reviewed in 
Rosenfeld & Glass, 2001). 
 
Different ligands have been shown to result in differential coregulator recruitment for 
the GR (Kroe et al., 2007; Wang et al., 2004; Wang & Simons, 2005; Wang et al., 
2007b; Coghlan et al., 2003; Garside et al., 2004; Cho et al., 2005; Miner et al., 
2007; Tao et al., 2008). Strong evidence exists for a steroid-dependent cofactor 
binding model whereby the transcriptional response of a steroid receptor to agonists 
and antagonists is linked to the recruitment of cofactors which activate or repress 
gene transcription, respectively, while partial agonists recruit a mixture of these 
cofactors (Kang et al., 2004). In support of such a model, it has been shown that 
agonist-bound GR binds GRIP-1 to a greater extent than partial agonist-bound GR 
(Cho et al., 2005). However, Wang et al. (2007b) found that GR recruited equal 
amounts of TIF2 (GRIP-1) when liganded to the agonist dexamethasone (dex) and 
the antagonist RU486.  
  
A recent investigation by Ronacher et al., (2009) in COS-1 cells provided strong 
biochemical support for a model in which GR-mediated ligand-selective differential 
interactions with GRIP-1, SRC1, NCoR and SMRT is a major determinant of ligand-
selective and promoter-specific effects for both transactivation and transrepression. 
Interestingly, it was found that the relative preference of liganded-GR for GRIP-1 
versus SRC-1A is clearly dependent on the ligand. Previous investigators have 
shown that on the MMTV promoter, the PR liganded to progesterone interacts 
preferentially with SRC-1 rather than GRIP-1 (Li et al., 2003). Similarly, the MR when 
liganded to aldosterone, shows preferential interaction with SRC-1-4a peptides but 
not with GRIP-1 peptides (Hultman et al., 2005), while the GR liganded to dex 
interacts preferentially with GRIP-1 rather than SRC-1 (Li et al., 2003). The finding 
that the GR cofactor selectivity shifts towards a preference for SRC-1A rather than 
GRIP-1 when liganded to progesterone, MPA or aldosterone suggests that the ligand 
plays a role in cofactor selectivity independent of the receptor, within the MR, PR 
and GR family (Ronacher et al., 2009). This would be consistent with crystal 
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structure studies suggesting that the GR and PR share a common mechanism of 
cofactor selectivity (Bledsoe et al., 2002). 
 
Besides mediating ligand-specific effects, differential cofactor recruitment provides a 
mechanism to elicit tissue specific effects to systemic GCs. The requirement for 
different p160 cofactors by GR has been shown to be different in astrocytes of the 
central nervous system, and Schwann cells of the peripheral nervous system 
(Trousson et al., 2007; Grenier et al., 2006). This could depend on the relative 
endogenous levels of coregulators present in different cell types, which have been 
shown to vary between different cell lines (Zhang et al., 2004) and tissues (Meijer et 
al., 2000). An interesting report by Fryer and co-workers (2000) demonstrates ligand- 
and tissue-specific effects of cofactor recruitment on gene transactivation. It was 
found that exogenous GR liganded to RU486 recruited the chromatin remodelling 
factor BRG1, and elicited subsequent transactivation of an MMTV promoter, in an 
osteosarcoma cell line, but not in a breast cancer cell line, while other GR 
antagonists failed to elicit an effect in either cell line. Thus differential recruitment of 
cofactors is an important step in mediating both ligand- and cell type-specific effects 
of GR ligands.  
 
1.3.11 Ligand-dependent turnover of GR 
 
GR levels have been found to be ligand-dependently downregulated (Bellingham et 
al., 1992; Hoeck et al., 1989), by a mechanism involving both decreased 
transcription of the GR gene, and increased receptor turnover (reviewed in Oakley & 
Cidlowski, 1993). While protein degradation can occur via ubiquitin-dependent and –
independent pathways, it has been shown that the GR is ubiquitinated (Wallace & 
Cidlowski, 2001), and that the proteasome is recruited to activated GR, which is 
required for rapid GR cycling at promoter sites (Stavreva et al., 2004). Proteasomal 
degradation of proteins is a tightly-regulated process involving a series of fairly well-
characterised steps. Proteins must be tagged with a poly-ubiquitin tag, which occurs 
at conserved lysines via an ATP-dependent three-step enzyme cascade, to identify 
them as degradation targets (Kinyamu et al., 2005). Following ubiquitination, the 
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target protein is degraded by a multi-protein complex called the 26S proteasome 
(reviewed in Glickman & Ciechanover, 2002; Kinyamu et al., 2005). 
 
Several groups have identified ligand-specific differences in the rate of ligand-
mediated turnover of GR (Cidlowski & Cidlowski, 1981; Hoeck et al., 1989). Most 
recently, a thorough study of GR turnover with a wide panel of ligands has identified 
a positive correlation between the half-life of liganded GR and the potency and 
efficacy of transcription elicited by a particular ligand (Dr C. Avenant, PhD thesis). 
This observation could indicate that proteasomal degradation of activated GR acts 
as a negative feedback mechanism to modulate the response to GCs. However, the 
molecular mechanism underlying ligand-dependent GR turnover is not fully 
understood.  
 
1.3.12 GR ligand-independent signalling 
 
As mentioned previously, a number of non-GC signalling molecules have been 
identified which modulate GR activity (Dr A. Kotitschke, PhD thesis, 2009). The 
relative levels of such molecules in different tissues can have an impact of the 
specific activity of GR in a given cell-type. For instance, gonadotropin releasing 
hormone (GnRH), the peptide ligand of the GnRH receptor (GnRHR), has recently 
been found to activate GR, causing phosphorylation, nuclear translocation and 
binding to the GnRHR gene promoter (Kotitschke et al., 2009). Because this 
response is mediated by the GnRHR itself, this signalling pathway would only occur 
in cells which express endogenous GnRHR, such as pituitary gonadotropes and 
reproductive tissues (Kotitschke et al., 2009).  
 
Non-GC signalling molecules may also augment a GC response, as in the case of 
GnRH and dex, which together elicit a synergistic effect on transcription (Kotitschke 
et al., 2009). It has not been determined whether such interactions may be ligand-
selective, for instance co-treatment of cells with GnRH and another GR ligand may 
41 
 
not result in a synergistic effect on gene transcription. This possibility warrants 
further investigation. 
 
1.3.13 Post-translational modifications of the GR 
 
In this section, known post-translational modifications (PTMs) of GR will be 
discussed. It is becoming increasingly evident that cross-talk occurs between 
different residues of the GR, such that different post-translational modifications can 
modulate each other. For instance, Davies and co-workers reported cross-talk 
between GR sumoylation and phosphorylation (Davies et al., 2008); while 
preliminarily evidence suggests that nitration at tyrosine residues may enhance 
ubiquitination of GR, resulting in its degradation by proteasomes (Ito, 2007). 
Furthermore, a complex relationship between GR phosphorylation at different sites 
has been identified (Wang et al., 2007a). This interplay between GR post-





The GR, like all steroid hormone receptors, is constitutively phosphorylated and 
undergoes hyperphosphorylation upon ligand binding (Faus & Haendler, 2006). Most 
of the phosphorylation sites identified thus far are serine residues in the N-terminal 
domain, namely S113, S141, S203, S211 and S226 (Ismaili & Garabedian, 2004), 
while S404 near the DBD has also been identified as a phosphorylation site 
(Galliher-Beckley, Williams, Collins, & Cidlowski, 2008). GR phosphorylation appears 
to form part of a complex regulatory mechanism controlling GR transcriptional 
activity. The phosphorylation status of one site can affect the phosphorylation at 
other sites in a particular GR molecule, as well as transcriptional efficacy (Wang et 
al., 2002), and these effects are gene-specific (Chen et al., 2008). GR 
phosphorylation has been implicated in regulating its interaction with the cofactor 
GRIP1 (Avenant et al., 2010), TSG101, a mediator of ubiquitin-dependent 
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proteolysis and DRIP150, a subunit of the mediator complex (Ismaili & Garabedian, 
2004). Furthermore, phosphorylation of hGR at S404 has been shown to be required 
for recruitment of p300 (Galliher-Beckley et al., 2008). 
 
The three best characterised phosphorylation sites are S211, S226 and S203, which 
are conserved between human, mouse and rat GRs. GR phosphorylation at S211 
appears to be closely linked with the transcriptional activity of the GR, since this site 
is rapidly phosphorylated in the presence of dex, and GR phosphorylated at S211 is 
located mainly inside the nucleus (Wang et al., 2002). However introduction of an 
S211A mutation to abolish phosphorylation resulted in increased transcription on 
some promoters, and decreased transcription on others (Chen et al., 2008). S226 is 
also rapidly phosphorylated in the presence of dex and GR phosphorylated at S226 
is also located primarily in the nucleus (Wang et al., 2002), but mutation of this site to 
abolish phosphorylation (S226A) increases the potency and efficacy of GR 
transcription on a number of endogenous genes (Chen et al., 2008), indicating that 
this site may be required to negatively modulate the GR response. In contrast, S203 
exhibits higher basal phosphorylation than S211 or S226, and a smaller dex-
mediated increase in phosphorylation in U2OS-hGR and A549 cells (Chen et al., 
2008). This phospho-isoform is also located mainly in the cytoplasm (Wang et al., 
2002), and consistent with this, GR S203P was not immunoprecipitated on a variety 
of endogenous promoters (Blind & Garabedian, 2008). S211 and S226 phospho-GR 
isoforms have been shown to be recruited to the promoters of tyrosine 
aminotransferase (tat) and sulfonyltransferase-1A1 (sult) genes in rat hepatoma 
cells, and the glucocorticoid-induced leucine zipper (GILZ) gene in human U2OS 
cells, and differences in the kinetics of recruitment to different promoters have been 
identified, adding another layer of complexity to the role of differential GR 
phosphorylation (Blind & Garabedian, 2008). Although the phosphorylation status of 
different residues has been found to correlate with the subcellular localisation of the 
GR, this could indicate that phosphorylation determines the subcellular localisation, 
or that the subcellular localisation determines the phosphorylation status of the GR. 
Another possibility is that another upstream factor (e.g. GR conformation) 
determines both the phosphorylation status of the GR and its subcellular localisation. 
A recent finding that mutation of hGR to abolish phosphorylation at S203, S211 and 
S226 did not affect nuclear translocation of the GR (Avenant et al., 2010) points 
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towards one of the latter two possibilities. However further work is needed to fully 
elucidate the role of nuclear translocation in GR phosphorylation.  
 
Mitogen activated protein kinases (MAPKs), cyclin dependent kinases (CDKs) and 
casein kinase II have been implicated in GR phosphorylation (reviewed in Faus & 
Haendler, 2006). Several reports have suggested that the serine-threonine 
phosphatase, PP5 is responsible for dephosphorylation of the GR (Ismaili & 
Garabedian, 2004). PP5 is a TPR protein which can associate with the GR-Hsp-
heterocomplex. Dissociation of PP5 from the Hsp-heterocomplex has been 
suggested to be a crucial step enabling GR phosphorylation upon ligand binding 
(Wang et al., 2007a). PP5 was also recently shown to mediate dephosphorylation 
GR at S211 within the nucleus, resulting in reduced GR-mediated transactivation of 
MKP1 and serum/glucocorticoid regulated kinase (SGK) genes (Zhang et al., 2009).  
 
Chen et al., (2008) elegantly demonstrated that GR phosphorylation is both cell-type 
and ligand-specific. Distinct temporal patterns and kinetics of GR phosphorylation 
were identified between stably transfected U2OS-hGR and A549 cells. In particular, 
dex mediated phosphorylation at S226 was found to be lower in A549 than in U2OS 
cells. The reason for these cell-type specific differences remains to be elucidated, 
but could include differential expression of kinases or phosphatases. Using a panel 
of 9 ligands, Chen et al., (2008) observed differential phosphorylation of S211, S226, 
and S203 of stably expressed GR in U2OS cells. Furthermore, the ratio of 
S211P:S226P was found to vary with different ligands. Another study found that 
while phosphorylation at S226 is ligand-selective and correlates with transcriptional 
efficacy for transcription on three different promoters, mutation of S226 to abolish 
phosphorylation caused the same relative increase in transcription for all ligands, 
indicating that phosphorylation at S226 inhibits maximal transcription, but does not 
determine the rank order of ligand-selective transcription (Dr C. Avenant, PhD 
thesis). Taken together, this strongly suggests that differential GR phosphorylation is 
an important regulator of the ligand-selective efficacy of GR responses, although GR 
phosphorylation alone does not determine the relative transcriptional response to a 






Acetylation of lysine residues plays an important role in the activity of several 
transcription factors (reviewed in Glozak et al., 2005). To date, only two reports 
investigating the effect of GR acetylation have been published (Ito et al., 2006; 
Nader et al., 2009). Ito et al., (2006) found that the overall acetylation status of GR 
increased on co-incubation with dex and IL1β. Although ligand-dependency was not 
demonstrated, this report showed that residues K494/495 were acetylated in the 
presence of dex. The authors further report that GR acetylation at K494/495 reduces 
its ability to interact with the p65 subunit of NFκB, and thus its ability to repress gene 
expression. Furthermore, HDACs 1 and 3 were shown to deacetylate the GR in vitro. 
Nader et al., (2009) implicate the circadian rhythm modulator CLOCK in GR 
acetylation at several lysine residues within the hinge region. Overexpression of 
CLOCK and its heterodimerisation partner, brain-muscle-arnt-like protein 1 (BMAL1), 
in HeLa cells was found to decrease DNA-binding by the GR, and thereby reduce 
transactivation.  
 
The possibility of SR acetylation as a mechanism of control of tissue specific effects 
is both plausible and intriguing. Ito et al., (2006) showed that knockdown of specific 
HDACs could affect the acetylation status of the GR. Therefore, the relative ratio of 
endogenously expressed HAT and HDAC proteins could fine-tune the GR response 
for a particular setting, since HAT and HDAC expression and subcellular distribution 
varies in different cell and tissue types (Meijer et al., 2000; Petrie et al., 2003; Van 
den Wyngaert et al., 2000; Igarashi-Migitaka et al., 2005). However, to the best of 
the author’s knowledge, there are no reports investigating differences in acetylation 
levels or acetylated residues of SRs when activated by different ligands.  
 





Ubiquitin is a highly conserved 76 amino acid polypeptide, which is generally tagged 
onto a protein to target it for proteasomal degradation by a carefully controlled series 
of stepwise reactions (reviewed in Kinyamu et al., 2005). It is attached to serine 
residues within conserved Proline-Glutamate-Serine-Threonine (PEST) motifs 
(reviewed in Duma et al., 2006). The GR has been shown to become ubiquitinated, 
and K419 of hGR, found within a conserved degradation motif, has been implicated, 
as mutation of the corresponding residue in mGR results in a decrease in 
degradation of the protein (Wallace & Cidlowski, 2001).  
 
Sumoylation refers to the addition of a small ubiquitin-related modifier (SUMO) at 
lysine residues. SUMO is an 11 kDa (98 amino acid) polypeptide, which appears to 
play a role in a wide range of cellular functions, from subcellular localisation to 
protein stability (Faus & Haendler, 2006). GR has been shown to be sumoylated in 
vitro (Poukka et al., 2000) and in vivo on overexpression of SUMO-1 (Le Drean et 
al., 2002). Three sumoylation consensus sites have been identified, and mutation 
studies indicate that sumoylation of GR enhances its activity in a promoter-specific 
fashion (Tian et al., 2002), while overexpression studies indicate a role for 
sumoylation in increasing GR turnover (Le Drean et al., 2002). Since sumoylation is 
influenced by environmental cues, such as stress, this presents a possible 
mechanism to fine-tune GR activity to suit a cell’s particular physiological state 
(reviewed in Duma et al., 2006). 
 
Proteins can further be modified by nitration of tyrosine residues. GR has been 
reported to undergo tyrosine nitration on binding to NCX-1015, a member of a family 
of NO-donating ligands, termed nitrosteroids (Paul-Clark et al., 2003). GR nitration 
increased ligand-binding, nuclear translocation and transcriptional activity (Paul-
Clark et al., 2003).  
 
Protein methylation is a relatively common mechanism of regulating protein function. 
The methyltransferase, CARM1, is recruited to ER-regulated promoters through a 
GRIP1 interaction domain, and has been shown to methylate CBP/p300 (Chevillard-
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Briet et al., 2002) leading to synergistic transcriptional activation (Chen et al., 2000; 
Lee et al., 2002). Methylation of GR has not been demonstrated, so it is still unclear 
whether this particular post-translational modification may regulate GR activity 




An appropriate, cell-specific response to a systemic GC is crucial for homeostasis. 
Various systems have evolved to ensure that GR responses are carefully controlled 
in different cell and tissue types in the body. These mechanisms often involve 
varying the expression levels of endogenous GR, or GR interacting partners, to 
modulate the response. When these control mechanisms go awry, problems such as 
GC insensitivity may result, and have a significant physiological impact.  
 
The central role of GR in a number of biological processes has made it an excellent 
drug target for a number of disorders. However, the wide range of physiological 
effects and side-effects elicited by different GR ligands has made it clear that GR 
activation is far from a simple “on/off switch”. Subtle differences in ligand structure 
can cause GR responses to vary. Although the basis of ligand-specific effects seems 
to be differences in the conformation of the ligand-activated GR, these differences 
impact on several different steps in the GR transcriptional regulation pathway.  
 
This chapter has given a broad overview of the steps at which both ligand- and 
tissue specific GC effects can manifest. The specific DNA sequence at which the GR 
acts can also have a profound influence on the biological outcome of GR activity, 
adding to the complexity of GC responses. A deeper understanding of the molecular 
mechanisms behind these variations is critical to the design of more specific drugs, 
or treatment plans more tailored to individual patients. As highlighted in this review, 
GR-mediated gene regulation is an extremely complex process, regulated at many 
levels. Therefore the development of GC drugs with a high therapeutic index and 
negligible side-effects will be enormously challenging. However, given the 
47 
 
importance of GC therapy for a wide range of diseases, this lofty aspiration is 







AIMS AND HYPOTHESES 
 
Unravelling the molecular mechanisms of GR activity and uncovering the 
mechanisms responsible for ligand-specific responses of GR is an area of intensive 
research by many laboratories. The broad aims of the Hapgood laboratory include 
contributing to understanding these mechanisms. In order to achieve this aim, the 
process of GR transcriptional regulation has been broken down into individual steps, 
several of which have been the focus of intensive research by laboratory members. 
Important findings have recently been published on phosphorylation (Avenant et al., 
2010) and cofactor recruitment (Ronacher et al., 2009) by ligand-activated GR, as 
discussed in Chapter 1. This study therefore formed part of a wider research effort. 
 
Although acetylation of other SRs appears to play an important role in their function, 
there is a paucity of literature on GR acetylation. The first part of this thesis (Chapter 
3) aimed to elucidate the role of GR acetylation in transactivation. The hypotheses 
on which this work was based are: 
 that GR is acetylated at K494/495 when bound to and activated by ligand, 
when endogenously expressed or transiently overexpressed in COS-7 cells. 
 that GR acetylation at K494/495 plays a functional role in transactivation 
through modulation of one or several of the following steps: ligand binding, 
nuclear translocation, phosphorylation, DNA binding, or cofactor recruitment.  
 that FKBP52 plays a role in modulating the biological activity of acetylated 
GR. 
 
Chapter 1 highlights the lack of understanding of the role of ligand in determining the 
extent of nuclear localisation of the GR. Few reports exist in the literature 
investigating ligand-selective nuclear translocation of GR, and the results appear 
contradictory. Thus the second aim of this project (results reported in Chapter 4) was 
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to investigate the relationship between ligand-selective differences in transcriptional 
regulation by the GR and differential nuclear localisation of the GR when bound to 
different ligands. The following hypotheses were formulated and subsequently 
investigated: 
 that different ligands at saturating concentrations will result in different 
transcriptional responses via the GR on promoter-reporter constructs and 
endogenous genes in U2OS cells. 
 that different ligands at saturating concentrations will cause differences in the 
extent of nuclear localisation of endogenous GR in U2OS cells. 
 that different ligands at saturating concentrations will cause different extents 
of phosphorylation at serine-211 of activated endogenous GR in U2OS cells. 
 that the extent of ligand-specific differential nuclear localisation of GR and/or 
phosphorylation at serine-211 will correlate with the biological response of 






Critical role of lysines 494/495 in GR ligand binding and function: 
Functional implications of GR acetylation 
 
The glucocorticoid receptor (GR) and other steroid receptors undergo multiple 
post-translational modifications, including phosphorylation and acetylation, 
which play an important role in modulating their biological effects. GR has 
previously been shown to be acetylated at residues K494 and K495. However 
the role of GR acetylation in transcriptional activation is unclear. The 
functional consequences of GR acetylation were investigated at several steps 
in the GR transactivation pathway, using expressed hGR mutants as compared 
to wild-type GR (WT hGR). The acetylation deficient K494/495A hGR mutant 
showed a loss of GR nuclear translocation, ligand-dependent phosphorylation, 
in vitro DNA-binding and transactivation activity on a synthetic glucocorticoid 
response element (GRE). This is consistent with the finding that this mutant 
exhibits undetectable ligand-binding, although its expression levels and 
cytoplasmic immunofluorescence staining pattern are indistinguishable from 
that of WT hGR. Results with the K494/495Q acetylation mimic mutant strongly 
support the argument that acetylation of the GR at K494/495 is important for 
ligand-binding and the resulting downstream actions of the GR. Compared to 
WT hGR, the K494/495Q mutant has an enhanced ligand binding capacity and 
transactivation efficacy on a GRE reporter gene. While in vitro DNA-binding 
activity is unaltered, the K494/495Q mutant surprisingly displays reduced 
nuclear translocation and phosphorylation at S211 and S226 compared to WT 
hGR. Chromatin immunoprecipitation (ChIP) on the endogenous GRE-
containing GILZ gene supports a model in which interaction of the 
immunophillin FKBP52 with acetylated K494/495 of the hGR plays an important 
role in GR function by acting as a GR coactivator. Taken together, the results 
suggest that modulation of GR acetylation at K494/K495 represents an 
attractive physiological mechanism for regulation of glucocorticoid sensitivity 




The GR is a ligand-activated transcription factor that regulates expression of a wide 
range of genes (reviewed in Zhou & Cidlowski, 2005; Nicolaides et al., 2010). It 
belongs to the family of steroid receptors encompassing the androgen, 
mineralocorticoid, estrogen, and progesterone receptors (AR, MR, ER, and PR 
respectively). Unliganded GR resides largely in the cell cytoplasm, in a complex with 
heat shock proteins (Hsps) 40, 70, 90 and the Hsp 90-binding tetratricopeptide 
(TPR) containing immunophilin, FK506-binding protein 51 (FKBP51) (Davies et al., 
2002). Upon ligand binding the complex undergoes a functional exchange of 
FKBP51 for FK506-binding protein 52 (FKBP52) (Davies et al., 2002). Ligand 
binding also results in a conformational change, hyperphosphorylation and nuclear 
translocation of the GR, where it can either positively or negatively regulate gene 
expression by direct DNA binding, or interaction with other DNA binding proteins 
(reviewed in Zhou & Cidlowski, 2005).  
 
FKBP52 is an immunophilin cochaperone that has been found in Hsp 
heterocomplexes of AR, MR, PR and GR (Tai et al., 1986; Gallo et al., 2007; Barent 
et al., 1998). FKBP52 has been shown to promote GR activity at several steps in the 
transcriptional activation process. Firstly, its presence in the Hsp heterocomplex 
improves the ligand binding ability of the GR (Riggs et al., 2003; Riggs et al., 2007). 
After ligand binding, FKBP52 interacts with dynein to facilitate movement of the GR 
heterocomplex along the microtubules into the nucleus (Harrell et al., 2004; 
Galigniana et al., 2002). However, a significant portion of FKBP52 resides in the 
nucleus (Czar et al., 1994; Perrot-Applanat et al., 1995). Nuclear FKBP52 has 
recently been shown to play a gene-specific role in transactivation by GR, since 
targeted ablation of FKBP52 significantly reduces expression of GILZ, but has no 
effect on GR-mediated SGK expression (Wolf et al., 2009). Furthermore, 
overexpression of FKBP52 has been shown to increase agonist-mediated 
transactivation potency of the GR (Riggs et al., 2003). However the molecular 
mechanism of modulation by FKBP52 of GR-mediated transcription in the nucleus 
remains to be determined, and whether or not FKBP52 is recruited to a GRE 
promoter has not previously been established. Interestingly, FKBP52 has been 
shown to interact directly with the GR between amino acids 465 and 500 in vitro 
(Silverstein et al., 1999). Although FKBP52 primarily docks to a site on the Hsp 90 
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dimer (Young et al., 1998), it contains a conserved sequence of 8 amino acids with 6 
negatively charged residues which are electrostatically complementary to the GR 
NLS (490-RKTKKKIK-497) (Czar et al., 1995). Furthermore lysine residues within 
this region of the GR have been implicated as acetylation targets (Ito et al., 2006), 
suggesting that GR acetylation at residues between amino acids 465 and 500 may 
regulate FKBP52-mediated transcriptional effects on the GR.  
 
The GR and other steroid receptors have been shown to undergo multiple post 
translational modifications, such as phosphorylation, ubiquitinylation, sumoylation 
and acetylation, which play an important role in modulating their biological actions 
(reviewed in Faus & Haendler, 2006). Although acetylation has not been reported for 
the MR or PR, several studies have investigated the functional role of lysine 
acetylation for the AR, ER and GR. The AR, GR, MR and PR share a highly 
conserved KXKK motif (where K= lysine and X= any amino acid), within a nuclear 
localisation signal (NLS) in their DNA binding domains (DBD) (Kim et al., 2006). 
Lysine residues within this region have been shown to be acetylated for the AR and 
GR, and results support a functional role for these acetylated lysines in 
transcriptional regulation (Ito et al., 2006; Fu et al., 2000; Nader et al., 2009). Lysine 
residues in the DBD of both the AR and ERα have been shown to be acetylated 
directly by p300 in vitro, which resulted in increased DNA binding for ERα (Kim et al., 
2006; Fu et al., 2000). Acetylation of the AR at residues within the KXKK motif has 
been shown by mass spectrometry and Edman degradation, and has been shown to 
be ligand-independent (Fu et al., 2000). AR acetylation appears to play a key role in 
its nuclear translocation, cofactor recruitment and transactivation (Gaughan et al., 
2002; Fu et al., 2002; Fu et al., 2004; Fu et al., 2003). Acetylation of ERα in the DBD 
has also been shown by 3H-acetyl CoA incorporation assays under basal conditions 
with a small increase being observed in the presence of ligand (Kim et al., 2006). 
The GR has also been reported to undergo an increase in overall acetylation on 
ligand binding, while lysine residues 494 and 495 have been shown by 
immunoprecipitation experiments to be acetylated in the presence of dex and the 
proinflammatory cytokine IL1β in A549 cells. This acetylation resulted in reduced 
association with p65-NF-κB, lifting the transrepressive effect of the GR (Ito et al., 
2006). The deacetylation of the GR by histone deacetylase 2 (HDAC-2) increased its 
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binding affinity for p65. Another report in HCT116 cells showed an increase in dex-
mediated GR acetylation at K494/495 was only observed in the presence of 
overexpression of the CLOCK/BMAL1 heterocomplex, which possesses HAT activity 
(Nader et al., 2009). The hGR undergoes dex-mediated phosphorylation at S226 and 
S211 which influences maximal efficacy for transactivation (Chen et al., 2008; 
reviewed in Duma et al., 2006; Ismaili & Garabedian, 2004). The relationship 
between GR phosphorylation and acetylation is not known, but results with the ER 
(Cui et al., 2004) and AR (Fu et al., 2004) suggest that these modifications may 
modulate each other.  
 
In the current study, the role of acetylation of the hGR at lysines 494 and 495 was 
investigated in transactivation, nuclear translocation, phosphorylation of the GR at 
S211 and S226, DNA-binding and ligand-binding. Furthermore, the role of FKBP52 





MATERIALS AND METHODS 
 
Cell lines and test compounds COS-7 monkey kidney and A549 human lung 
fibroblast cells (ATCC) were cultured in high glucose (1 g/ml) Dulbecco’s Modified 
Eagles Medium (DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) fetal calf 
serum (FCS) (Delta Bioproducts), 100 IU/ml penicillin and 100 g/ml streptomycin 
(Gibco Invitrogen) (complete medium) at 37 C in a water jacket incubator (90% 
humidity and 5% CO2). Dexamethasone ((11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-
methylpregna-1,4-diene-3,20-dione) (dex) and 4α-Phorbol 12-myristate 13-acetate 
(PMA) were purchased from Sigma-Aldrich, dissolved in absolute ethanol, and 
stored at -20˚C. Trichostatin A (TSA) was purchased from Sigma-Aldrich. 
 
Plasmids The pTAT-GRE-E1b-luc reporter plasmid containing two copies of the 
Glucocorticoid response element (GRE) from the tyrosine amino transferase (TAT) 
promoter has been described previously (Sui et al., 1999). The hemagglutanin (HA) 
tagged WT hGR (WT HAhGHR) in pCMV vector was a gift from Dr M.J. Garabedian 
(New York University, USA). pcDNA3 WT hGR (WT hGR) was a gift from Dr D. Ray 
(University of Manchester, UK), and the pcDNA3 K494/495A hGR (K494/495A hGR) 
mutant was donated by Dr K. Ito (Imperial College, London). The HA-tagged 
K494/495Q HAhGR (K494/495Q HAhGR) mutant was generated with pCMV-HA-
hGRwt as a template. Briefly, the mutant was generated by PCR using overlapping 
sense (GGAAGCTCGAAAAACAcAGcAAAAAATAAAAGGAAT) and anti sense 
(ATTCCTTTTATTTTTTgCTgTGTTTTTCGAGCTTCC) primers (mutated bases are 
indicated in lowercase) using Accusure  Bioline Taq polymerase (BIO 20168) 
according to the manufacturer’s specifications using the following conditions: 95 C 
for 10 min followed by 18 cycles of 95 C for 45 sec, 55 C for 45 sec and 68 C for 14 
min. The PCR product was purified and concentrated using the Zymogen clean and 
concentrator kit (Zymogen Research, D 4003). The template DNA was subsequently 
removed by digestion with Dpn I (Fermentas). DNA was then re-purified, 
concentrated and transformed into Escherichia coli (E.coli) DH5  according to a 




Acetylation experiments in A549 cells Cells were plated at a density of 1 x 105 
cells/ml in 6 cm dishes in complete medium. Cells were treated for 24 h with 1 ng/ml 
PMA or vehicle (ethanol) in serum-free DMEM. Dex was added to a final 
concentration of 100 nM, for 1 h. Cells were lysed and harvested in 200 µl cytobuster 
(Novagen) with protease inhibitors 1 mM PMSF, 2 µg/ml aprotinin, 5 µg/ml leupeptin 
and 10 µg/ml TSA. After centrifugation at 15000g for 15 min, 1 µg anti-GR H300 
(Santa Cruz Biotechnology) was added to the supernatant. After 1 h incubation at 
4˚C on a rotating wheel, protein A/G beads (sc-2003, Santa Cruz Biotechnology) (20 
µl) were added, for a further 2 h. Beads were then washed in PBS, resuspended in 
30 µl 2 x SDS sample buffer, and analysed by Western blotting as described below. 
Membranes were probed with an antibody towards acetylated lysine, before being 
stripped and reprobed for total GR.  
 
Transactivation promoter-reporter assay COS-7 cells were seeded into 10 cm 
dishes at a density of 1  106 cells per dish. After 24 h the cells were transfected with 
5 µg of plasmid constructs encoding either WT hGR, K494/495A hGR, WT HAhGR 
or K494/495Q HAhGR and with 5 µg pTAT-GRE-E1b-luc, using the DEAE-Dextran 
method as previously described (Ausubel, 1999) with modifications. Briefly, cells 
were incubated for 1 h in a transfection mix consisting of 100 µM chloroquine 
diphosphate, 0.1 mg/ml DEAE dextran and DNA in serum-free DMEM. Transfection 
mix was then replaced with 1 volume of 10% DMSO in PBS for 3 min. Cells were 
then returned to the incubator in DMEM containing 10% FCS. The following day cells 
were replated into 24 well plates, and allowed to adhere for a further 24 h. The 
following day, cells were treated with 100 nM dex in serum free DMEM for 24 h. 
Cells were then harvested in 50 µL reporter lysis buffer (Promega) and 10 µL of the 
lysate was used for the luciferase assay (Luciferase Assay System, Promega), which 
was read using a Modulus microplate reader (Turner Biosystems). The protein 
concentration of the lysate in each well was determined using a standard Bradford 
assay (Pierce). The values obtained from the luciferase assay were normalised to 
protein concentration of the lysate and values and were expressed relative to WT 




Immunofluorescence COS-7 cells were plated into 10 cm dishes at a density of 1  
106 cells per dish, and transfected with 5 µg of plasmid constructs encoding either 
WT hGR, K494/495A hGR, WT HAhGR or K494/495Q HAhGR, as described above. 
After 24 h, cells were replated onto coverslips, and allowed to adhere for a further 24 
h. Cells were treated for 1 h with 1 µM dex, before being fixed and permeabilised in 
methanol at -20˚C for 15 min. Coverslips were blocked with 3% bovine serum 
albumin (BSA) in PBS for 1 h, and then incubated with primary antibody (anti-GR, 
H300, Santa Cruz Biotechnology; 1:500 in 5% BSA/PBS) for 1 h. Coverslips were 
then washed and incubated in secondary antibody (anti-Rabbit, Alexa 488 
(Invitrogen), 1:500 in 5% BSA/PBS) for 1 h. Hoechst nuclear stain was used to 
counterstain nuclei, before mounting coverslips on glass slides using Mowiol 
mounting medium (13% (w/v) Mowiol, 33% glycerol in 0.2 M Tris pH 8.5). Slides 
were incubated at room temperature overnight to allow the mounting medium to set, 
and then examined on a Zeiss Axiovert 200 M fluorescent microscope and analysed 
with AxioVision Rel 4.7 software. Confocal microscopy was performed on a Zeiss 
LSM510 META NLO Inverted microscope, using an Argon laser with 488 nm 
excitation line.  
 
Western blotting and antibodies COS-7 cells were transfected, replated and 
treated as described above. Cells were washed with PBS, harvested in 2 x SDS 
sample buffer, and boiled at 100˚C for 5 min. Proteins were separated on an 8 or 
10% polyacrylamide gel by SDS-PAGE at 200V. Proteins were transferred from the 
gel to Hybond ECL membrane (Amersham Biosciences), by electroblotting at 180mA 
for 1 h. Membranes were then blocked in 5% non-fat milk powder in Tris-buffered 
saline containing 0.1% Tween-20 (TBST), and probed with specific antibodies 
overnight at 4˚C. Membranes were then washed three times for 5 min each in TBST, 
incubated in secondary antibody for 1 h at room temperature, and washed again as 
previously. Blots were developed using Amersham ECL Western blotting detection 
reagents (GE Healthcare). After probing, blots were stripped by incubation in 
stripping buffer (62.5 mM Tris pH6.5, 1% SDS, 0.7% (v/v) β-mercaptoethanol) at 
65˚C for 30 min, before being blocked and probed as previously. Antibodies included 
anti-GR (H-300, sc-8992, Santa Cruz Biotechnology), anti-β tubulin (T4026, Sigma 
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Aldrich), anti-ε acetylated lysine (#9441, Cell Signalling Technology), anti-GR 
phospho-S211 and phospho-S226 (Dr M.J. Garabedian, New York University, USA).  
 
Whole cell binding Competitive whole cell binding assays were performed as 
previously described (Koubovec et al., 2005) with minor modifications. Briefly, COS-
7 cells were seeded into 10 cm tissue culture dishes at 1 x 106 cells per dish. On day 
two, cells were transiently transfected with 5 g of various GR constructs per well 
using FuGENE 6 (Roche) according to the manufacturer’s instructions. On day three 
the cells were replated into 24 well plates. On day four, cells were washed twice with 
prewarmed PBS and incubated with DMEM containing 10 nM [3H]- dex (50 Ci/mmol, 
AEC-Amersham) and 10 µM excess unlabelled dex or vehicle for 90 min at 37 C. 
Thereafter cells were placed on ice and washed three times for 15 min with ice cold 
PBS containing 0.2% (w/v) BSA. Cells were lysed with 100 l reporter lysis buffer 
(Promega) and total binding was determined by liquid scintillation counting.  
 
In vitro DNA binding assay The DNA binding assay was performed essentially as 
previously described  (Ronacher et al., 2009) with minor modifications. COS-7 cells 
were transfected with WT or mutant GR constructs as described above, and 
incubated for 48 h. Cytosols were prepared from COS-7 cells overexpressing WT 
hGR or mutant GR by trypsinising and pelleting cells. The pellet was snap frozen at -
80˚C, and resuspended in TAPS buffer (0.1 M TAPS, pH9.5). Cells were incubated 
on ice for 1 h with vigorous vortexing every 10 min. Cellular debris was pelleted by 
centrifugation at 15 000 g for 10 min at 4˚C. The supernatant was aliquotted and 
stored at -80˚C. The GRE oligonucleotides (sense: biotin-GAT CCT GTA CAG GAA 
TGT TCT AGC TACA; Antisense: biotin-TGT AGC TAG AAC ATT CCT GTA CAG 
GATC) were annealed by mixing equimolar amounts, heating to 100˚C for 5 min and 
allowing to cool slowly overnight. The annealed biotinylated oligonucleotides were 
incubated with streptavidin coated agarose beads (E5529, Sigma Aldrich) for 2 h at 
4˚C to facilitate binding of oligonucleotides to beads. Cytosols containing liganded-
GR complexes were activated by heating at 20 C for 30 min, followed by overnight 
incubation with biotinylated DNA on streptavidin-agarose beads. Beads were then 
washed with 1 ml HEPES wash buffer (10 mM HEPES pH7.5, 1 mM EDTA, 10% 
(v/v) glycerol) and bound proteins were eluted in 30 µl 2 x SDS sample buffer. GR 
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levels were detected by Western blotting as described above, using an antibody 
towards GR (H300, Santa Cruz Biotechnology). 
 
Quantitative real time PCR COS-7 cells were plated in 6-well plates at a density of 
0.5 x 105 cells per well, and transfected with 2.5 µg per well of either empty vector 
(pcDNA 3.1), WT HAhGR, or K494/495Q HAhGR. After 24 h the medium was 
replaced with serum-free DMEM and after 2 h of serum starvation, 1 µM dex was 
added for a further 2 h. The cells were then washed with PBS, and RNA was 
extracted using Tri Reagent (Sigma-Aldrich) according to the manufacturer’s 
protocol. RNA (0.5 µg) was reverse transcribed with Oligo-dT priming, using the 
Transcriptor First Strand cDNA synthesis kit (Promega, Madison, WI), and an equal 
volume of each cDNA synthesis reaction (1 µl) was used as template for real time 
PCR, using the Sensimix dT Kit (Quantace). Quantitative PCR was carried out using 
QuantiTect primers (QT00091035, Qiagen) for Glucocorticoid-induced leucine zipper 
(GILZ). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a 
housekeeping gene for normalization (F: 5’ TGAACGGGAAGCTCACTGG 3’; R: 5’ 
TCCACCACCCTGTTGCTGTA 3’) (Ishibashi et al., 2003). Standard curves were 
used to determine the efficiency of each primer set, and the relative expression of 
GILZ in each sample was calculated according to the Pfaffl mathematical model 
(Pfaffl, 2001).  
 
Chromatin immunoprecipitation (ChIP) ChIP was performed as previously 
described (Ma et al., 2003) with some modifications. COS-7 cells were seeded at 1 x 
106 cells/ dish in 15 cm dishes and transfected with WT HAhGR or K494/495Q 
HAhGR. After 24 h each 15 cm dish was replated into two 10 cm dishes to ensure 
equal transfection efficiency between treatment conditions. Expression of WT 
HAhGR and K494/495Q HAhGR was compared by Western blotting as described 
above. Cells were serum starved for 2 h and treated for 2 h with 1 µM dex before 
being crosslinked with formaldehyde (1% final concentration) for 10 min at 37˚C. 
Crosslinking was stopped by addition of glycine (0.125 M final concentration) for 5 
min at room temperature. Cells were scraped in 3 ml PBS, centrifuged and 
resuspended in 300 µl nuclear lysis buffer (1% SDS, 50 mM Tris-HCl pH8, 10 mM 
EDTA, 1 mM PMSF, 2 µg/ml aprotinin, 5 µg/ml leupeptin). Cells were sonicated in a 
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bioruptor (Diagneode), (30 sec on, 30 sec off for 10 cycles) at 4˚C and debris was 
pelleted by centrifugation. Concentration of sonicated chromatin was measured on a 
nanodrop, and samples were diluted to an equal concentration with NLB before 
being aliquotted and stored at -80˚C. For input samples, 15 – 30 µg of chromatin 
were aliquotted. For immunoprecipitation equal amounts (50-100 µg) of DNA were 
diluted to 1 ml with IP dilution buffer (0.01% SDS, 20 mM Tris-HCl pH8, 1.1% Triton 
X 100, 167 mM NaCl, 1.2 mM EDTA, 1 mM PMSF, 2 µg/ml aprotinin, 5 µg/ml 
leupeptin). Protein A/G beads (sc-2003, Santa Cruz Biotechnology) were pre-
blocked by incubation with salmon sperm DNA (0.2 mg/ml) and bovine serum 
albumin (BSA) (1 mg/ml) for 1 h on a rotating wheel at 4˚C. The beads were 
resuspended in IP dilution buffer (0.01% SDS, 20 mM Tris-HCl pH8, 1.1% Triton X 
100, 167 mM NaCl, 1.2 mM EDTA, 1 mM PMSF, 2 µg/ml aprotinin, 5 µg/ml 
leupeptin) as a 50% slurry, and stored at 4˚C. The chromatin was precleared by 
incubation with preblocked protein A/G agarose beads (Santa Cruz Biotechnology) 
for 1 h. The supernatant was incubated with 2 µg of antibody overnight at 4˚C on a 
rotator. Exogenously expressed GR was immunoprecipitated using anti-HA (y-11) 
(Santa Cruz Biotechnology). Endogenous FKBP52 was immunoprecipitated using 
anti-FKBP52 (N-17) (Santa Cruz Biotechnology). Negative control 
immunoprecipitations were performed in parallel, using 2 µg anti-rabbit-HRP, or anti-
mouse-HRP (sc2313 or sc2005, respectively, Santa Cruz Biotechnology).  
 
The following day 40 µl of pre-blocked beads were added, and the mixture was 
incubated for 6 h. Beads were then washed sequentially with 1 ml each of wash 
buffer I (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-Cl pH8, 
and 150 mM NaCl), wash buffer II (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM 
EDTA, 20 mM Tris-Cl pH8, and 500 mM NaCl), and wash buffer III (1% (v/v) NP-40, 
1% (v/v) sodium deoxycholate, 500 mM LiCl, 1 mM EDTA, 10 mM Tris-Cl pH8), 
followed by three 1 ml washes with TE (10 mM Tris pH8, 0.1 mM EDTA). 
Immunoprecipitated complexes were eluted from beads in 300 µl elution buffer (1% 
SDS, 100 nM NaHCO3) for 30 min at room temperature. For input, 30 µl of chromatin 
solution was stored at -20˚C overnight, before addition of 90 µl elution buffer, and 
processing in parallel with immunoprecipitated samples. 
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NaCl was added to input and IP eluate to a final concentration of 300 mM, and 
eluates were incubated at 65˚C overnight to reverse crosslinks. Following proteinase 
K treatment, DNA was isolated using a QiaQuick PCR purification column (Qiagen). 
The purified DNA was subjected to quantitative real time PCR, using specific primers 
annealing to the promoter of the endogenous monkey GILZ gene, spanning the 
equivalent of GREs 3-6 of the human GILZ promoter (Chen, Rogatsky, & 
Garabedian, 2006) (GILZ F 5’-AGT TAA GCT CCT GAT TTA AGA AG-3’; GILZ R 5’-
CCC GAT CTC AGG ACA TTC-3’), and based on homology between the human, 
chimp and rhesus monkey GILZ promoter sequences (Avenant et al., 2010). Real 
time PCR on input and immunoprecipitated samples was performed using Sensimix 
dT Kit (Quantace). 
Statistical analysis Statistical analysis was performed using GraphPad Prism 
software, with tests as indicated in figure legends. When comparing several different 
treatment conditions, one way Anova was used, with a Dunnet’s or Tukey’s post test 
for comparison of all values to a control value, or comparison of all values to each 
other, respectively. For comparison of only two treatment conditions, a student’s t-







Endogenous hGR is acetylated in the absence and presence of ligand 
To investigate whether endogenous hGR is acetylated in the absence or presence of 
agonist, A549 cells were incubated in the absence or presence of 1 M dex and in 
the absence or presence of 1 ng/ml PMA. PMA was included to mimic a state of 
inflammation, and investigate whether this would modulate the GR response in any 
way. Endogenous GR was immunoprecipitated with an anti-GR antibody in the 
presence of the HDAC inhibitor TSA, followed by Western blotting and probing for 
GR and acetyl-lysine. The results show that GR was precipitated from the lysates in 
equal amounts irrespective of whether the cells were untreated or treated with dex. 
When the same blot was stripped and reprobed with an acetyl lysine antibody, a 
band with similar intensity that co-migrated with the GR was detected both in the 
absence and presence of dex (figure 3.1). This result suggests that the hGR is 
basally acetylated in a dex-independent manner. Similar results were obtained when 
the experiments were performed in the absence of PMA in A549 cells and in U2OS 
cells (data not shown). No signal was detected when immunoprecipitation was 
performed using a non-specific antibody (data not shown). These results show that 
endogenous hGR is basally acetylated in A549 and U2OS cells, in the absence and 
presence of PMA, and that addition of dex does not change the GR acetylation 







Figure 3.1. Endogenous GR is acetylated in the absence and presence of 
ligand. A549 cells were treated with PMA or vehicle (-PMA) for 24 h followed 
by 1 h treatment with 100 nM dex or vehicle (EtOH). GR was 
immunoprecipitated in the presence of 10 µM TSA, and immunoprecipitated 
proteins were analysed by Western blot, probing for acetyl lysine and then GR.  
 
Mutation of K494/495 to abrogate or mimic acetylation affects transactivation 
efficacy, suggesting that acetylation of K494/495 is required for hGR-mediated 
transactivation of a GRE 
In order to investigate the effect of GR acetylation at K494/495 on transactivation, 
two GR mutants were exploited. The K494/495 to A (K494/495A hGR) mutant 
cannot be acetylated because it does not have an amide side chain, which is 
required for transfer of the acetyl group from acetyl CoA. The K494/495Q HAhGR 
mutant contains glutamine substitutions that mimic the charge and size of an acetyl 
lysine group. The transactivation activity of these mutants was tested using a cell-
based reporter gene assay. Briefly, COS-7 cells were transfected with expression 
vectors for WT hGR, K494/495A hGR, WT HAhGR and K494/495Q HAhGR, and a 
luciferase reporter construct containing the minimal tyrosine amino transferase (TAT) 
promoter, which contains two GREs. After 24 h of stimulation with 100 nM dex, 
whole cell lysates were prepared and luciferase activity was determined (figure 3.2A 
and B). As expected, WT hGR efficiently transactivated the reporter gene in a ligand-
dependant manner (figure 3.2A and C). However, the hGR K494/495A mutant failed 
to transactivate the reporter gene above untransfected levels in the absence or 
presence of dex (figure 3.2A). Interestingly the K494/495Q HAhGR mutant, which 
mimics acetylated GR, resulted in a 2-fold increase in reporter gene activity relative 
to WT HAhGR (figure 3.2C). These differences could not be explained by different 
expression levels, since similar levels of GR were expressed with the different 





Figure 3.2. The K494/495A GR mutant exhibits no transactivation efficacy 
while the K494/495Q GR mutant exhibits increased dex-induced 
transactivation. COS-7 cells were transfected in 10 cm dishes with WT hGR 
and K494/495A hGR (A) or WT HAhGR and K494/495Q HAhGR (B), as well as 
a GRE-luciferase reporter plasmid. Cells were subsequently replated into 24 
well plates. Cells were then treated for 24 h with 1 µM dex or vehicle control 
(EtOH). Luciferase activity was measured and normalised to total protein in 
each well as determined by a standard Bradford assay. Graph shows pooled 
results of three (A) or two* (B) independent experiments, each performed in 
triplicate analysed by one way Anova with Tukey’s multiple comparison test. (C) 
and (D) show pooled relative expression levels of each construct, measured by 
Western blotting, for each of the experiments relative to GAPDH (C) or β-
tubulin (D) with WT GR being set as 100% in each case. (E) and (F) show 
representative Western blots of expression levels of each construct. 
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*One of these independent experiments was performed by Dr M. Tomasicchio. 
 
Mutation of K494/495 to alanine almost abolishes, while mutation to glutamine 
reduces GR ligand-dependant nuclear translocation  
The lack of transactivational ability displayed by the K494/495A hGR mutant 
compared to WT hGR could be a result of decreased nuclear translocation ability. 
Similarly, the significant increase in transactivation observed for the GR acetylation 
mimic, K494/495Q HAhGR, versus WT HAhGR may be a result of increased nuclear 
translocation. To test this hypothesis COS-7 cells were transfected and incubated 
with 1 µM dex for 1 h. On microscopic examination of fluorescently stained GR, while 
WT hGR translocated to the nucleus upon dex treatment, the K494/495A hGR 
mutant remained localised in the cytoplasm (Fig 3.3A). The even distribution of 
hGRwt and mutant GR in the cells indicates that the expressed proteins are not 
targeted to the proteasomes for degradation, suggesting they are correctly folded, 
and the mutation does not create a null mutant.  
 
The K494/495Q HAhGR mutant did exhibit dex-dependent nuclear translocation, but 
to a lesser extent than WT HAhGR (Fig 3.3B). K494/495Q HAhGR showed a strong 
fluorescent signal in the cell cytoplasm, even after dex treatment. In order to 
investigate whether the reduced nuclear translocation by both mutants was time-
dependent (i.e. slower kinetics of nuclear import relative to WT GR), GR localisation 
was also examined after 16 h of dex treatment. The results looked similar to the 1 h 
treated cells (Appendix C, figure C.1); indicating that the difference between WT and 
mutant GRs was not simply due to slower nuclear import. These results were 
confirmed by subcellular fractionation by another member of the Hapgood laboratory 
(data not shown). Taken together the biochemical fractionation and 
immunofluorescence results show that the K494/495A hGR mutant is unable to enter 
the nucleus, consistent with a loss of transactivation efficacy. However K494/495Q 
HAhGR, while still able to enter the nucleus, exhibited less nuclear translocation than 
WT HAhGR. Thus the increase in transactivation by K494/495Q HAhGR acetylation 












Figure 3.3. K494/495A hGR and K494/495Q HAhGR exhibit less nuclear 
translocation than WT GR, but the same even distribution. COS-7 cells 
were transfected in 10 cm dishes with WT hGR and K494/495A hGR (A) or WT 
HAhGR and K494/495Q HAhGR (B) constructs. Cells were replated onto 
coverslips, and 24 h later, treated for 1 h with 1 µM dex or vehicle (EtOH), 
before being fixed with methanol and immunostained for GR. Results shown 
are representative of at least 100 cells per condition from three (A) or two (B) 
independent experiments.  
 
The uniform distribution of the WT and mutant GR in the cells, and the absence of 
GR protein aggregates, indicates that the protein expressed in each case is not 
targeted to the proteasome for degradation, suggesting it is correctly folded, and that 
the mutation does not create a null mutant. Even the presence of dex does not 
induce a speckling pattern indicative of proteasomal degradation or misfolding 
(Thomas et al., 2004).  
 
Mutation of K494/495 to alanine abolishes, while mutation to glutamine 
reduces hGR ligand-dependant phosphorylation at Serines 211 and 226. 
GR phosphorylation at serines 211 (S211) and 226 (S226) is a well-established 
marker of GR activation by ligand (reviewed in Weigel & Moore, 2007). To determine 
the ligand-dependent phosphorylation of these two serine residues in WT and 
mutant GR molecules, GR phospho-serine specific antibodies were used. As 
expected, both WT GR constructs showed a statistically significant increase in 
phosphorylation at S211 and S226 upon dex treatment (figure 3.4). However, 
phosphorylation of K494/495A hGR was completely abolished at both S211 (figure 
3.4A and B) and S226 (figure 3.4C and D). Even the relatively low levels of 
phosphorylated S211 observed in the absence of ligand was lost in the K494/495A 
hGR mutant (figure 3.4A, lane 1 vs. lane 3). Experiments in the absence of 
expressed GR showed that phosphorylation of K494/495A hGR was not above 
background levels of endogenous GR (data not shown). Although not statistically 
significant, a small, reproducible dex-dependent increase in S211 (figure 3.4E and F) 








Figure 3.4. Mutation of K494/495 to alanine abolishes, while mutation 
to glutamine decreases phosphorylation of hGR at S211 and S226. 
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COS-7 cells were transfected with WT hGR and K494/495A hGR (A-D) or 
WT HAhGR and K494/495Q HAhGR (E-H) constructs in a 10cm dish 
before being replated into 12 well plates. Cells were treated for 1 h with 
vehicle (EtOH) or 100 nM dex before being lysed and analysed by 
Western blot for GR phospho-S211 (A, B, E, F) or GR phospho-S226 (C, 
D, G, H) and total GR. Representative Western blots are shown (A, C, E, 
G). Bands on phospho- and total GR Western blots were quantified using 
Alphaease software, normalised to total GR levels, and plotted relative to 
WT hGR EtOH. Results from three independent experiments were pooled 
and analysed by one way Anova, repeated measures, with Tukey’s post-
test (B, D, E, H). 
 
Mutation of K494/495 to alanine abolishes, while mutation to glutamine 
increases, ligand binding of the GR 
The observations that K494/495A hGR neither became phosphorylated nor moved to 
the nucleus, caused uncertainty as to whether this mutant was capable of binding 
ligand. Thus, it was decided to compare the ligand binding capacity of both the GR 
mutants to WT GR, using a competitive whole cell binding assay with tritiated dex. 
 
Competitive binding assays in COS-7 cells showed that K494/495A hGR bound 
significantly less dex than the corresponding WT construct. In fact, the ligand binding 
capacity of this mutant GR was barely above background (figure 3.5A). Conversely, 
K494/495Q HAhGR consistently bound slightly more dex than the WT HAhGR 
construct (although not statistically significantly different from WT HAhGR) (figure 
3.5B). In order to ensure that observed differences in GR ligand binding capacity 
were not due to differences in GR expression levels, GR expression was quantified 
in parallel by Western blot for each experimental repeat, and the average expression 
of three independent experiments shows little variation between WT and mutant GR 
constructs (figure 3.5C and D). However, transfection of a WT GR construct resulted 
in significantly higher expression of GR than in untransfected cells. These results 
strongly suggest that the acetylation status of GR K494/495 determines its ligand-







Figure 3.5. Mutation of K494/495 to alanine abolishes, while mutation to 
glutamine increases the ligand binding capacity of the GR. COS-7 cells 
were plated in 10 cm dishes and transfected with WT hGR and K494/495A 
hGR (A) or WT HAhGR and K494/495Q HAhGR (B), before being replated in 
24 well plates. 24 h later, cells were incubated for 90 min with 10 nM [3H]-dex, 
in the absence (total binding) or presence of 10 µM unlabelled dex (non-
specific binding) before being washed and lysed. Specific binding (total binding 
minus non-specific binding) normalised to the total protein per well as 
measured by a standard Bradford assay, is shown. Pooled results of four (A) or 
three (B) experiments performed in triplicate are shown, analysed by one-way 
Anova, with a Tukey’s post-test comparison. (C) and (D) For each experimental 
repeat, expression of each GR construct was compared to untransfected (UT) 
COS-7 cells by Western blot, quantified, and plotted in histograms.  
 
Mutation of K494/495 to alanine results in a decrease, while mutation to 
glutamine does not affect DNA-binding in vitro 
Since K494/495 are in the DNA binding domain of the GR, and mutation of lysines in 
the ERα DBD has been reported to affect DNA binding (Kim et al., 2006), the effect 
of mutation of these residues on the DNA binding capacity of the GR was 
investigated. Having previously shown that mutation of these residues causes 
differences in ligand binding (figure 3.5) and nuclear import (figure 3.4), an in vitro 
DNA binding assay was employed. Since this assay requires neither ligand binding 
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nor nuclear translocation (as it is performed on whole cell lysates) (Cho et al., 2005) 
differences in ligand binding or nuclear translocation between WT and mutant GR 
would not obscure differences in DNA binding, as measured by this assay.  
 
As shown in figure 3.6A, WT hGR bound the GRE sequence in the absence and 
presence of dex, and only background levels of WT hGR bound the beads in the 
absence of GRE oligonucleotides. The fact that there is no dex-dependent increase 
in GRE binding is expected, since in this assay, GR is activated by heat-shock, 
which is independent of ligand (Cho et al., 2005). K494/495A hGR does not give a 
signal above background in the presence of GRE oligonucleotides, indicating that 
this mutant has reduced DNA binding capacity compared to WT hGR (figure 3.6A, 
C), over and above its ligand binding and nuclear import deficiencies. Since the 
K494/495Q HAhGR mutant elicited higher maximal transactivation than WT HAhGR, 
one might expect it to exhibit more efficient DNA binding than WT HAhGR. However 
the results of the in vitro DNA binding assay revealed this is not the case (figure 
3.6B, D). This could indicate that mutation to Q does not affect DNA binding by GR, 
or could indicate the limitations of the assay setup, such as possible limiting 




Figure 3.6. Mutation of K494/495 to alanine results in a decrease, while 
mutation to glutamine does not affect DNA-binding in vitro. Whole cell 
lysates of COS-7 cells overexpressing WT hGR or K494/495A hGR (A, C) or 
WT HAhGR or K494/495Q HAhGR (B, D) were treated with 10 µM dex or 
vehicle, heat activated, and incubated with agarose beads coated with DNA 
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oligonucleotides encoding the GRE sequence, or uncoated beads (Neg). The 
beads were subsequently washed and bound proteins were analysed by 
Western blot. Representative Western blots of four (A) or two (B) experiments 
are shown. The relative intensities of WT and mutant GR bands were quantified 
and pooled histograms of four (C) or two (D) experiments are shown, analysed 
by one way Anova with Dunnett’s post test relative to WT EtOH. 
 
WT HAhGR and K494/495Q HAhGR mutant both upregulate the endogenous 
GILZ gene, but an increase in GR recruitment to the GILZ promoter is only 
apparent for WT HAhGR  
The results thus far are consistent with a role for GR acetylation in ligand binding. 
However the mechanism of increased transactivation activity of the glutamine 
acetylation mimic is still unclear, although it could be partly due to increased ligand 
binding. Towards gaining further insight into this mechanism, it was decided to 
pursue a ChIP approach in intact cells, on an endogenous promoter. Before 
examining the recruitment of GR to the endogenous GILZ promoter in COS-7 cells, it 
was necessary to confirm that this gene is indeed regulated by GR in these cells. 
Real time PCR confirmed that GILZ expression increased in the presence of dex, 
and that this effect was greater in the presence of overexpressed WT HAhGR or 
K494/495Q HAhGR than in cells transfected with empty vector (figure 3.7A).  
 
ChIP analysis of the GILZ promoter showed a reproducible 2 fold increase in 
promoter occupancy by WT HAhGR in response to dex treatment. However, no dex-
dependent increase in K494/495Q HAhGR was observed (figure 3.7B). Western 
blotting confirmed the expression levels of WT and K494/495Q HAhGR were similar 
for the real time and ChIP experiments (figure 3.6 C and D). The apparent lack of 
recruitment of GR to the GILZ promoter was perplexing and given the observed dex-
dependent upregulation of the gene in the presence of exogenous K494/495Q 
HAhGR indicating that this mutant must be active on the GILZ promoter to a similar 
extent as WT HAhGR, although it was not detectable by the ChIP technique. This 
was not due to different GR expression levels (figure 3.7C and D), nor enhanced 
receptor degradation of K494/495Q HAhGR in the presence of dex, since Western 
blot confirmed that K494/495Q HAhGR levels were the same as, or slightly higher 
than, WT HAhGR levels after 24 h dex treatment (Dr Tomasicchio, data not shown). 
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Furthermore, in vitro DNA binding assays indicated that K494/495Q HAhGR was 
capable of efficient binding to a minimal GRE sequence (figure 3.6B and D). 
Therefore, the data suggest that a different complex may be formed by K494/495Q 
HAhGR at the promoter, preventing access of the antibody to the DNA-bound GR. 
This phenomenon has previously been reported for the ERα, the presence of which 






Figure 3.7. WT HAhGR and K494/495Q HAhGR mutant regulate the 
endogenous GILZ gene, but an increase in GR recruitment to the GILZ 
promoter is only apparent for WT hGR (A) COS-7 cells were transfected with 
WT HAhGR or K494/495Q HAhGR, and treated for 2 h with 1 µM dex or 
vehicle. After treatment, RNA was extracted, reverse transcribed, and 
endogenous GILZ expression was measured by real-time PCR, normalising to 
GAPDH expression levels. Pooled results from three independent experiments 
are plotted, and analysed by one-way Anova with Dunnet’s post-test relative to 
WT HAhGR EtOH (B) COS-7 cells transfected with WT or K494/495Q HAhGR, 
were treated for 1 h with 1 µM dex or vehicle (EtOH). ChIP was carried out 
using an anti-HA antibody to immunoprecipitate exogenous GR, and primers 
specific for the endogenous GILZ promoter for PCR amplification. Negative 
refers to immunoprecipitation with non-specific IgG. Pooled results of three anti-
HA immunoprecipitations or four negative control immunoprecipitations are 
shown. Statistical significance is determined by a paired t-test. Prior to ligand 
treatment, GR expression was analysed by Western blot for each experiment, 
quantified and plotted relative to WT HAhGR for real time expression analysis 
(C) or ChIP (D). 
 
FKBP52 is dex-dependently recruited to the GILZ promoter in the presence of 
the hGR K494/495Q mutant 
Given multiple lines of evidence implicating FKBP52 as a direct interaction partner 
for the GR DNA binding domain (Silverstein et al., 1999), and as playing a role in 
GR-mediated transcription of the GILZ gene (Wolf et al., 2009), it was decided to 
investigate recruitment of FKBP52 to the GILZ promoter. ChIP was used to 
determine whether FKBP52 was dex-dependently recruited to the GRE-rich region of 
the endogenous GILZ promoter. A small, non-significant increase in FKBP52 was 
observed in the presence of WT HAhGR (Fig 3.8). However, in the presence of 
overexpressed acetylation mimic, K494/495Q HAhGR, a significant increase in 
FKBP52 recruitment (p<0.05) was observed upon dex treatment (Fig 3.8). This 
increase in FKBP52 at the promoter may be responsible for the apparent lack of 
increase in the K494/495Q HAhGR mutant levels on the GILZ promoter, by forming 
a complex with GR that blocks access of the anti-HA antibody to the HA-tagged 
K494/495Q HAhGR mutant. The increased recruitment of FKBP52 by the glutamine 
mutant as compared to WT HAhGR could be due to an increase in the % of GR in 
the “acetylated” form for the mutant as compared to WT HAhGR. These results 
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suggest that GR acetylation at K494 and/or K495 recruits FKBP52 which acts as a 






Figure 3.8. Endogenous FKBP52 is dex-dependently recruited to the GILZ 
promoter in COS-7 cells overexpressing the K494/495Q HAhGR mutant. 
COS-7 cells transfected with WT or K494/495Q HAhGR, were treated for 1 h 
with 1 µM dex or vehicle. ChIP was carried out using an anti-FKBP52 antibody 
to immunoprecipitate endogenous FKBP52, and primers specific for the 
endogenous GILZ promoter were used for PCR amplification. Negative refers 
to immunoprecipitation with non-specific IgG. Pooled results of three anti-
FKBP52 immunoprecipitations, or four negative control immunoprecipitations 
are shown. Statistical analysis performed was a paired t-test. 
 
Determination of levels of association between FKBP52 and WT GR was attempted 
using a co-immunoprecipitation approach, but unfortunately this approach was not 
successful, as shown in Appendix E (figure E.3.2). This experimental technique 






Several studies suggest a functional role of lysine acetylation for the AR, ER and 
GR, while acetylation has not been reported for the MR or PR (Faus & Haendler, 
2006). These studies collectively suggest a role for steroid receptor acetylation at 
one or more steps in the receptor pathway, including nuclear translocation, DNA-
binding and transactivation efficacy, although many issues remain unclear. The 
present study investigated the functional consequences of GR acetylation in COS-7 
cells using two expressed GR mutants as compared to WT hGR. Results with the 
acetylation deficient K494/495A hGR mutant, showed a loss of transactivation on a 
synthetic GRE (figure 3.2A) and also for the first time, a loss of nuclear translocation 
(figure 3.3A), and a loss of ligand-dependent phosphorylation at S211 and S226 
(figure 3.4A-D). These results are all consistent with the novel finding that this 
mutant does not bind ligand (figure 3.5A). Results of the in vitro DNA binding assay 
strongly suggest the K494/495A hGR also displays reduced DNA binding capacity 
compared to WT hGR (figure 3.6A). However, it is possible that the mutation affects 
the ability of the GR to respond to heat shock. Therefore, more experimentation 
would be required to conclusively show reduced DNA binding ability. However, since 
this mutant neither binds ligand, nor translocates to the nucleus, the in vitro assay 
was a useful strategy to examine DNA binding in the absence of these confounding 
factors.  
 
Results with the K494/495Q HAhGR acetylation mimic mutant strongly support the 
argument that acetylation of the GR at these residues is important for ligand binding 
and resulting downstream actions of the GR. It is further demonstrated that this 
mutant has an enhanced transactivation efficacy via a synthetic GRE reporter gene 
(figure 3.2B) and an endogenous gene (figure 3.7A) and exhibits increased ligand-
binding, as compared to WT HAhGR (figure 3.5B). However it displays reduced 
nuclear translocation (figure 3.3B) and phosphorylation at S211 and S226 (figure 3.4 
E - H), as compared to WT HAhGR.  
 
It is well-established that acetylation occurs within the DBD of the AR, ER and GR. 
However whether this occurs in a ligand-dependent manner appears to be 
76 
 
controversial. Although a dex-dependent increase in GR acetylation was not 
observed in A549 cells (figure 3.1), the results suggest that the endogenous hGR is 
basally acetylated. The A549 result differs from a previous report that the hGR is 
acetylated in a ligand-dependent manner in the presence of both dex and IL-1  in 
A549 cells (Ito et al., 2006). A possible reason for this difference could be that the 
latter experiments were conducted in the presence of IL1-β, presumably to mimic a 
state of chronic inflammation, and allow investigation of transrepression by the GR. 
While no increase in GR acetylation was observed in A549 cells in the presence of 
dex plus a similar pro-inflammatory compound, PMA, (figure 3.1) it is possible that 
the ligand-dependent increase in acetylation observed by Ito et al. was dependent on 
the presence of IL1β. Results in the absence of IL1β, in HCT116 cells with 
overexpressed hGR indicate that no GR acetylation was detectable in the absence 
of overexpressed circadian rhythm controlling proteins CLOCK (a HAT) and BMAL1 
(Nader et al., 2009). However, in the presence of overexpressed CLOCK and 
BMAL1, GR became dex-dependently acetylated at several lysine residues in the 
hinge region, including K494 and K495 (Nader et al., 2009). Interestingly, acute 
systemic inflammation has been shown to increase expression of the Bmal1 gene in 
vivo (Murphy et al., 2007). Furthermore, in experiments performed to demonstrate 
ligand-dependent acetylation of GR at K494/495 of the conserved KXKK motif, 
preincubation of cells with the HDAC inhibitor TSA was employed, prior to treatment 
with dex (K. Ito, personal communication). This may increase the apparent ligand-
dependent acetylation of the GR. However, the physiological relevance of this 
approach is yet to be established. Variation in experimental conditions and biological 
responses may make it difficult to establish whether ligand-dependent acetylation is 
a general feature for steroid receptors under physiological conditions. Factors could 
include a dynamic equilibrium between acetylated and unacetylated forms, critically 
dependent on the relative concentrations of acetylases and deacetylases, which is 
dependent on the cell type and physiological state. In addition, only a small 
percentage of the receptors may become acetylated in a ligand-dependent manner 
(Kim et al., 2006) and there may be cell-specific and receptor-specific differences in 
the role and mechanisms of acetylation. Moreover, localizing acetylation residues 
may be challenging by immunoprecipitation techniques since ligand-dependent 
increases in acetylation of particular residues may be masked by the steady level of 
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acetylation of other lysine residues. Nevertheless the results presented here show 
that endogenous GR is basally acetylated in U2OS and A549 cells, in the absence 
and presence of PMA, and there is no detectable change in overall GR acetylation 
upon ligand stimulation under these conditions. This result does not, however, 
exclude the possibility that under physiological conditions GR acetylation levels are 
modulated at particular lysine residues in response to ligand. 
 
For the AR, early reports indicated that lysine acetylation was ligand independent 
(Fu et al., 2000; Gaughan et al., 2002), however later reports hinted at ligand 
dependent acetylation of the same residues (Fu et al., 2003; Fu et al., 2006). A 
shortcoming of these later papers is that they do not include loading controls, making 
the results inconclusive, since DHT is known to increase total AR levels (Grad et al., 
1999). Fu et al., (2003) comment on the possibility that the observed increase in AR 
acetylation following DHT treatment is simply a result of increased AR levels. 
Interestingly they also found that TSA treatment in the absence of AR ligand was 
sufficient to cause an increase in AR acetylation, suggesting that ligand is not 
necessary for acetylation of these residues. In a later report, Fu et al., (2006) once 
again report inconclusive findings, showing an increase in AR Ac-K after 24 h 
treatment with DHT, but failing to show input levels of total AR. Thus, although there 
is currently no consensus on this issue, available data seem to point towards ligand 
independent acetylation of the AR at the conserved KXKK motif. So, while the effect 
of SR ligand binding on acetylation requires further investigation, it is important to 
note that at least some basal acetylation has been reported at the conserved lysines 
at K494/495 of the GR DBD (Ito et al., 2006; Nader et al., 2009), or equivalent 
positions for AR (Fu et al., 2000). The effect of acetylation of these residues on GR 
activity was therefore investigated.  
 
This report is the first to directly investigate the effect of GR receptor acetylation on 
ligand binding. Results showing a loss of ligand binding with K494/495A hGR mutant 
and an increase in ligand binding with the K494/495Q HAhGR mutant strongly 
support a requirement for acetylation at these residues for ligand-binding by the 
hGR. These results would at first appear to be inconsistent with the finding by Ito et 
al. (2006), that the same K494/495A hGR mutant is dex-responsive for 
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transrepression in the presence of IL1β. However several results are consistent, with 
the report by Ito et al. (2006), who also found that K494/495A hGR did not give a 
response above background for transactivation of an endogenous gene. The 
observed effect of the alanine mutant by Ito et al. (2006) on transrepression and 
ligand-dependent p65 interaction, would suggest that sufficient ligand-binding does 
occur for nuclear translocation and transrepression. One possible explanation for 
these results is that the alanine mutant exhibits very low affinity for ligand binding, 
sufficient at high receptor concentrations to facilitate some nuclear translocation and 
transrepression. Since agonist-activated GR has about a tenfold higher potency for 
transrepression than for transactivation (Ronacher et al., 2009), it is possible that 
such a low affinity could result in a measurable response for transrepression of some 
genes, but not transactivation. An alternative explanation is one of ligand-
independent activation. Results from the Hapgood laboratory have recently shown 
that endogenous GR can be activated in a ligand-independent manner via a G-
protein coupled receptor (Kotitschke et al., 2009). Thus it is possible that the alanine 
mutant undergoes ligand-independent activation via the IL1β receptor since the 
experiments were performed in the presence of dex and IL1β (Ito et al., 2006). Yet 
another possible explanation is that the observed interaction between K494/495A 
hGR and p65 occurs in the cytoplasm, and the reduced transactivation is thus a 
result of cytoplasmic sequestration of the p65. Since p65 has also been shown to be 
acetylated (Furia et al., 2002), it is also possible that pretreatment with HDAC 
inhibitors could modify the acetylation status of p65, thereby confounding the results.  
 
While there are some discrepancies, several of the findings presented here concur 
with aspects of a recent study on GR acetylation by Nader et al., (2009). Nader and 
co-workers found that a K494/495A hGR mutant exhibited slightly reduced 
transactivation compared to WT hGR. This drop in transactivation would be 
consistent with reduced ligand binding by the alanine mutant, although the authors 
did not investigate ligand binding. Furthermore, ChIP analysis of the GILZ promoter 
in HeLa cells under conditions which favour GR acetylation at K494/495 indicated no 
apparent increase in GR recruitment, similar to what was observed in COS-7 cells 
with K494/495Q HAhGR in this study (figure 3.7B). Unfortunately, the authors did not 
investigate expression of the GILZ gene under these conditions, so it is unclear 
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whether this apparent lack of GR recruitment correlated with reduced GILZ 
expression. Taken together, results by Nader and co-workers (2009) lead the 
authors to conclude that GR acetylation reduced DNA binding and transcriptional 
activity of the GR, which is inconsistent with their results showing decreased 
transactivation with the alanine mutant compared to WT GR, and is also not in 
agreement with results presented here. Differences in the experimental strategy (vis. 
overexpression of HAT proteins versus use of site-specific mutants in different cell 
lines) may be responsible for this apparent discrepancy. 
 
AR acetylation mutants have been widely used, and the results from different groups 
do not always concur. For instance, Fu et al., (2002) generated a K632/633A mutant 
of the AR, and showed that this mutant exhibited greatly reduced transactivation 
compared to WT AR in DU145 cells. Thomas et al., (Thomas et al., 2004) showed 
that in HeLa cells this mutant responded to ligand by misfolding and forming 
subcellular aggregates. The K632/633A mutant AR has also been shown to exhibit a 
decrease in ligand-dependent phosphorylation compared to WT AR (Fu et al., 2004) 
and differential cofactor recruitment compared to WT AR, while the AR conformation, 
sumoylation and DNA binding capacity reportedly remained unchanged (Fu et al., 
2002). Cutress and co-workers (2008) generated a triple lysine mutant, 
K630/632/633A AR, and found that ligand responsiveness (transactivation and 
nuclear translocation) was completely ablated in COS-7 cells, which would be 
consistent with results presented here on the ligand binding capacity of the 
corresponding hGR mutant K494/495A hGR (figure 3.5A). Shiota et al (2009) 
generated a triple arginine mutant AR (K630/632/633R), and also found that it was 
unresponsive to ligand for nuclear translocation in PC-3 cells. Although this mutant is 
reported to transactivate a reporter plasmid in both PC-3 cells and LNCaP cells, to a 
lesser extent than WT cells, no indication of background transactivation in the 
absence of overexpressed AR is given. Thus it is not clear whether this mutant can 
cause transactivation above background levels. 
 
Shiota et al (2009) also used a triple glutamine AR mutant (K630/632/633Q AR) to 
mimic acetylation at all three conserved lysines. This mutant exhibited largely the 
same subcellular localisation as WT AR. While it did not exhibit greater ligand-
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dependent transactivation than WT, K630/632/633Q AR demonstrated higher 
transactivation than WT AR in the absence of ligand in both PC-3 and LNCaP cells. 
This could indicate greater sensitivity of the acetylation mimic AR to low levels of 
androgens present in the growth medium, which would be consistent with results 
presented here that an acetylation mimic HAhGR construct binds ligand more 
efficiently that WT HAhGR. Indeed, while direct ligand binding has not been 
investigated, mutation of K630 to Q has been shown to increase hormone sensitivity 
of the AR, while also increasing transactivation activity, and cell proliferation (Fu et 
al., 2003).  
 
A recent study by Faus and Haendler (Faus & Haendler, 2008) highlighted the 
specificity of acetylation at different sites in the AR KXKK motif. Single, double and 
triple K→A mutations all had different effects on transcriptional efficacy of the AR 
response. Furthermore, this effect was promoter-specific, and thus independent of 
the effect of each mutation on ligand binding and nuclear import. This could certainly 
explain some of the discrepancies identified in the literature, and suggests that 
steroid receptor acetylation is a precisely regulated process with promoter-specific, 
and possibly also cell type-specific effects. While many parallels can be drawn 
between the AR and GR in terms of the highly conserved KXKK motif, residues 
around this motif are not conserved between AR and GR (Kim et al., 2006). 
Therefore it is not clear whether this hypothetical interaction site for FKBP52 on the 
GR would function similarly in the AR. A putative site for a direct interaction between 
FKBP52 and the surface region of the AR hormone binding domain has recently 
been identified, and small molecule inhibitors of this interaction are currently under 
development (Meneses De Leon et al., 2009). The development of specific 
modulators of SR:FKBP52 interactions could have important pharmacological 
applications. 
 
Determination of levels of association between FKBP52 and WT GR was attempted 
using a co-immunoprecipitation approach, but unfortunately this approach was not 
successful. The conditions required for co-immunoprecipitation of immunophilins with 
the GR-Hsp complex are extremely mild, as this interaction is quite labile (Davies et 
al., 2002; Echeverría et al., 2009). However, in the present author’s hands, only very 
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weak association was detected, and no ligand-dependent change in levels of co-
immunoprecipitated FKBP52 were observed using two previously published methods 
in A549 cells (Appendix E, figure E.3.2). Failure to observe the expected swap of 
FKBP51 for FKBP52 upon ligand binding, which was a positive control for the assay, 
indicated that the co-immunoprecipitation assay was not working, and thus 
differences between WT and mutant GR could unfortunately not be examined. These 
results do not exclude an involvement of a GR: FKBP52 interaction that is sensitive 
to GR acetylation levels in modulating ligand binding, since ligand-dependent 
acetylation was also not observed in the A549 model system (figure 3.1), despite 
having been shown in A549 cells under similar conditions (Ito et al., 2006). Thus, 
although experimental error could account for the failure to observe ligand-
dependent GR acetylation and immunophilin exchange, both of which have been 
reported in A549 cells (Ito et al., 2006; Croxtall et al., 2003), an alternative 
explanation may be an unknown difference in the experimental system used here, 
compared to those of previous studies. 
 
Failure to observe changes in levels of GR-associated FKBP52 was not due to 
changes in total FKBP52 levels. Although FKBP52 expression has not been shown 
to be regulated by steroid receptors FKBP51 expression has been shown to be 
regulated by the PR (Hubler et al., 2003) and by GCs (Baughman et al., 1997). Since 
the levels of FKBP52 recruited to the GRE-containing region of the GILZ promoter 
differed between WT and mutant hGR, experiments were conducted to assess 
whether the WT and mutant GR differentially regulated FKBP52 expression, but after 
1 h dex treatment (time point at which ChIP was performed), there was no difference 
in FKBP52 levels (Appendix C, figure C.3). However, since FKBP52 activity is known 
to be modulated by casein kinase II phosphorylation (Miyata et al., 1997), the 
possibility that FKBP52 activity may be differentially modulated by phosphorylation 
cannot be excluded here.  
 
Another interesting line of research would be to determine the effects of K494/495Q 
HAhGR on transrepression. Although Ito et al., (2006) suggested GR has to be 
deacetylated at these sites in order to interact with p65 and transrepress gene 
expression at NFκB containing promoters, they failed to demonstrate this using the 
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K494/495Q mutant. They did however show that the acetylation deficient GR 
mutants (K494/495A and K494/495N) behaved similarly to WT hGR in a p65 
immunoprecipitation assay in the presence of IL1β, but differently to WT hGR in the 
presence of TSA. It is possible that if acetylation status governs FKBP52 association 
with the GR heterocomplex, this could also affect transrepression in a gene specific 
manner.  
 
In this report, promoter-reporter assays indicated that K494/495Q HAhGR caused a 
three times greater transcriptional response than WT HAhGR (figure 3.2B), while 
transcription of the endogenous GILZ gene was activated to a similar extent by both 
WT HAhGR and K494/495Q HAhGR (figure 3.7A). This discrepancy is most likely 
due to the differences in experimental protocols followed for each assay. Since a 
reporter assay requires translation of a transcript, a longer time is needed before the 
transcriptional response is measured than an assay in which mRNA levels are 
measured. The luciferase reporter assay was incubated for 24 h before activity was 
measured, while mRNA levels of GILZ were measured after just 2 h of incubation 
with dex. Thus, it is possible that the transactivation by K494/495Q HAhGR is more 
sustained than WT HAhGR, but that this is not evident after a short incubation. This 
possibility could be further investigated by performing a time course analysis of 
reporter activity elicited by WT and K494/495Q HAhGR. 
 
It was noteworthy that the K494/495Q HAhGR mutant gives a remarkably strong 
transcriptional response, despite its reduced nuclear import compared to WT 
HAhGR. This suggests that the transcriptional activation per molecule of nuclear GR 
is much greater for the K494/495Q HAhGR mutant than for WT HAhGR. It was thus 
postulated that the complex formed by the K494/495Q HAhGR mutant on the 
promoter could differ from that formed by WT HAhGR. 
 
ChIP results of the endogenous GILZ promoter are consistent with this theory, since 
no increase in K494/495Q HAhGR recruitment was observed upon dex treatment 
(figure 3.7B), although gene transcription was increased (figure 3.7A). This indicates 
that whatever complex of proteins and coregulators was recruited to the GILZ 
promoter was able to block access of the immunoprecipitation antibody to its antigen 
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on the mutant, but not the WT HAhGR. It was subsequently found that FKBP52 is 
recruited to the GILZ promoter upon dex treatment, but this was only significant in 
the presence of the K494/495Q HAhGR mutant (figure 3.8). Since FKBP52 has been 
shown to be required for the maximal dex response on the GILZ gene by WT hGR 
(Wolf et al., 2009), it is likely that the presence of FKBP52 with WT HAhGR on the 
promoter may be masked by recruitment of other cofactors such as GRIP1, which 
has been shown to be recruited to this promoter by WT HAhGR (Avenant et al., 
2009). It would be interesting to examine the relative recruitment of other cofactors, 
such as p160s and p300, by WT versus K494/495Q HAhGR.  
 
The data generated in this study, together with available literature, support a model 
in which acetylation of K494/495 mediates the interaction of GR with FKBP52, which 
increases the efficiency of ligand binding by the GR, so that for K494/495A hGR 
mutant, ligand binding is impaired due to a weaker interaction with FKBP52, resulting 
in a loss of GR nuclear translocation, phosphorylation and transactivation. 
Conversely, according to such a model, the acetylation mimic K494/495Q HAhGR 
would be expected to exhibit a strong interaction with FKBP52, resulting in the 
observed increase in ligand binding over WT hGR. However, a strong interaction 
with FKBP52 (and thus dynein and microtubules) may actually retard nuclear 
translocation, resulting in less dex-mediated nuclear localisation of K494/495Q 
HAhGR than WT HAhGR. If one were to further speculate that GR phosphorylation 
at S211 and S226 occurs on or after nuclear import, the reduction in nuclear 
translocation may be responsible for the corresponding reduction in dex-mediated 
phosphorylation of K494/495Q HAhGR compared to WT HAhGR.  
 
In conclusion, it has been shown for the first time that mutations of K494 and K495 of 
the hGR that prevent or mimic acetylation, can abolish or increase ligand-binding by 
the hGR, to decrease or increase transactivation, respectively. Results presented 
here are consistent with a model in which basal GR acetylation is required for ligand-
binding and associated downstream effects such as increased GR phosphorylation 
at S211 and S226, nuclear translocation, DNA binding and transactivation. These 
results do not exclude the possibility of a role for interaction of acetylated GR with 
FKBP52 in regulating ligand binding and nuclear translocation, which is furthermore 
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supported by the literature. Chromatin immunoprecipitation data on the endogenous 
GRE-containing GILZ gene strongly support a model in which interaction of FKBP52 
with acetylated residues at K494 and K495 of the GR plays an important role in GR 
function by acting as a cofactor in transactivation. These results suggest that 
modulation of GR acetylation at K494/K495 represents an attractive physiological 





Differential nuclear localisation of the GR 
plays a role in its ligand-specific transcriptional responses 
 
The glucocorticoid receptor (GR) is a ligand-activated transcription 
factor, for which a number of ligands, both endogenous hormones 
and synthetic compounds, exist. A panel of eight different ligands 
was used, and cells were treated with saturating concentrations of 
each to control for differences in the GR binding affinity of the 
different ligands. It was found that different GR ligands elicit 
different maximal responses for gene transactivation and 
transrepression, via endogenous GR in U2OS cells, on synthetic and 
endogenous promoters. In order to find out how these ligand-
specific differences in transcriptional efficacy arise, the extent of 
nuclear translocation elicited by different GR ligands, was examined 
using subcellular fractionation and immunofluorescence 
microscopy. It was found that the extent of GR nuclear localisation 
differed for different ligands, and correlated with the maximal 
biological activity of the GR as well as the extent of GR 
phosphorylation at Serine-211. These results suggest that nuclear 
import may be the rate-limiting step for both GR phosphorylation 
and transactivation, or that a common upstream event modulates all 
of these processes, resulting in the same rank order for different 
ligands.  
The glucocorticoid receptor (GR) is a ligand-activated transcription factor that 
regulates transcription of many target genes via several mechanisms. These include 
transactivation via binding of liganded GR to consensus glucocorticoid-response 
elements (GREs) as well as transrepression via tethering mechanisms where the GR 
mutually interferes with other transcription factors such as activator protein-1 (AP-1) 
and nuclear factor kappa B (NFκB) (Hayashi et al., 2004). A wide range of ligands 
bind to the GR resulting in a range of transcriptional responses for both 
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transactivation and transrepression in a ligand-, promoter-, and cell-specific manner. 
In order to effect its biological responses, the liganded GR must translocate from the 
cytoplasm to the nucleus via the nuclear pores. However, the extent to which nuclear 
localisation contributes to ligand-selective biological responses has not been 
determined for steroid receptors. The GR and its endogenous ligand play a key role 
in many physiological processes and synthetic glucocorticoids are extensively used 
in treating several diseases. It is thus important to understand the biochemical basis 
for ligand-selective transcription via the GR, with a view to developing new drugs 
with fewer side-effects (Rhen and Cidlowski, 2005).   
 
 
It is generally accepted that ligand-selective maximal responses by steroid receptors 
are due to the induction of ligand-specific conformations of the liganded receptor, 
exposing different interacting surfaces. There is substantial evidence that different 
ligands induce different conformations in the ligand-binding domain of the GR 
(Kauppi et al., 2003); (Kroe et al., 2007) and that these result in differential 
recruitment of coregulators by liganded GR (Coghlan et al., 2003; Wang et al., 
2004); (Garside et al., 2004; Cho et al., 2005; Wang & Simons, 2005); (Kroe et al., 
2007); (Wang, et al., 2007b; Miner et al., 2007; Ronacher et al., 2009). However, the 
effect that these different conformations of GR have on its nuclear translocation is 
not understood. Only a few studies have addressed the issue of differential nuclear 
localisation of the GR when bound to different ligands. Of these studies some show 
no difference in GR nuclear localisation between ligands (Pariante et al., 2001; 
Schaaf et al., 2005), while others report ligand-selective differences (Vicent et al., 
2002; Croxtall et al., 2003; Peeters et al., 2008). Unfortunately these reports suffer 
weaknesses such as the use of concentrations of ligands which result in differences 
in the fractional occupancy of GR, thus confounding the results (Croxtall et al., 2003; 
Peeters et al., 2008), or differences in treatment times, which prevents quantitative 
comparison between different ligands (Schaaf et al., 2005). In addition, most of the 
above studies use too few ligands (two to four ligands, usually only full agonists and 
antagonists) to establish a general conclusion (Croxtall et al., 2003; Peeters et al., 




A critical evaluation of the literature reveals that there are no studies investigating a 
direct relationship between the extent of nuclear localisation by liganded GR and the 
potency (ligand concentration for half maximal response) or efficacy (maximal 
response) for transactivation. In this study the quantitative relationship between the 
extent of nuclear localisation elicited by saturating concentrations of different ligands, 
phosphorylation of GR at serine-211, and the efficacy of the transcriptional effect for 
both transactivation and transrepression was investigated. A model system 
consisting of endogenously expressed GR in U2OS cells, and  panel of eight ligands, 
including agonists, partial agonists and antagonists, were used. 
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MATERIALS AND METHODS 
 
Cell lines and test compounds U2OS cells (ATCC) were cultured in high glucose 
(1 g/ml) Dulbecco’s Modified Eagles Medium (DMEM) (Sigma-Aldrich) supplemented 
with 10% (v/v) fetal calf serum (FCS) (Delta Bioproducts), 100 IU/ml penicillin and 
100 g/ml streptomycin (Gibco Invitrogen) at 37 C in a 5% CO2 incubator. 
Dexamethasone (dex) ((11β,16α)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-
1,4-diene-3,20-dione), cortisol (cort) (11β,17α,21-Trihydroxypregn-4-ene-3,20-dione-
17-Hydroxycorticosterone), prednisolone (pred) (1,4-Pregnadiene-11β,17α,21-triol-
3,20-dione), progesterone (prog) (4-Pregnene-3,20-dione), MPA (6 -Methyl-
17 hydroxyprogesterone acetate), NET-A (NET) (Norethisterone-17-acetate), 
aldosterone (ald) (11β,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al), RU486 
(Mifepristone, 11β-(4-Dimethylamino)phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-
dien-3-one), dihydroxy testosterone (DHT) and R5020 were purchased from Sigma 
Aldrich. R1881 and mibolerone were purchased from Perkin Elmer Life and 
Analystical Science. Test compounds were dissolved in absolute ethanol and stored 
at -20˚C. The final concentration of each GR ligand was calculated to give a 
fractional GR occupancy of more than 96.5%, according to RBA data reported in 
Ronacher et al. (2009) (100 nM dex, 1 µM pred, 1 µM cort, 100 nM MPA, 10 µM ald, 
1 µM prog, 100 nM RU486, and 10 µM NET). More details of these calculations are 
given in Appendix A.  
 
Plasmids and antibodies Plasmids encoding human steroid receptors GR, GRβ, 
PR, AR and MR (pCMV-HAhGR, pCMV-hGRβ, pMT-hPRβ, pSV ARo, and 
pRS.hMR) were kind gifts from Dr M. Garabedian (New York University School of 
Medicine), Dr. J. Cidlowski (National Institute of Environmental Health Sciences, 
North Carolina), Dr S. Okret (Karolinska Institute, Sweden), Dr F. Classens 
(University of Leuven, Belgium), and Dr R. Evans (Salk Institute, La Jolla) 
respectively. pCMV-β gal was purchased from Clontech, while pAP-1-Luc 
(containing 7x AP-1 site upstream of a TATA box) and pNFκB-Luc (containing 5x 
NFκB site upstream of TATA box) were purchased from Stratagene. The pTAT-
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GRE-E1b-Luc plasmid containing two copies of the hormone response element 
(HRE) from the TAT gene was a kind gift from Dr G. Jenster (Erasmus University, 
Rotterdam) and has been described previously (Sui et al., 1999). Antibodies towards 
the AR (sc-7305), MR (sc-11412), PR A/B (sc-810), and GR (sc-8992) were 
purchased from Santa Cruz Biotechnology. The antibody towards GRβ (PA3-514) 
was purchased from Affinity Bioreagents. The anti-GR phosphoserine 211 antibody 
was a kind gift from Dr M. Garabedian (New York University School of Medicine). 
The anti-β tubulin antibody (T4026) was from Sigma Aldrich. Markers for subcellular 
fractionation were anti-GAPDH (14C10, Cell Signalling) and anti-histone H3 
(ab1791, Abcam). The antibody towards FKBP52 (sc-1803) was purchased from 
Santa Cruz Biotechnology. Secondary antibodies used were anti-rabbit-HRP, or anti-
mouse-HRP (sc2313 or sc2005 respectively, Santa Cruz Biotechnology). Details of 
the concentrations at which different antibodies were used can be found in Appendix 
B.  
 
Reporter assays For transactivation assays U2OS cells were seeded into 24 well 
plates at a density of 0.5 x 105 cells per well. The next day the cells were transfected 
with 0.25 µg pTAT-GRE-E1b-luc and 0.05 µg p-CMV-β gal using Fugene 6 (Roche) 
according to the manufacturer’s instructions. In cases where a particular steroid 
receptor was overexpressed, 125 ng of plasmid DNA encoding the receptor of 
interest was included in the transfection mix. After 24 h, the cells were stimulated 
with different compounds for 24 h in serum-free DMEM. Thereafter the cells were 
washed with PBS and lysed in 50 l per well of Reporter lysis buffer (Promega). 
Luciferase activity in the lysate was measured using the Luciferase Assay System 
(Promega) and a Veritas microplate luminometer (Turner Biosystems). The values 
obtained were normalised to expression of β-galactosidase to normalize for 
transfection efficiency between wells, which was measured using the GalactoStar 
Assay Kit from Tropix. 
 
siRNA siRNA transfection conditions were optimised as shown in Appendix E.4. 
U2OS cells were plated in 12-well plates at a density of 0.8 x 105 cells per well. After 
8 h, cells were transfected with 10 nM siRNA (Qiagen), directed against either the 
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GR (GR6), or a validated non-silencing control sequence (NSC) using HiPerfect 
transfection reagent (Qiagen). 16 h later, cells were transfected with the pTAT-GRE-
E1b-luc reporter plasmid using Fugene 6 transfection reagent. Cells were left for a 
further 24 h, before being treated with ligands and reporter activity was analysed as 
above. Parallel samples were analysed by Western blot as described below to check 
for successful GR knockdown. Blots were probed with antibodies towards GR and β-
tubulin which served as a loading control. 
 
Real time PCR quantification of endogenous gene expression U2OS cells were 
plated in 12-well plates at a density of 2.5 x 105 cells per well. After 24 h the cells 
were treated. For the glucocorticoid-induced leucine zipper (GILZ) gene, medium 
was replaced with serum-free DMEM and after 2 h of serum starvation, the different 
GR ligands were added for 2 h. For interleukin 8 (IL8) and collagenase 3 (COL3) 
gene expression analysis, cells were serum starved for 2 h followed by a 2 h 
simultaneous treatment with 25 ng/ml PMA (Sigma Aldrich) and ligand. For 
osteocalcin (OCN) gene expression analysis, cells were serum starved for 2 h 
followed by a 5 h simultaneous treatment with 25 ng/ml PMA (Sigma Aldrich) and 
ligand. For tumour necrosis factor α (TNFα) gene expression analysis, cells were 
pre-treated with GC for 30 min before stimulation with 20 ng/ml TNFα (Sigma 
Aldrich) for a further 3.5 h. Following treatment, the cells were washed with PBS, and 
RNA was extracted using Tri Reagent (Sigma-Aldrich). RNA was analysed by 
formaldehyde gel electrophoresis for integrity, before being reverse transcribed with 
Oligo-dT priming, using the Transcriptor First Strand cDNA synthesis kit (Promega). 
An equal volume of each cDNA synthesis reaction was used as template for real 
time PCR, using the Sensimix dT Kit (Quantace). Quantitative PCR was carried out 
using QuantiTect primers (Qiagen) for GILZ, COL3 and IL8. OCN primers were 
described in Diefenderer et al. (2003). Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as a housekeeping gene for normalization (F: 5’ 
TGAACGGGAAGCTCACTGG 3’; R: 5’ATTCGTTGTCATACCAGG 3’). Standard 
curves were used to determine the efficiency of each primer set, and the relative 
expression of transcript of interest in each sample was calculated according to the 




Nuclear fractionation U2OS cells were plated in 6 cm dishes at a density of 8 x 105 
cells per dish. After 24 h, cells were serum starved for 2 h and treated for 2 h with 
different ligands at GR-saturating concentrations. Cells were washed with PBS and 
scraped in 100 µl of a low ionic strength buffer (10 mM HEPES pH 7.9, 1.5 mM 
MgCl2, 10 mM DTT and 0.05% NP40) and incubated on ice for 10 minutes. 
Thereafter, the nuclear pellet and cytoplasmic fractions were separated by 
centrifugation at 3000 g for 5 min at 4˚C. The nuclear pellet was washed with 1 ml 
PBS before being resuspended in 80 µl DNaseI buffer (40 mM Tris pH 7.9, 10 mM 
NaCl, 6 mM MgCl2, 10 mM CaCl2, 0.25 units/µl DNaseI) and incubated at 37˚C for 
10 min before addition of 20 µl 5x SDS sample buffer. Equal amounts for 
cytoplasmic and nuclear fractions were separated by 10% SDS-PAGE, and analysed 
by Western blot as described below.  
 
Indirect immunofluorescence U2OS cells were plated on glass coverslips at a 
density of 5 x 104 cells/ml, in DMEM 10% FCS. The following day, cells were serum 
starved for 2 h, before treatment with saturating concentrations of different ligands 
for 2 h. Cells were fixed and permeabilised by incubation in methanol at -20˚C for 15 
min. Coverslips were blocked in 3% BSA/PBS for 1 h, and then incubated in primary 
antibody (anti-GR H300 (Santa Cruz Biotechnology), 1:500 in 5% BSA/PBS) for 1 h. 
Coverslips were then washed and incubated in secondary antibody (anti-Rabbit, 
Alexa 488 (Invitrogen), 1:500 in 5% BSA/PBS) for 1 h. Hoechst DNA stain (1:1000, 
Sigma Aldrich) was used to counterstain nuclei, before mounting coverslips on glass 
slides using mowiol mounting medium (13% (w/v) mowiol, 33% glycerol in 0.2 M Tris 
pH 8.5). Slides were incubated at room temperature overnight to allow mowiol to set, 
and then examined on a Zeiss fluorescent microscope. Quantification of nuclear 
fluorescence was performed using Zeiss Axiovision Rel 4.7 densitometry software, 
which measures the intensity of the signal within a selected region of interest. At 
least 40 randomly selected nuclei were quantified per condition, per experiment.  
 
Western blot analysis of phosphorylated GR U2OS cells were treated exactly as 
described above for indirect immunofluorescence. Cells were then washed with PBS, 
harvested in 2x SDS sample buffer (100 mM Tris-HCl, pH 6.8, 5% (v/v) SDS, 20% 
(v/v) glycerol, 5% β-mercaptoethanol, and 0.1% bromophenol blue) and boiled for 5 
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min. Proteins were separated by electrophoresis on an 8% polyacrylamide gel by 
SDS-PAGE, at 200V. Proteins were transferred from the gel to Hybond ECL 
membrane (Amersham Biosciences) by electroblot at 180 mA for 1 h, and blocked 
for 1 h in 4% ECL advance blocking powder (Amersham Biosciences) in Tris-
buffered saline containing 0.1% Tween-20 (TBST). Membranes were incubated on a 
shaker at 4˚C overnight in primary antibody solution in TBST. The following day, 
membranes were washed 3 x 5 min in TBST on a shaker, and incubated in 
secondary antibody diluted in 5% non-fat milk powder for 1 h, before washes were 
repeated. Dilutions at which primary and secondary antibodies were used are 
included in Appendix B. Blots were developed using Amersham ECL Western 
blotting detection reagents (GE Healthcare). For consecutive detection steps, 
membranes were stripped by incubation in stripping buffer (100 mM β-
mercaptoethanol, 2% (v/v) SDS, 62.5 mM Tris-Cl, pH 6.8) for 30 min at 65˚C 
(Sambrook et al., 1989).  
 
Chromatin Immunoprecipitation (ChIP) assay ChIP was performed as described 
in Ma et al. (2003), with modifications. U2OS or A549 cells were plated at 2 x 106 
cells per dish in 15 cm dishes and grown for 48 h. Cells were then washed and 
incubated in serum-free DMEM for 2 h, before treatment with 100 nM dex or vehicle 
for 1 h. Cells were crosslinked for 10 min at 37˚C by addition of formaldehyde to a 
final concentration of 1%. Crosslinking was stopped by addition of glycine to a final 
concentration of 0.1 mM for 5 min at room temperature. Cells were scraped in PBS, 
pelleted by centrifugation at 1200 g for 10 min, and resuspended in 300 µl nuclear 
lysis buffer. Chromatin was sheared by sonication in a Bioruptor (Diagenode) (30 
second on/off x 10 cycles), before centrifugation at 15000 g for 10 min. The 
concentration of DNA in the supernatant was quantified by measuring absorbance at 
260 nm, and the different samples were diluted to equal concentration with nuclear 
lysis buffer. This chromatin was then aliquotted and frozen at -80˚C. Separate 
aliquots were made for analysis of input samples.  
 
Protein A/G beads (sc-2003, Santa Cruz Biotechnology) were pre-blocked by 
incubation with salmon sperm DNA (0.2 mg/ml) and bovine serum albumin (BSA) (1 
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mg/ml) for 1 h on a rotating wheel at 4˚C. The beads were resuspended in IP dilution 
buffer (0.01% SDS, 20 mM Tris-HCl pH8, 1.1% Triton X 100, 167 mM NaCl, 1.2 mM 
EDTA, 1 mM PMSF, 2 µg/ml aprotinin, 5 µg/ml leupeptin) as a 50% slurry, and 
stored at 4˚C. For immunoprecipitation, 100 µl of chromatin (50-100 µg of DNA) was 
diluted with 900 µl IP dilution buffer. This solution was precleared with 10 µl of pre-
blocked protein A/G agarose beads (sc-2003, Santa Cruz Biotechnology) for 1 h at 
4˚C. Beads were spun down, and 2 µg anti-GR (H300) (Santa Cruz Biotechnology) 
was added to the supernatant, which was incubated on a rotator at 4˚C overnight. 
The following day, 30 µl of preblocked protein A/G beads were added, and tubes 
were incubated on a rotator for 6 h at 4˚C. Beads were washed with 1 ml each of 
wash buffer I (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-Cl 
pH8, and 150 mM NaCl), II (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 
mM Tris-Cl pH8, and 500 mM NaCl), and III (1% (v/v) NP-40, 1% (v/v) sodium 
deoxycholate, 500 mM LiCl, 1 mM EDTA, 10 mM Tris-Cl pH8). Beads were then 
washed three times with 1 ml TE buffer (10 mM Tris pH8, 0.1 mM EDTA). Proteins 
were eluted from the beads by addition of 300 µl elution buffer (1% SDS, 100 nM 
NaHCO3) for 30 min at room temperature on a rotating wheel. For input, 30 µl of 
chromatin solution was stored at -20˚C overnight, before addition of 90 µl elution 
buffer, and processing in parallel with immunoprecipitated samples. 
 
Of a 5 M NaCl stock solution, 18 µl or 7.2 µl was added to eluate and input samples 
respectively, to yield a final concentration of 300 nM NaCl. Tubes were then 
incubated at 65˚C overnight to reverse crosslinks. The following day EDTA, Tris-HCl 
pH 6.5 and proteinase K (Roche) were added. For eluate samples 10 µl of a 0.5 M 
EDTA stock (for a final concentration of 15 nM EDTA), 40 µl of a 1 M Tris pH 6.5 
stock (for a final concentration of 125 nM Tris) and 2 µl of a 10 mg/ml proteinase K 
stock (for a final concentration of 0.67 ng/µl proteinase K) were added. For input 
samples 5 µl of a 0.5 M EDTA stock, 20 µl of a 1 M Tris pH 6.5 stock, and 1 µl of a 
10 mg/ml proteinase K stock were added to yield the same final concentrations as 
the eluate samples. All samples were then incubated at 45˚C for 1 h. DNA was 
purified using Qiagen PCR cleanup columns. Real time PCR was performed on a 
Corbett Rotorgene, using the Sensimix dT Kit (Quantace), which measures SYBR 
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Green fluorescence. Primers corresponding to the promoter region of human GILZ 
were used (Wang et al., 2004). 
 
Quantification and statistical analysis Densitometric analysis of bands on 
Western blots was performed using AlphaEase software. Statistical analyses were 
carried out using GraphPad Prism software, using one-way analysis of variance with 
either Tukey’s or Dunnett’s post tests. Correlations were carried out using two-tailed 
Pearson correlation analysis. Statistical significance of differences are denoted by *, 




Endogenous GR in U2OS activates a GRE reporter gene, but no other steroid 
receptors induce transactivation 
 
Since this study aimed to compare a large panel of steroid receptor ligands, it was 
important to characterise the steroid receptors expressed in the selected model 
system. Several of the ligands in the panel are capable of activating other members 
of the steroid receptor family, in addition to the GR. U2OS human osteosarcoma 
cells are widely believed not to express GR (Rogatsky et al., 1997). However, when 
reporter assays were performed in the cells in the absence of overexpressed GR, a 
significant induction of transcription by the GR-specific agonist dexamethasone (dex) 
was observed (figure 4.1A). Specific agonists for the AR (mibolerone (mib)), MR 
(aldosterone (ald)), and PR (R5020) did not elicit a transcriptional response on the 
hormone response element (HRE)-containing promoter (figure 4.1A). While mib and 
R5020 were used at 1 µM, ald was used at 10 nM. This was because ald exhibits 
weak binding to the GR, and would saturate approximately 87% of any endogenous 
GR present at 1 µM. At 10 nM, ald would only saturate about 6% of the GR (for more 
information see Appendix A, table A.1). When used at these concentrations, all of 
the above-mentioned receptor-specific agonists did give a response on this reporter 
construct when the specific steroid receptor was co-transfected (Appendix D, figure 
D.1), indicating that the assay was working. Results shown in figure 4.1A indicate 
that U2OS cells endogenously express a functional GR, but no detectable AR, MR or 
PR. 
 
In order to confirm that the observed transcriptional response to dex was due to the 
GR, specific siRNA was transfected to knock down the GR. This experimental 
technique was first optimised as shown in Appendix E.4. The Western blot (figure 4.1 
B) shows that expression levels of β-tubulin were not affected by transfection of 
siRNA, which is in agreement with microscopic examination of cells, indicating 
siRNA transfection had no adverse effect on cell growth (data not shown). However 
GR expression levels were efficiently reduced by transfection of siRNA (GR6) 
compared to NSC. GR knockdown did not affect the basal transcriptional response in 
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the absence of dex, but resulted in a loss of the dex-mediated transcriptional 
response, confirming a requirement for the GR in this response (figure 4.1C).  
 
The results of the reporter assay (figure 4.1A) were confirmed using a Western blot 
approach (figure 4.1D). COS-1 cells were transiently transfected with constructs 
encoding each SR, to serve as positive controls for antibody specificity and 
technique. It was found that PR, GRβ and MR were undetectable in U2OS cells, 
while a band corresponding in size to the positive control was detected with the anti-
AR antibody, indicating that endogenous AR is expressed in U2OS cells. Since this 
was not in agreement with the reporter assay, which indicated no response to the 
AR-specific ligand mib, further reporter assays were carried out to investigate 
whether endogenous AR would give a response to other AR-specific ligands (figure 
4.1E). All of the AR-specific ligands tested (mibolerone, DHT and R1881) induced a 
strong transcriptional response in the presence of transiently overexpressed AR, but 
showed no activity above background in WT U2OS cells. This strongly suggested 
that the AR band detected on the Western blot (figure 4.1D) is transcriptionally 
incompetent AR, or that the levels of endogenously expressed AR are too low to 





Figure 4.1. Only GR is expressed in U2OS cells, and not AR, MR, PR 
or GRβ. (A) U2OS cells were transfected with pCMV -galactosidase 
reporter and the HR responsive luciferase reporter construct pTAT-GRE-
E1b-luc. Cells were treated with vehicle (EtOH) or 1 µM dex, 1 µM mib, 10 
nM ald, or 1 µM R5020 for 24 h. Luciferase activity of cell lysates was 
monitored and normalised to β-galactosidase activity for each well to 
control for transfection efficiency. Histogram shows pooled results of three 
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independent experiments each performed in triplicate, analysed by one 
way Anova with Dunnett’s post-test. (B) A representative Western blot, 
showing the efficiency of knockdown by GR6 siRNA compared to NSC in 
U2OS cells is shown. (C) Reporter assays were conducted in U2OS as in 
A, with cotransfection of GR siRNA (GR6), or a non-silencing control 
(NSC). Cells were then treated with vehicle (EtOH) or 1 µM dex for 24 h, 
before luciferase activity of cell lysates was monitored and normalised to 
β-galactosidase activity for each well to control for transfection efficiency. 
The histogram shows pooled results of two independent experiments 
each performed in triplicate, analysed by one way Anova with Dunnett’s 
post-test. (D) A Western blot is shown in which lysates from cells 
overexpressing PR-B, GR-β, MR and AR (positive controls) were 
analysed in parallel with WT U2OS cell lysate. (E) Luciferase reporter 
assays were performed as described in A, in the presence or absence of 
overexpressed AR in U2OS cells. Cells were treated with different AR 
agonists for 24 h before being lysed and the luciferase activity of the 
lysates were analysed, and normalised to β-galactosidase activity to 
normalise for transfection efficiency. The graph shows the result of a 
single experiment performed in triplicate.  
 
At saturating concentrations, different GR ligands give different maximal 
transcriptional responses, via endogenous GR on a GRE-driven reporter gene 
 
Since only GR, and not MR, PR or AR, gave a detectable transcriptional response in 
U2OS cells (figure 4.1A), it was concluded that all transcriptional responses to 
steroidal ligands were elicited by the GR. A panel consisting of eight different GR 
ligands (see appendix A for structures) was compared for their transcriptional effect 
elicited on a GRE-containing promoter, via endogenous GR in U2OS cells. The 
panel was selected to include full agonists (dex, pred, cort), partial agonists (MPA, 
ald, prog), an antagonists (NET), and a dissociated glucocorticoid (RU486), as 
defined by Ronacher et al., (2009). The Ki values published in Ronacher et al., 
(2009), measured in COS-1 cells overexpressing HAhGR, were used to determine 
the concentration of each ligand which would cause occupation of at least 97% of 
the endogenous GR in U2OS cells, and these concentrations were used in 
subsequent assays in the present study (these calculations are shown in Appendix 
A). Although the Ki values were calculated in COS-1 cells, and absolute binding of 
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different ligands may thus differ from the U2OS cell system, this allowed 
normalisation for differences in relative binding affinity between different ligands.  
 
As shown in figure 4.2, dex, a full agonist, gave the highest response of 
approximately 50-fold increase in reporter luciferase activity, while RU486, a GR 
antagonist, gave no response. It was interesting that NET caused a small response 
in this cell system. NET has been reported to be a GR antagonist, which competes 
with dex for GR binding, but causes no transactivation in COS-1 cells 
overexpressing GR (Ronacher et al., 2009). It is possible that this ligand could act 
differently at different intracellular concentrations of GR, as shown by Zhao et al., 
(2003) for a subset of steroid ligands, as GR concentrations in WT U2OS are likely 
to be much lower in WT U2OS cells than transiently transfected COS-1 cells 




Figure 4.2. Ligand-specific transcriptional maxima observed in 
reporter assay. U2OS cells were transfected with pCMV -galactosidase 
reporter and the GR responsive luciferase reporter construct pTAT-GRE-
E1b-luc. Cells were treated with vehicle (EtOH) or saturating 
concentrations of GC ligands (100 nM dex, 1 µM pred, 1 µM cort, 100 nM 
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MPA, 10 µM ald, 1 µM prog, 100 nM RU486, and 10 µM NET) for 24 h. 
Luciferase activity of cell lysates was monitored and normalised to β-
galactosidase activity for each well to control for transfection efficiency. 
Histograms show pooled results of three independent experiments plotted 
relative to EtOH (1 ± SEM), analysed by one way Anova with Dunnett’s 
post-test, relative to EtOH.  
 
At saturating concentrations, different GR ligands give different maximal 
transcriptional responses, via endogenous GR on the endogenous GRE-driven 
gene GILZ 
 
In order to determine whether the results observed in the reporter assay shown in 
figure 4.2 were representative of the effect on an endogenous gene, GR-mediated 
transactivation of the endogenous GILZ gene was measured by real-time PCR. GILZ 
is a negative regulator of NFκB in airway epithelial cells and plays a major role in 
anti-inflammatory response (Eddleston et al., 2007). The promoter of the GILZ gene 
contains a number of GRE sequences (Wang et al., 2004). 
 
The results show clear differences in maximal transcription between the different 
ligands, ranging from a significant 6-fold increase in GILZ mRNA upon dex 
stimulation, to no change in mRNA levels for the antagonists RU486 and NET (figure 
4.3). This is in contrast to the reporter assay, in which NET resulted in a small 
increase in transactivation. Only full agonists (dex, pred and cort) elicited a 
significant increase in transcription. However, similarities were observed between 







Figure 4.3. Regulation of the endogenous GILZ gene by GR ligands. 
U2OS cells were serum starved for 2 h, before treatment with saturating 
concentrations different ligands (100 nM dex, 1 µM pred, 1 µM cort, 100 
nM MPA, 10 µM ald, 1 µM prog, 100 nM RU486, and 10 µM NET) for 2 h. 
RNA was harvested, reverse transcribed and subjected to real time PCR 
analysis, using primer sets specific for GILZ and GAPDH. Levels of GILZ 
mRNA transcripts were normalised to GAPDH levels for each sample. 
The graph shows pooled results of three independent experiments +/- 
SEM. One way Anova was performed, with Dunnet’s post-test relative to 
EtOH.  
 
The differential responses to different ligands observed on the GILZ gene are 
mediated by endogenous GR 
 
In order to confirm that transcription of the endogenous GILZ gene measured in 
response to different ligands was mediated by the GR, GR knockdown was 
performed. In U2OS cells transfected with siRNA targeting the GR mRNA expression 
of endogenous GR was reduced by approximately 60- 70% compared to cells 




The reduction in GR expression coincided with an almost complete loss of GILZ 
induction (figure 4.4A), thus confirming a requirement for the GR in this 
transcriptional response. Although the dex-induced fold induction in GILZ in this 
experiment was slightly lower than in the previous figure (approximately 4.5-fold vs. 
approximately 6-fold), quantification of the Western blot shows that GR levels in cells 
transfected with NTC were slightly lower than in untreated cells. Although not 
statistically significant, this difference could account for the slight discrepancy in 
maximal efficacy of dex in the two experiments.  
 
 
Figure 4.4. GR is required for the observed response to GR ligands 
on the GILZ gene. (A) U2OS cells were transiently transfected with 10 
nM siRNA encoding GR (GR6) or an equivalent amount of NSC, for 48 h. 
Cells were then serum starved and treated with saturating concentrations 
of different ligands (100 nM dex, 1 µM pred, 1 µM cort, 100 nM MPA, 10 
µM ald) for 2 h. RNA was harvested, reverse transcribed, and GILZ 
expression was quantified by means of real time PCR, normalising to 
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GAPDH for each sample. Results from 3 independent experiments were 
pooled and the graph represents mean +/- SEM, analysed by one-way 
Anova with Dunnet’s post-test relative to NSC EtOH. (B) A representative 
Western blot showing GR levels relative to β-tubulin is shown. (C) Whole 
cell lysate samples harvested in parallel with RNA were analysed by 
Western blot. Relative GR levels in untreated (UT), NSC transfected, and 
GR6 transfected cells were quantified, and results of three independent 
experiments were pooled, and shown as mean +/- SEM. Results were 
plotted relative to NSC, and analysed by one-way Anova, with Dunnett’s 
post-test relative to NSC. 
 
Different ligands induce transrepression of promoter-reporter plasmids to 
different extents 
 
Having confirmed that different GR ligands elicit different extents of transactivation 
via the GR, the question of whether the same applies to transrepression was next 
investigated. Transrepression in U2OS via endogenous GR was first examined on 
transiently transfected promoter-reporter constructs. The promoters contain multiple 
copies of the AP-1 response element or NFκB response element. Promoter activity 
was induced by PMA treatment in order to provide a high background against which 
to visualise GR-mediated transrepression.  
 
Promoter reporter assays showed that transrepression by endogenous GR was 
ligand-selective and promoter-specific. However, the trend observed for 
transactivation (i.e. full agonists give higher maximal efficacy than partial agonists or 
antagonists) was not observed. On the AP-1 promoter (figure 4.5A), only dex, cort 
and ald caused significant repression, with NET causing a significant increase in 
promoter activity. On the NFκB promoter, none of the ligands tested resulted in 





Figure 4.5. Endogenous GR can weakly transrepress in a ligand-
selective, promoter-specific fashion. U2OS cells were co-transfected 
with a β-gal reporter and either (A) an AP-1-Luc or (B) and NFκB-Luc 
reporter plasmid, and treated with saturating concentrations of different 
ligands (100 nM dex, 1 µM pred, 1 µM cort, 100 nM MPA, 10 µM ald, 1 
µM prog, 100 nM RU486, and 10 µM NET), in the presence of PMA, as 
described in materials and methods. Thereafter luciferase activity was 
measured and normalised to β-gal to control for transfection efficiency. 
Pooled results of two independent experiments, each performed in 
triplicate, are shown. One-way Anova with Dunnett’s post-test relative to 
EtOH treated cells was performed. 
 
Transrepression of endogenous genes is ligand-selective and promoter 
specific 
 
In order to investigate whether the transrepression results observed on synthetic 
promoter reporters provide an accurate reflection of the transrepression of 
endogenous genes, with a complex chromatin structure, transrepression of 
endogenous genes was measured by quantitative real time PCR. Several 
endogenous genes, with different promoter architecture were selected to represent 
different modes of GR-mediated transrepression. 
 
TNFα is a pro-inflammatory cytokine, the expression of which is auto-induced and 
transrepressed by GCs (Beutler et al., 1986). TNFα is involved in the pathogenesis 
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of osteoporosis (Pacifici, 1996). Expression of the TNFα gene was strongly induced 
by incubation of cells in the presence of TNFα. However, of all the ligands, only dex 
was capable of eliciting significant transrepression on this promoter via endogenous 
GR in U2OS cells (figure 4.6A).  
 
Interleukin 8 (IL8) is a proinflammatory chemokine released from a variety of cells in 
response to inflammatory stimuli (reviewed in Atta-ur-Rahman et al., 1999). The IL8 
promoter is repressed by GR binding to an NFκB response element (Nissen & 
Yamamoto, 2000; Garside et al., 2004; Rogatsky et al., 2002). Although strong 
induction of this gene was observed upon PMA treatment (figure 4.6B), the partial 
agonist prog caused a further significant increase in IL8 expression. No significant 
transrepression of IL8 was observed with any ligand. This is in stark contrast to 
results observed by Rogatsky and co-workers (Rogatsky et al., 2002) who report a 
56-fold repression of IL8 mRNA in U2OS.rGR cells upon 2 h simultaneous treatment 
with 25 ng/ml PMA and 100 nM dex. These are the same treatment conditions as 
used in the present study, except for the fact that Rogatsky and co-workers (2002) 
performed experiments in U2OS cells stably transfected with GR. One must 
therefore conclude that GR expression levels play a critical role in determining the 
extent of transrepression elicited by the GR. Indeed, this was confirmed using 
reporter assays on synthetic AP-1 and NFκB promoter-reporter constructs in the 
absence and presence of overexpressed hGR (Appendix D, figure D.2). However, as 
this study aimed to examine the effects of endogenous GR, further experimentation 
in the presence of overexpressed GR was not conducted.  
 
Collagenase 3 (COL3) is a matrix metalloprotease that has been implicated in 
tumour migration and metastasis (reviewed in Leeman et al., 2002). GR represses 
COL3 expression by binding to an AP-1 response site in the promoter of the COL3 
gene (Tuckermann et al., 1999). In stably transfected U2OS.GR cells, COL3 is 
maximally induced by PMA at 2 h, and induction by PMA has been shown to be 
stronger than that induced by TNF  or LPS. Reporter assays showed that 25 and 50 
ng/ml PMA resulted in a 15- or 20-fold increase in promoter activity respectively, 
which was completely lost upon addition of 100 nM dex in U2OS.rGR cells 
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(Rogatsky et al., 2001). This is in contrast to the results observed in WT U2OS cells 
(figure 4.6C), where an induction of only 4-fold was measured upon treatment with 
25 ng/ml PMA for 2 h. On this promoter dex, pred, cort and ald resulted in significant 
repression. Similarities were noted between the results observed on reporter and 
endogenous genes. For instance, dex, cort and ald gave significant transrepression 
on an AP-1 reporter (figure 4.5A), and on COL3, an AP-1-regulated endogenous 
gene (figure 4.6C). Similarly, significant transrepression was not observed on the 
NFκB-regulated promoter in a reporter assay (figure 4.5B) nor on an endogenous 
gene (figure 4.6C).  
 
The last model gene examined was osteocalcin (OCN). The OCN promoter is 
negatively regulated by glucocorticoids because the GR response element, which 
resembles the consensus GRE, except for three non-conserved bases, overlaps with 
the TATA box, thereby forming a competitive nGRE (Strömstedt et al., 1991). U2OS 
cells constitutively express OCN, detectable by reverse transcription PCR 
(Benayahu et al., 2001), and it has been shown that treatment with 1 µM dex for 42 h 
completely depletes OCN mRNA in an osteoblast cell line (Leclerc et al., 2005). In a 
promoter reporter study, U2OS.rGR cells were treated overnight with 25 ng/ml PMA 
in the presence or absence of 100 nM dex, resulting in about 10-fold repression of 
the reporter gene by dex (Rogatsky et al., 2002). Thus, in previous reports of dex-
mediated transrepression of the OCN promoter treatment times of at least 16 h were 
used. However, for the real-time PCR experiment in the present study, it was 
desirable to avoid indirect effects of GCs (i.e. GC alters transcription of an 
intermediate transcription factor which subsequently regulates OCN). For this 
reason, incubation times were kept as short as possible in the present study. In the 
case of OCN, induction with 50 ng/ml PMA was performed for 5 h. Unfortunately, no 
transrepression was observed for any ligand under these conditions (figure 4.6D). 
This is unlikely to be due to excessive gene induction, such that the limited 
endogenous GR was not able to transrepress the gene adequately, since the 






Figure 4.6. GR ligands elicit weak transrepression of endogenous 
genes in a ligand-selective fashion. U2OS cells were either uninduced 
or treated with TNFα or PMA to induce gene expression. Treatment with 
saturating concentrations of different GR ligands (100 nM dex, 1 µM pred, 
1 µM cort, 100 nM MPA, 10 µM ald, 1 µM prog, 100 nM RU486, and 10 
µM NET) was performed as described in materials and methods. RNA 
was harvested, reverse transcribed and expression of (A) tumour necrosis 
factor α (TNFα), (B) interleukin 8 (IL8), (C) collagenase 3 (COL3), and (D) 
osteocalcin (OCN) were analysed by real time PCR, normalising to 
GAPDH for each sample. Uninduced treatment refers to expression in the 
absence of stimulation by TNFα (A) or PMA (B-D). Pooled results of three 
independent experiments are presented as mean +/- SEM for each gene, 
and analysed by one-way Anova with Dunnet’s post-test relative to EtOH 




Different ligands induce different extents of GR nuclear localisation 
 
Having shown that different ligands result in ligand-specific differences in maximal 
transactivation and transrepression in a promoter-specific fashion in U2OS cells 
(figures 3.2- 3.7), the mechanism by which these differences arise was investigated. 
In order to examine whether differential GR nuclear localisation could be the cause, 
nuclear localisation of the GR was investigated by both biochemical fractionation and 
immunofluorescence microscopy.  
 
It was decided to examine nuclear localisation of GR under the same conditions 
under which GILZ transactivation was examined (i.e. 2 h serum starvation followed 
by 2 h GC treatment at saturating concentrations). This treatment time was also 
used for analysis of IL8 and COL3 expression, in the presence of PMA. When 
comparing the subcellular localisation of GR after a 2 h GC treatment, ligand-specific 
differences were observed. Dexamethasone caused a significant three-fold increase 
in GR nuclear localisation (figure 4.7A), while the GR partial agonists and 
antagonists caused no increase in GR nuclear localisation compared to untreated 
cells. Although the quantification of GR in the cytoplasmic fraction did not yield 
statistically significant differences between different ligands, a decrease in 
cytoplasmic GR was observed after dex treatment (figure 4.7B). The co-incubation of 
blots with a mix of antibodies for GR and cytoplasmic and nuclear marker proteins 
(GAPDH and histone H3, respectively), shows that the total protein loaded per lane 








Figure 4.7. Ligand-specific differences in nuclear import. U2OS cells 
were treated with saturating concentrations of different steroidal ligands 
(100 nM dex, 1 µM pred, 1 µM cort, 100 nM MPA, 10 µM ald, 1 µM prog, 
100 nM RU486, and 10 µM NET) for 2 h, before being fractionated into (A) 
nuclear and (B) cytoplasmic fractions. The fractions were analysed by 
Western blot, with GAPDH and histone H3 serving as markers of efficient 
separation of nuclear and cytoplasmic fractions, and as controls for equal 
protein loading. Bands on Western blots were quantified using Alphaease 
software, and the intensity of the GR signal was normalised to Histone H3 
(nuclear fractions) or GAPDH (cytoplasmic fractions) to control for 
differences in protein loading. Histograms show pooled results from 3 
independent experiments, analysed by One-way Anova with Dunnet’s 
post-test relative to EtOH treated cells. Western blots are representative.  
 
In order to confirm the ligand-selective nuclear localisation of endogenous GR 
observed upon subcellular fractionation, an immunofluorescence approach was 
employed. GR subcellular localisation was examined by indirect 
immunofluorescence, under exactly the same treatment conditions (i.e. 2 h serum 
starvation followed by 2 h GC treatment at saturating concentration) (figure 4.3). 
Images were selected randomly by selecting fields of view based on Hoechst stain. 
There was quite a high degree of variability in the intensity of the Alexa 488 
immunostain across each coverslip, however randomly selected images (figure 4.3A) 
show a high ratio of nuclear to cytoplasmic stain for dex-treated cells, and a much 
lower ratio for NET, following the same trend as observed upon biochemical 
fractionation. Despite the large error, quantification of the relative intensity of Alexa 
488 stain for GR within the nucleus was possible by measuring 40 nuclei for each 
treatment, and pooling data from four independent experiments (figure 4.3B). 








Figure 4.8. Differential nuclear localisation of endogenous GR 
detected by immunofluorescence (A) U2OS cells were treated with 
saturating concentrations of different steroidal ligands (100 nM dex, 1 µM 
pred, 1 µM cort, 100 nM MPA, 10 µM ald, 1 µM prog, 100 nM RU486, and 
10 µM NET) for 2 h and GR localisation was examined by indirect 
immunofluorescence. Scale bars (red) represent 10 µm. (B) Nuclear 
fluorescence was quantified in 40 randomly selected cells from 4 fields of 
view using Axiovision Rel. 4 software. Background fluorescence was 
subtracted from these values, and EtOH was set as 1. Results of 4 
independent experiments were pooled and one way Anova with Dunnet’s 
post-test was performed to determine statistical significance relative to 
EtOH. 
 
While only dex and pred showed significantly more nuclear GR by biochemical 
fractionation, cortisol was also significantly different from vehicle control (EtOH) in 
this experiment. However, on the whole, the same pattern is observed as for 
biochemical fractionation, with full agonists exhibiting the greatest extent of nuclear 
localisation. 
 




GR phosphorylation at Serines 211 (S211) and 226 (S226) is a well-known marker of 
GR activation (Ismaili & Garabedian, 2004). In order to determine whether S211 
phosphorylation would correlate with transactivation or nuclear translocation for any 
of the ligands investigated, S211 phosphorylation was examined by Western blot, 
using an antibody that specifically recognises GR phosphorylated at S211 (GR-
P211). Blots were then stripped and reprobed for total GR levels as a loading 
control.  
 
Figure 4.9. Differential phosphorylation of S211 of endogenous GR in 
U2OS cells. U2OS cells were plated in 12 well plates and treated with 
vehicle (EtOH) or different ligands at saturating concentrations (100 nM 
dex, 1 µM pred, 1 µM cort, 100 nM MPA, 10 µM ald, 1 µM prog, 100 nM 
RU486, and 10 µM NET) for 2 h before being lysed and analysed by 
Western blot, probing for GR phosphorylated at S211, and total GR. (A) 
Bands on phospho-Western blots were quantified using Alphaease 
software, normalised to total GR levels, and plotted relative to EtOH, 
which was set as 1. Results from four independent experiments were 
pooled and analysed by one way Anova, with Dunnett’s post-test, relative 
to EtOH. (B) A representative Western blot is shown, with the top panel 
showing GR phosphorylated at S211and the bottom panel showing total 
GR levels.  
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As shown in figure 4.9, different ligands resulted in different extents of 
phosphorylation of GR at S211, under the same conditions at which nuclear 
localisation was measured. Wang et al (2002) have shown differential 
phosphorylation at GR S211 using a small panel of ligands in U2OS overexpressing 
GR. Similar to the results shown here, agonists dex and pred caused 
phosphorylation of GR at S211, while the antagonist RU486 did not. Thus there did 
appear to be a correlation with transactivation, but this was not quantified. 
Furthermore, the concentration selected for treatment of different ligands were not 
saturating for all ligands, and the issue of differential GR binding by different ligands 
was not corrected for. To the best of the present author’s knowledge, the current 
study is the first time differential phosphorylation of endogenous GR with different 
ligands has been reported, although similar studies have been performed using 
overexpressed GR (E. Stubsrud, 2005, M.Sc. thesis; Chen et al., 2008). 
 
Correlation between nuclear import, S211 phosphorylation and transcriptional 
response on a GRE-reporter and the endogenous GILZ gene 
Correlation analysis of transactivation, S211 phosphorylation, and nuclear 
localisation was performed using a Pearson two-tailed correlation analysis on 
GraphPad Prism software, and the results (showing R2 and p values) are 
summarised in Table 4.1. Graphs of these correlations plotted in GraphPad Prism 











Table 4.1. Summary of correlation analysis 
 
Values obtained for GR-mediated reporter transactivation (figure 4.2), GR 
nuclear localisation as measured by biochemical fractionation (figure 
4.7A), GR nuclear localisation as measured by immunofluorescent 
microscopy (figure 4.8B), transactivation of the endogenous GILZ gene by 
GR (figure 4.3) and GR phosphorylation at S211 (GR-P211) (figure 4.9) 
for saturating concentrations of different ligands, were analysed by two-
tailed Pearson correlation. The R2 values (coefficient of determination) 
give an indication of the fraction of the variance shared by the two factors 
being compared. The p values give an indication of whether the 
correlation is statistically significant.  
 
Good, and significant correlations were obtained between measurements of 
transactivation, nuclear localisation and phosphorylation. There was no correlation 
between transrepression and nuclear import, except for transrepression on the AP-1 
reporter construct, which showed a weak (R2= 0.5415) but significant (p= 0.0238) 
correlation with the nuclear immunofluorescence measurements. Transrepression on 
the AP-1 reporter also correlated weakly with phosphorylation at S211 (R2= 0.5586, 
p=0.0206). The fact that correlations between transrepression and nuclear import 
were weaker than those between transactivation and nuclear localisation of the GR, 
could indicate that some additional factors are involved in transrepression compared 
to transactivation. 






This report has shown that different GR ligands elicit differences in maximal 
transcriptional effect for both transactivation and transrepression on both 
endogenous and synthetic promoters. To further investigate the mechanism 
underlying these differences, GR nuclear localisation was examined by biochemical 
fractionation and immunofluorescence microscopy, and was found to correlate with 
the transactivation efficacy for a panel of eight different ligands. Furthermore, a 
correlation was identified between nuclear translocation and GR phosphorylation at 
Serine-211.  
 
The U2OS osteosarcoma cell line was used in this study, as a model to investigate 
the effects of GR on transactivation and transrepression. This model system was 
selected after stably transfected U2OS cells exhibited reduced GR expression over 
time (Appendix E, figure E.5.1), which highlights the importance of regular monitoring 
of the expression from exogenous constructs in stably transfected cell lines. It was 
interesting that WT U2OS, which are widely believed not to express GR (Rogatsky et 
al., 1997), gave significant transactivation in response to dex on both synthetic and 
endogenous promoters. Although this finding in this system may cast doubt on the 
authenticity and purity of the cell line used, it is supported by Rogatsky et al., (1997), 
who detected a band corresponding to GR when WT U2OS cell lysates were 
immunoprecipitated with an antibody against GR. GR expression levels have been 
shown to affect both the potency and efficacy of GR-regulated transactivation 
(Vanderbilt et al., 1987) and transrepression (Zhao et al., 2003). This implies that 
results obtained in model cell systems with high GR levels may not represent the 
effects occurring in cells/tissues with low GR levels. This makes the results reported 
here more significant since this study examines the effects of different GR ligands in 
a model cell system expressing relatively low levels of endogenous GR. Since the 
panel of ligands selected included some compounds with high binding affinity for 
other steroid receptors, endogenous expression levels of other closely related 
steroid receptors of the nuclear receptor superfamily (i.e. AR, MR, PR) (Lu et al., 
2006) were examined by reporter assay and Western blot. No steroid receptor-
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specific agonists besides dex gave a response on a synthetic HRE-containing 
reporter in U2OS, and it was thus inferred that all transcriptional responses observed 
were mediated by the GR. Furthermore, involvement of the GR in observed 
transactivation was confirmed by specific protein knockdown, which validated the 
selected model system. 
 
In order to assess the validity of using promoter-reporter assays as models of 
endogenous genes, correlation analyses were performed between the efficacies of 
different ligands on synthetic and endogenous promoters. There was a significant 
correlation between transactivation of the synthetic GRE promoter and the 
endogenous GRE-containing GILZ promoter (R2= 0.7728, p=0.004). This supports 
the physiological relevance of the results on synthetic promoters. However, no 
correlation was observed between activity on synthetic and endogenous promoters 
containing either AP-1 or NFκB response elements (COL3 and IL8 respectively). 
This suggests that other factors (besides AP-1 and NFκB) or cis-elements may play 
a role in transrepression of these endogenous genes, and highlights a fundamental 
mechanistic difference between transactivation and transrepression downstream of 
ligand binding and nuclear translocation.  
 
Another surprising difference identified between transactivation and transrepression, 
was that transrepression was generally much weaker than transactivation measured 
in WT U2OS. Maximum transrepression observed was about 50% with dex on the 
AP-1-Luc reporter (figure 4.5) and TNFα and COL3 promoters (figure 4.6), while an 
approximately 6-fold increase in transactivation was observed on the endogenous 
GILZ promoter (figure 4.3), and a 50-fold increase in reporter activity was measured 
(figure 4.2). Reporter assays conducted in the absence and presence of exogenous 
GR showed that higher levels of GR caused a greater extent of transrepression on 
AP-1 and NFκB promoters (Appendix D, figure D.2.). This suggests that low levels of 
GR present in U2OS cells were responsible for the weak transrepression. This 
finding may thus indicate that relative efficacy for transrepression is dependent on 
receptor levels, and caution should be taken when comparing results in different cell 
lines, or in cells expressing different levels of GR. Indeed, the efficacy of GR for 
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transrepression has previously been reported to increase with increasing receptor 
levels (Zhao et al., 2003). Furthermore, some ligands (MPA and RU486) have been 
identified which switch biocharacter from full agonists for transrepression at high 
receptor concentration to antagonists for transrepression at low receptor 
concentration (Zhao et al., 2003). Another possibility for the weak transrepression 
may be the treatment times used in this study. These were kept short in order to 
avoid indirect effects. Although the treatment conditions used here for IL8 (Rogatsky 
et al., 2002) and COL3 (Rogatsky et al., 2001) expression had previously been 
shown to yield close to 100% transrepression in U2OS cells stably transfected with 
GR in the presence of dex, it is possible that at low concentrations of GR the kinetics 
of transrepression may be slower, and thus a longer incubation with ligand may be 
necessary for complete transrepression.  
 
Despite the very weak levels of GR-mediated transrepression observed in this study, 
interesting ligand- and promoter specific differences in GR mediated transcription 
were identified. When investigating differential transrepression of the IL8 gene, it was 
found that Prog caused a significant 2-fold increase in IL8 expression. This was 
unexpected, but similar upregulation of IL8 by progesterone has been observed in 
endocervical cells (N. Verhoog, Hapgood laboratory, unpublished observation). The 
effect of NET on transactivation appears to be promoter-specific, since no 
transactivation of the GILZ gene was induced by NET in this model cell system, after 
a 2 h treatment (figure 4.3), although an increase in transcription of a GRE-Luc 
reporter plasmid was observed upon treatment with NET (figure 4.2). Alternatively, 
the effect on the reporter construct could be indirect. In the reporter assay cells are 
incubated for 24 h in the presence of ligand, which could allow time for upregulation 
of another transcription factor in response to NET, which may subsequently increase 
transcription from the TAT-GRE promoter. This would not be observed in the real 
time PCR assay, as the incubation time of 2 h would be too short to allow for 
translation of this hypothetical intermediary transcription factor. Similarly, the partial 
agonist MPA elicited a response on the synthetic reporter promoter (figure 4.2), but 




Having identified ligand-specific differences in transactivation and transrepression 
efficacy, the mechanism by which these arise was investigated, and ligand-specific 
differences in the extent of GR nuclear localisation were found (figure 4.7 and 4.8). 
Nuclear localisation of GR measured by both biochemical fractionation and 
immunofluorescence microscopy was found to correlate with efficacy for 
transactivation. It was also shown that differential nuclear import of the GR correlates 
well with its ligand-dependent phosphorylation at S211, which has not previously 
been shown for endogenous GR. This could be explained by one of three 
possibilities: either (1) differential phosphorylation caused by binding of different 
ligands causes differential nuclear import, or (2) differential nuclear import causes 
differential phosphorylation at S211 of the GR, or (3) a common upstream event 
determines ligand-selectivity of both nuclear import and phosphorylation at S211.  
 
Wang et al. (2002) observed that GR P211 was localised to the nucleus, and 
speculated that GR is phosphorylated at Serine-211 before entering the nucleus, 
which is in agreement with possibility 1 above. However, a closer look at their results 
reveals a subtle difference between the subcellular localisation observed by 
biochemical fractionation and immunofluorescence microscopy, similar to what was 
observed in this study when comparing total GR localisation by the two different 
techniques. Upon dex treatment, it appears that the majority of GR is nuclear by 
immunofluorescent microscopic analysis, while biochemical fractionation indicates 
that a large amount of GR remained in the cytoplasm, notwithstanding differences in 
protein loading. Similarly Wang et al. (2002) observed that upon dex treatment, the 
majority of GR-P211 was nuclear when examined by immunofluorescence 
microscopy, but biochemical fractionation indicated that the majority of the GR-P211 
remained cytoplasmic. One possible explanation for this apparent discrepancy is that 
the GR becomes phosphorylated at S211 on interaction with the nuclear envelope, 
and harsh biochemical fractionation conditions result in the nuclear envelope-
associated GR remaining in the cytoplasmic fraction, as in hypothetical possibility (2) 
above, that differential nuclear import leads to differential phosphorylation of GR. 
Studies with mutant GR constructs in which phosphorylation at S211 is abolished are 
also consistent with this hypothesis, since such mutations had no effect on GR 
nuclear localisation (Webster et al., 1997; Avenant et al., 2010). Thus it seems likely 
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that either GR is phosphorylated on or after nuclear import, or a common upstream 
event determines ligand-selectivity of both nuclear import and phosphorylation at 
S211. Differences in the conformation of GR when bound to different ligands could 
represent a likely possibility for this common upstream event.  
 
This report has investigated the extent of GR nuclear localisation at a fixed time point 
(2 h), at saturating concentrations of GR ligand. Thus the question of nuclear import 
rate has not been examined, and it would be interesting to find out whether the 
observed differences are a result of different kinetics of nuclear import and export, or 
lower maximal nuclear import. The former seems a more likely explanation in light of 
published observations that different ligands caused different rates of nuclear import 
(Vicent et al., 2002). However Robertson et al., (2009) performed a time course 
analysis of nuclear import of GR when liganded to dex versus the dissociated GR 
ligand Compound A, and found that dex caused higher maximal GR nuclear 
localisation than Compound A. Initial investigations into the kinetics of GR nuclear 
localisation by the present author (data not shown) were confounded by the effect of 
ligand-dependent GR turnover, which has been shown to be more rapid when GR is 
liganded to more potent ligands (Dr C. Avenant, PhD thesis). Differential GR 
turnover caused different amounts of total GR to be present after treatment with 
different ligands, thus it was not possible to quantify the percentage of total GR in the 
nucleus after long treatments. Since it takes approximately 8 h for 50% reduction of 
GR levels in the presence of dex (Dr C. Avenant, PhD thesis), the effect of turnover 
would be negligible after 2 h treatment, and would only became problematic after 
longer incubation times. 
 
In conclusion, nuclear import of the GR is not simply a result of GR ligand binding, 
but the nature of the ligand which binds can determine the extent of nuclear 
localisation of the GR. Nuclear localisation correlates well with GR transactivation, 
probably as a result of the nuclear fraction of total GR binding DNA, and recruiting 
cofactors to increase gene transcription from a GRE. This suggests that nuclear 
translocation may be a rate-limiting step for transactivation. GR nuclear localisation 
with different ligands also correlates with GR phosphorylation at S211, which could 
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suggest GR becomes phosphorylated on interaction with the nuclear envelope or 
nuclear pore complex. The importance of differential GR nuclear localisation induced 







Future perspectives and conclusions 
 
This research work has further raised many interesting possibilities for future 
research, which could not be addressed in this project due to time-constraints. These 
will be discussed below, under the subheadings Acetylation and Nuclear 




The present studies have provided valuable insight into the molecular mechanism of 
action of the GR. It has been shown that lysines 494 and 495 play a critical role in 
GR transactivation, probably through acetylation, which modulates ligand binding, 
and thus downstream steps including nuclear translocation and phosphorylation. 
ChIP assays have implicated the immunophilin FKBP52 as a GR cofactor on the 
GILZ gene, and suggest the interaction may be modulated by GR acetylation at 
K494/495. 
 
The extent of ligand-dependent acetylation of GR in intact cells is an important issue 
that was not conclusively determined in the present study. Since 
immunoprecipitation results presented here, showing no increase in overall GR 
acetylation in response to dex or PMA (figure 3.1), contradict previously published 
results stating that “GR becomes acetylated after ligand binding” (Ito et al., 2006), 
this is clearly an area which warrants further research. As mentioned in Chapter 3, 
this poses some technical difficulties. To the best of the author’s knowledge, all the 
studies showing ligand-dependent SR acetylation in vivo employ a pre-treatment 
with HDAC inhibitors, before examining the acetylation state of the SR (Ito et al., 
2006; Fu et al., 2002; Kim et al., 2006), presumably since acetyl groups are 
vulnerable to cleavage by HDACs during the immunoprecipitation step, and HDACs 
must therefore be inhibited prior to cell lysis. This is in contrast to studies in which 
123 
 
HDAC pre-treatment of cells was not performed, which largely show ligand-
independent acetylation of SRs as reported here (Wang et al., 2001; Gaughan et al., 
2002). In addition, some studies are inconclusive due to the lack of loading controls 
(Fu et al., 2003; Fu et al., 2006). Furthermore, ligand-dependent acetylation of GR 
was only shown upon co-incubation with IL1β and dex (Ito et al., 2006), or 
overexpression of the HAT proteins CLOCK and BMAL1 (Nader et al., 2009) which 
further complicates interpretation of the results. These discrepancies should be 
addressed by a comprehensive analysis of GR acetylation in the absence and 
presence of IL1β and alternative pro-inflammatory stimuli such as PMA, to determine 
whether the effect of IL1β is specific, or a general feature of the GR response to pro-
inflammatory stimuli.  Comparison should also be made between GR acetylation in 
the absence or presence of pre-treatment with HADC inhibitors, and in the absence 
and presence of CLOCK. Furthermore, WT hGR and K494/495 mutants need to be 
compared in parallel to conclusively ascertain whether the specific residues K494 
and K495 are dex-dependently acetylated in addition to changes in overall GR 
acetylation status. These studies could be done by an immunoprecipitation 
approach, or by incubation with tritiated acetyl-CoA, to examine incorporation of the 
radioactive acetyl group.  
 
Another approach to answer the question of in vivo GR acetylation involves 
development of an antibody specific towards acetyl-GR K494/495. This has already 
been developed by the Ito laboratory (Prof K. Ito, personal communication), but 
unfortunately could not be supplied on request. This will be useful in determining the 
acetylation status of the GR in liganded and unliganded states, and should ideally be 
used in experiments with minimal post-treatment processing steps, in order to 
minimise the chance of HDAC removal of acetyl groups, for example 
immunofluorescence microscopy and ChIP assays.  
 
It has been assumed, that since the K494/495A hGR mutant construct used in this 
study, and a similar K494/495Q hGR mutant construct to the one used in this study, 
have previously been shown to have lower levels of acetylation than WT hGR (Ito et 
al., 2006), that the same would apply to the model system used here. Ideally, this 
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should have been tested by the same technique used by Ito and co-workers. This 
approach involved immunoprecipitation of WT and mutant GR after dex treatment 
and analysis of total acetylation levels by Western blotting. This would lend strong 
support to the argument that changes in acetylation status under the conditions used 
in the current study are responsible for the functional consequences observed with 
the mutant GR constructs, rather than some other non-specific effect of the 
mutations. To further strengthen the argument that acetylation at K494/495 
influences the ligand binding capacity of the GR, competitive binding curves could be 
performed, to establish the Kd of WT versus mutant GR.  
 
Although the acetylation deficient mutant caused significantly decreased 
transactivation of a synthetic promoter-reporter construct, and decreased nuclear 
translocation of GR, it may be argued that this should be confirmed on an 
endogenous gene, such as GILZ, by quantitative real-time PCR. Similarly, 
performing a ChIP assay to show a lack of recruitment of K494/495A hGR to the 
GILZ promoter would strongly support other findings presented here, such as a lack 
of nuclear localisation and ligand-binding displayed by this mutant. As mentioned in 
Chapter 3, the lack of in vitro DNA binding by the K494/495A hGR mutant may 
reflect a resistance to heat activation of the mutant rather than a decrease in DNA 
binding activity per se. To clarify this issue, WT hGR and K494/495A hGR could be 
separated by centrifugation through a sucrose gradient after a heat transformation 
treatment, or corresponding control treatment. Untransformed GR would be 
expected to be found in a 9S complex, while after heat transformation, a 4S complex 
would be expected (reviewed in Pratt, 1987). If K494/495A hGR did not form a 4S 
complex after heat transformation, this would indicate that the difference in in vitro 
DNA binding capacity between WT and mutant is most probably due to difference in 
response to heat activation.  
 
In this study, mutation of K494/495 of GR was shown to affect GR transactivational 
ability. As mentioned in chapter 3, it would be very interesting to investigate the role 
of these residues in GR-mediated transrepression, especially since acetylation of 
these residues has been implicated in modulating the interaction between GR and 
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the NFκB subunit p65 (Ito et al., 2006). Ito and co-workers (2006) used co-
immunoprecipitation assays to show an interaction between p65 and K494/495A 
hGR, but did not include the K494/495Q mutant as a control, which would be useful. 
Further investigation of the functional effect of K494/495 acetylation on 
transrepression could be done quite simply by promoter-reporter assays with WT 
and mutant GR constructs, using reporter constructs containing NFκB-sites. Results 
obtained in promoter-reporter assays could further be confirmed on endogenous 
genes using quantitative real-time PCR, and compared to transrepression via AP-1 
sites, to investigate whether the effect is specific to NFκB, or a general feature of GR 
transrepression. If the effects of acetylation on transactivation and transrepression 
are found to be different, then modulation of GR acetylation status could play an 
important role in the development of selective GR agonists with greater potency for 
transrepression than transactivation.  
 
The present study showed, for the first time, that mutation of lysine residues 494/495 
of human GR to abrogate or mimic acetylation at these sites modulated the 
phosphorylation status of the GR at S211 and S226. It would be very interesting to 
examine the effect of these mutations on other known phosphorylation sites such as 
S203 and S404. GR phosphorylated at S203 has been found to localise mainly to 
the cytoplasm, to be relatively high in the absence of ligand (Wang et al., 2002), and 
to be greater when S226 is not phosphorylated (Wang et al., 2007a). These factors 
indicate this is a potential phosphorylation site in K494/495A hGR, which does not 
bind ligand, translocate to the nucleus, or display phosphorylation at S226. If the 
K494/495A mutant were found to be a target of phosphorylation at S203, it would 
strengthen the argument that this mutant is correctly folded and active in some 
respect, rather than simply being a null-mutant. Furthermore, GR phosphorylation at 
S404 has been implicated in the interaction between GR and p65 (Galliher-Beckley, 
Williams, Collins, & Cidlowski, 2008). Since acetylation of GR at K494/495 has also 
been implicated in this interaction (Ito et al., 2006), it is probable that there may be 
an interplay between these two post-translational modifications, which would be 




In addition to examining the role of K494/495 in GR transactivation, this study also 
implicated FKBP52 as a GR interacting partner via acetylated K494/495 residues, 
and as a GR cofactor on the GILZ promoter. However, many elements of this work 
are speculative, and further experimentation is needed to make the speculations 
presented more conclusive. For instance, ChIP analysis of GR occupancy at the 
GILZ promoter using an anti-HA antibody did not show increased levels of 
K494/495Q HAhGR on this promoter in response to dex, although quantitative real-
time PCR indicated that the mutant GR must have been recruited in order to cause 
increased GILZ transcription in response to dex. This argument would have been 
strengthened by immunoprecipitation with antibodies recognising other epitopes of 
the GR, which may have shown an increase in total mutant GR recruitment to the 
promoter. Furthermore, ChIP assays with an FKBP52 antibody failed to show 
significant recruitment of FKBP52 to the GILZ promoter by WT HAhGR. This was 
perplexing given that FKBP52 has been shown to augment the GR-mediated 
transcriptional response at the GILZ gene in the presence of WT GR (Wolf et al., 
2009). As speculated in chapter 3, this could be due to formation of a multi-protein 
complex at the GILZ promoter, which prevented access of the polyclonal anti-
FKBP52 antibody to the FKBP52 present on the promoter. Low levels of 
endogenous FKBP52 may also contribute to this problem, therefore a possible 
solution may include stably transfecting a tagged FKBP52 which could be 
immunoprecipitated by its tag. As mentioned in chapter 4, transient transfection is 
unlikely to be useful for ChIP analysis because only a small percentage of cells 
express the exogenous protein, and the promoter of interest becomes a limiting 
factor. It would also be interesting to examine the differences in recruitment of other 
cofactors between WT HAhGR and K494/495Q HAhGR, for instance members of 
the p160 family such as GRIP1 and SRC1. This may give a better picture of the 
members of the complex recruited to the GILZ promoter by each GR construct. 
Furthermore it would be intriguing to investigate whether FKBP52 is accompanied by 
Hsp90 to the GILZ promoter by performing a ChIP assay using an anti-Hsp90 
antibody. Hsp90 has been shown to be recruited to other endogenous promoters 
(Freeman & Yamamoto, 2002), where it is implicated in rapid cycling on the 
chromatin. The presence of Hsp90 on the GILZ promoter in the presence of WT 
HAhGR would support the notion that FKBP52 may also be recruited but its 
presence is masked by the multitude of other cofactors recruited. The line of 
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investigation could also be pursued in a cell line with high levels of endogenous GR, 
such as A549.  
 
The results presented in chapter 3 support a model in which GR interaction with 
FKBP52, via acetylated lysine residues in its DBD/hinge region, modulates its ligand-
binding ability, and hence its nuclear translocation, phosphorylation and 
transactivation. Furthermore, FKBP52 is implicated as a gene-specific coactivator of 
the GILZ promoter. This last supposition would be strengthened by analysis of 
FKBP52 recruitment to another gene that has previously been shown to be 
unaffected by FKBP52 knockdown, such as SGK or p21 genes (Wolf et al., 2009). 
FKBP52 levels would be expected to show no increase on this promoter, although 
WT HAhGR recruitment would be expected to increase in a dex-dependent manner. 
Quantitative real-time PCR should first be used to compare the transactivational 
ability of WT HAhGR and K494/494Q HAhGR on the SGK promoter, as this may 
differ significantly from the GILZ promoter. It would then be interesting to examine 
recruitment of K494/495Q HAhGR to the SGK promoter, as well as other cofactors 
such as GRIP-1 and SRC1.  
 
The argument that GR acetylation at K494/495 modulates its interaction with 
FKBP52, as speculated here, could certainly be strengthened by further 
experimentation. Although this hypothesis is well-supported by the data presented in 
chapter 3, the precise role of acetylation at these sites has not been conclusively 
shown. This could be done by immunoprecipitation of WT and mutant GR protein, 
followed by analysis of co-immunoprecipitated immunophilins by Western blotting. 
Since FKBP51 has been shown to have an opposite effect to that of FKBP52 on GR 
ligand binding and transactivation (Denny et al., 2000), it would be interesting to use 
this technique to examine the hypothesis that FKBP51 is the predominant 
immunophilin present in the Hsp90 heterocomplex in the case of K494/495A hGR, in 
contrast to K494/495Q HAhGR which would be expected to be found in a complex 
comprising Hsp90, and FKBP52 as the predominant immunophilin. Another TPR 
protein found in Hsp90 heterocomplexes with GR is PP5. This would be an 
interesting candidate to investigate, since it has been shown to modulate the 
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phosphorylation status of the GR (Wang et al., 2007a; Zhang et al., 2009), and the 
present study has shown that alteration of GR acetylation status differentially affects 
phosphorylation at S211 and S226. It is possible that this could also be a result of 
differences within the Hsp90 heterocomplex brought about by GR acetylation status. 
Co-immunoprecipitation experiments conducted by the present author and other 
members of the Hapgood laboratory proved inconclusive due to technical difficulties. 
The conditions required to maintain the interaction between GR and immunophilin 
were insufficiently stringent to allow separation of exogenous GR from background 
levels of GR expressed in COS-7 cells. However, optimisation of this 
immunoprecipitation technique is a subject of ongoing research in the Hapgood 
laboratory. The temperature of incubation with ligand is a factor which must be 
optimised, as GR-immunophilin interaction in the cytoplasm is observed on 
incubation at 4˚C (Davies et al., 2002), while ChIP assays suggest an interaction at 
37˚C after nuclear localisation of the GR. It may be necessary to perform the 
treatments at both 4˚C and 37˚C to fully elucidate the role of GR-immunophilin 
interactions. 
 
If an immunoprecipitation approach should prove inconclusive, an alternative 
approach would be the use of fluorescence resonance energy transfer (FRET). In 
this technique labelled fluorescent proteins are expressed in combination so that a 
close association between proteins is indicated by excitement of one protein being 
induced by the fluorescence emission of the other. FRET may thus allow detection of 
differences in GR- immunophilin interactions between WT and mutant GR in COS-7 
cells.  
 
4.2 Nuclear localisation 
 
The present study show for the first time, using a large panel of GR ligands, and an 
endogenous GR model system, that the extent of nuclear localisation of the GR is 
selectively affected by the nature of the activating ligand, which correlates with the 
ligand-selective transactivation efficacy of the GR on the GILZ gene, and 
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phosphorylation at S211, but not transrepression on a number of endogenous 
genes.  
 
As highlighted in Chapter 1, the question of ligand-selective differences in nuclear 
translocation is often overlooked when investigating ligand-selective SR 
transcriptional responses (Wang et al., 2006; Garside et al., 2004; Kang et al., 2004). 
The results shown in Chapter 4 show that different ligands at saturating 
concentrations cause different extents of GR localisation, and this correlates well 
with ligand efficacy for transactivation of a synthetic reporter construct and an 
endogenous gene. Interestingly, no correlation was observed between nuclear 
localisation of the GR and efficacy for transrepression on promoter-reporter 
constructs or several endogenous genes. It is plausible that the use of PMA in 
transrepression assays may modulate nuclear translocation of the GR, and this 
could be investigated by repeating fractionation and immunofluorescence 
microscopy experiments in the absence and presence of PMA. However the weak 
transrepression observed in U2OS, as a result of the low endogenous GR levels 
(Appendix D figure D.2) makes it difficult to draw a robust conclusion. It would be 
interesting to repeat the transrepression experiments in a cell line with higher levels 
of endogenous GR, such as A549, which would be likely to yield higher levels of GR-
mediated transrepression. Use of a cell line with endogenous GR would be 
preferable to transfected GR, as transiently transfected constructs do no distribute 
evenly between the entire cell population, while stably transfected constructs have to 
be carefully monitored to ensure their expression levels do not decrease over time 
as shown in Appendix E, figure E.5.1. 
 
Another disappointing finding probably attributable to the low levels of GR in the 
selected U2OS model system was that the ChIP assay on the GILZ promoter did not 
yield reproducible results in the U2OS cell line, as this would have allowed further 
dissection of the relative roles of ligand-selective nuclear translocation and ligand-
selective promoter occupancy of GR in the transcriptional response. Examination of 
ligand-selective promoter occupancy by GR would very likely be possible using the 
A549 cell line, which has higher GR levels and gave a higher fold recruitment of GR 
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to the GILZ promoter in the ChIP assay. However, since it is established that varying 
GR levels may impact the transcriptional response (Vanderbilt et al., 1987; Zhao et 
al., 2003), it would be necessary to repeat experiments to investigate differential 
nuclear translocation and biological activity in the new model cell line. In itself this 
would be interesting, as the effect of GR levels on ligand-selective nuclear 
localisation is not known, however this could not be further investigated in this 
project due to constraints on time and budget. Furthermore, differential cofactor 
recruitment has been demonstrated for a wide panel of ligands in vitro and in 
mammalian two-hybrid assays (Ronacher et al., 2009), and it would be very 
interesting to examine recruitment of cofactors to endogenous promoters using the 
ChIP assay, to see whether observations from in vitro assays are reflected in vivo.  
 
One of the most interesting directions for follow-up from this research would be to 
uncover the mechanism of differential nuclear localisation of GR when bound to 
different ligands. The basis for these differences is likely to be different 
conformations of the GR when bound to structurally different ligands. As it has been 
shown that GR ligand-binding elicits a swop of FKBP51 for FKBP52 on the Hsp90 
heterocomplex (Davies et al., 2002), this was initially suspected to play a role. 
However, despite following two different published protocols, the present author was 
unable to detect a dex-mediated immunophilin swop on endogenous GR in U2OS 
(data not shown) or A549 cells (Appendix E., figure E.3.2). Thus, the possibility of 
differential immunophilin swop as a mechanism for differential GR nuclear 
translocation has not been excluded, but requires further optimisation. Alternative 
explanations which could also be explored include differential interaction of liganded 
GR with proteins of the nuclear pore complex, or importins.  
 
This report has investigated the extent of GR nuclear localisation at a fixed time point 
(2 h), at saturating concentration of GR ligand. Thus the question of nuclear import 
rate has not been examined, and it would be interesting to find out whether the 
observed differences are a result of different kinetics of nuclear import and export, or 
lower maximal nuclear import. Initial investigations into the kinetics of GR nuclear 
localisation by the present author (data not shown) were confounded by the effect of 
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ligand-dependent GR turnover, which has been shown to be more rapid when GR is 
liganded to more potent ligands (Dr C. Avenant, PhD thesis), thus it was not possible 
to quantify the percentage of total GR in the nucleus after long treatments. A 
possible strategy to avoid this complication, and investigate the kinetics of GR 
nuclear localisation with different ligands, would be to use live cell imaging of 
fluorescently labelled GR, which would allow constant monitoring of nuclear GR 
levels, by measuring nuclear fluorescence intensity from the moment of treatment to 
the maximal accumulation within the nucleus, and subsequent decline in GR levels 
due to turnover. This could give some basis for comparison of the rate of GR nuclear 
localisation elicited by different ligands, while taking into account the different rates 
of ligand-mediated GR turnover. 
 
In chapter 4 it was proposed that GR phosphorylation at S211 may occur in the 
nucleus or on interaction with the nuclear membrane, due to differences in 
subcellular localisation of GR-phospho-S211 observed with biochemical and 
microscopic techniques (Wang et al., 2002). This is an interesting hypothesis which 
warrants further investigation. Results from the Hapgood laboratory indicate that 
phosphorylation at S211 is not required for nuclear import (Avenant et al., 2010), 
which may indicate that the strong correlation observed between nuclear localisation 
and S211 phosphorylation reported in chapter 4 is a result of a causative effect of 
nuclear translocation on S211 phosphorylation. For further study in this area on 
endogenously expressed GR, it would be advantageous to use a cell line expressing 
higher levels of endogenous GR than U2OS (e.g. A549), since detection of 
phosphorylated GR was very difficult in this cell line. Detection of the S211 
phosphoisoform of GR in biochemically fractionated nuclear and cytoplasmic 
fractions of A549 cells, would allow confirmation of the results observed for 
overexpressed GR by Wang and co-workers (2002), with endogenous GR. 
Furthermore, use of a nuclear-translocation deficient mutant may yield interesting 
results, as phosphorylation of all known phosphorylation sites could be examined in 
the absence and presence of ligand, using Western blotting and phospho-specific 
antibodies. Lack of phosphorylation in the nuclear translocation deficient mutant GR 
would confirm that hypothesis that nuclear import is required for phosphorylation. 
However, if this mutant were phosphorylated, this could indicate that either GR 
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phosphorylation occurs in the cytoplasm, or on interaction with the nuclear envelope. 
One could further speculate that the subcellular location at which GR 
phosphorylation takes place may be ligand-selective, as comparison of the 
compartmentalisation of GR phospho-isoforms has only been performed in the 
presence of dex (Wang et al., 2002). This could be investigated by comparing the 
extent of phosphorylation of a nuclear translocation deficient GR mutant in the 
presence of different ligands.  
 
The finding that GR-mediated transactivation efficacy by a panel of ligands 
correlates with nuclear localisation, and phosphorylation at S211, as well as 
recruitment of the coregulators GRIP-1, SRC1, SMRT (Ronacher et al., 2009) is 
interesting. One might be tempted to speculate that ligand-selective differences 
based on differences in GR conformation at an upstream step cause the difference 
in downstream steps. If this is the case, nuclear import is unlikely to represent the 
key upstream step, since ligand-selective differences in cofactor recruitment 
(correlating with transactivation in COS-1 cells) are observed in vitro in whole cell 
lysates (Ronacher et al., 2009). GR phosphorylation is another unlikely possibility, 
since phosphorylation deficient mutants have been shown to exhibit unaltered 
nuclear localisation (Avenant et al., 2010). The key “first step” which defines these 
correlations thus remains to be established, but it seems unlikely that the GR 
conformation per se could affect interactions of the GR-ligand complex with several 
different interacting proteins to the same relative extent. It may be possible that an 
as-yet unidentified protein interacts with GR to variable degrees depending on the 
conformation induced by the particular ligand. As discussed in Chapter 3, a 
multifunctional protein like FKBP52 can modulate GR function at a number of steps, 
for example ligand binding, nuclear translocation, and by acting as a coregulator, 
making it a possible candidate. Thus the notion of an interacting partner as the 
reason for the strong correlation between several different steps of the GR 
transcriptional response is plausible. However work needs to be done to establish 




4.3  Conclusions 
 
Transcriptional regulation by the GR is a complex, multistep process, which is not 
fully understood. The present research has made an important contribution to our 
understanding of two aspects of ligand-selective GR activity. Firstly, it has 
investigated the functional effects of GR acetylation at lysines 494 and 495. Results 
strongly suggest that acetylation at K494/495 is essential for ligand binding and 
transactivation by the GR, possibly through a mechanism involving FKBP52 
interaction. Secondly, it has highlighted the importance of differential nuclear import 
as a key step in regulating ligand-specific transcriptional efficacy of the GR. This 
should not be overlooked when investigating the effects of different GR ligands at 
steps downstream of GR nuclear import, such as DNA binding, protein tethering or 
cofactor recruitment. Although many unanswered questions remain regarding the 
molecular mechanism of action of the GR, any advances in the field of GR function 
could one day have important implications for treatment of a multitude of diseases 






Adcock, I. M. (2000). Molecular mechanisms of glucocorticosteroid actions. Pulmonary 
Pharmacology & Therapeutics, 13(3), 115-26. 
Africander, D. (2009) Comparative study of the synthetic progestins medroxyprogesterone 
acetate and norethisterone enanthate/acetate. PhD thesis, Department of Biochemistry, 
University of Stellenbosch, Stellenbosch, South Africa. 
Atta-ur-Rahman, Harvey, K., & Siddiqui, R. A. (1999). Interleukin-8: An autocrine 
inflammatory mediator. Current Pharmaceutical Design, 5(4), 241-53. 
Ausubel, F. M. (1999). Transfection using DEAE-dextran. Short Protocols in Molecular 
Biology (4th ed.). New York, NY, USA. 
Avenant, C., Kotitschke, A., & Hapgood, J. P. (2010). Glucocorticoid Receptor 
Phosphorylation Modulates Transcription Efficacy through GRIP-1 Recruitment. 
Biochemistry. 49(5):972-85. 
Avenant, C. (2009) Molecular mechanism of action of the glucocorticoid receptor: Role of 
ligand-dependent receptor phosphorylation and half-life in determination of ligand-specific 
transcriptional activity. PhD thesis, Department of Molecular and Cell Biology, University of 
Cape Town, Cape Town, South Africa. 
Banerjee, A., Periyasamy, S., Wolf, I. M., Hinds, T. D., Yong, W., Shou, W., Sanchez, E.R., 
(2008). Control of glucocorticoid and progesterone receptor subcellular localization by the 
ligand-binding domain is mediated by distinct interactions with tetratricopeptide repeat 
proteins. Biochemistry, 47(39), 10471-80. 
Barent, R. L., Nair, S. C., Carr, D. C., Ruan, Y., Rimerman, R. A., Fulton, J., Zhang, Y., 
Smith, D. F., (1998). Analysis of FKBP51/FKBP52 chimeras and mutants for Hsp90 binding 
and association with progesterone receptor complexes. Molecular Endocrinology, 12(3), 
342-54. 
 
Barnes, P. J. (2006). How corticosteroids control inflammation: Quintiles Prize Lecture 2005. 
British Journal of Pharmacology, 148(3), 245-54. 
Baughman, G., Wiederrecht, G. J., Chang, F., Martin, M. M., & Bourgeois, S. (1997). Tissue 
distribution and abundance of human FKBP51, and FK506-binding protein that can mediate 
calcineurin inhibition. Biochemical and Biophysical Research Communications, 232(2), 437-
43. 
Beato, M., Chalepakis, G., Schauer, M., & Slater, E. P. (1989). DNA regulatory elements for 
steroid hormones. Journal of Steroid Biochemistry, 32(5), 737-47. 
Bellingham, D. L., Sar, M., & Cidlowski, J. A. (1992). Ligand-dependent down-regulation of 
stably transfected human glucocorticoid receptors is associated with the loss of functional 
glucocorticoid responsiveness. Molecular Endocrinology, 6(12), 2090-102. 
135 
 
Benayahu, D., Shur, I., Marom, R., Meller, I., & Issakov, J. (2001). Cellular and molecular 
properties associated with osteosarcoma cells. Journal of Cellular Biochemistry, 84(1), 108-
14. 
Beutler, B., Krochin, N., Milsark, I. W., Luedke, C., & Cerami, A. (1986). Control of cachectin 
(tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science, 232(4753), 
977-80. 
Biddie, S. C., & Hager, G. L. (2009). Glucocorticoid receptor dynamics and gene regulation. 
Stress, 12(3), 193-205. 
Bledsoe, R. K., Montana, V. G., Stanley, T. B., Delves, C. J., Apolito, C. J., McKee, D. D., 
Consler, T.G. Parks, D. J., Stewart, E. L., Willson, T. M. Lambert, M. H., Moore, J. T., 
Pearce, K. H., Xu, H E., (2002). Crystal structure of the glucocorticoid receptor ligand 
binding domain reveals a novel mode of receptor dimerization and coactivator recognition. 
Cell, 110(1), 93-105. 
 
Blind, R. D., & Garabedian, M. J. (2008). Differential recruitment of glucocorticoid receptor 
phospho-isoforms to glucocorticoid-induced genes. Journal of Steroid Biochemistry and 
Molecular Biology, 109(1-2), 150-7. 
Buckingham, J. C. (2006). Glucocorticoids: exemplars of multi-tasking. British Journal of 
Pharmacology, 147 Suppl, S258-68. 
Charmandari, E., Chrousos, G. P., Ichijo, T., Bhattacharyya, N., Vottero, A., Souvatzoglou, 
E., Kino, T., (2005). The human glucocorticoid receptor (hGR) beta isoform suppresses the 
transcriptional activity of hGRalpha by interfering with formation of active coactivator 
complexes. Molecular Endocrinology, 19(1), 52-64. 
Chen, D., Huang, S. M., & Stallcup, M. R. (2000). Synergistic, p160 coactivator-dependent 
enhancement of estrogen receptor function by CARM1 and p300. Journal of Biological 
Chemistry, 275(52), 40810-6. 
Chen, H., Lin, R. J., Schiltz, R. L., Chakravarti, D., Nash, A., Nagy, L., Privalsky, M. L., 
Nakatani, Y., Evans, R. M. (1997). Nuclear receptor coactivator ACTR is a novel histone 
acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. 
Cell, 90(3), 569-80. 
 
Chen, W., Dang, T., Blind, R. D., Wang, Z., Cavasotto, C. N., Hittelman, A. B., Rogatsky, I., 
Logan, S. K., Garabedian, M. J. (2008). Glucocorticoid receptor phosphorylation differentially 
affects target gene expression. Molecular Endocrinology, 22(8), 1754-66. 
 
Cheng, Y., & Prusoff, W. H. (1973). Relationship between the inhibition constant (K1) and 
the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic 
reaction. Biochemical Pharmacology, 22(23), 3099-108.  
Chevillard-Briet, M., Trouche, D., & Vandel, L. (2002). Control of CBP co-activating activity 
by arginine methylation. The EMBO journal, 21(20), 5457-66. 
136 
 
Cho, S., Blackford, J. A., & Simons, S. S. (2005). Role of activation function domain-1, DNA 
binding, and coactivator GRIP1 in the expression of partial agonist activity of glucocorticoid 
receptor-antagonist complexes. Biochemistry, 44(9), 3547-61. 
Cidlowski, J. A., & Cidlowski, N. B. (1981). Regulation of glucocorticoid receptors by 
glucocorticoids in cultured HeLa S3 cells. Endocrinology, 109(6), 1975-82. 
Coghlan, M. J., Jacobson, P. B., Lane, B., Nakane, M., Lin, C. W., Elmore, S. W., Kym, P. 
R., Luly, J. R., Carter, G. W., Turner, R., Tyree, C. M., Hu, J., Elgort, M., Rosen, J., Miner, J. 
N. (2003). A novel antiinflammatory maintains glucocorticoid efficacy with reduced side 
effects. Molecular Endocrinology, 17(5), 860-9. 
 
Collingwood, T. N., Urnov, F. D., & Wolffe, A. P. (1999). Nuclear receptors: coactivators, 
corepressors and chromatin remodeling in the control of transcription. Journal of Molecular 
Endocrinology, 23(3), 255-75. 
Croxtall, J. D., Paul-Clark, M., & Van Hal, P. T. (2003). Differential modulation of 
glucocorticoid action by FK506 in A549 cells. The Biochemical Journal, 376(Pt 1), 285-90. 
Cui, Y., Zhang, M., Pestell, R., Curran, E. M., Welshons, W. V., Fuqua, S. A. (2004). 
Phosphorylation of estrogen receptor alpha blocks its acetylation and regulates estrogen 
sensitivity. Cancer Research, 64(24), 9199-208. 
Cutress, M. L., Whitaker, H. C., Mills, I. G., Stewart, M., & Neal, D. E. (2008). Structural 
basis for the nuclear import of the human androgen receptor. Journal of Cell Science, 121(Pt 
7), 957-68. 
Cvoro, A., Tzagarakis-Foster, C., Tatomer, D., Paruthiyil, S., Fox, M. S., Leitman, D. C. 
(2006). Distinct roles of unliganded and liganded estrogen receptors in transcriptional 
repression. Molecular Cell, 21(4), 555-64. 
Czar, M. J., Lyons, R. H., Welsh, M. J., Renoir, J. M., & Pratt, W. B. (1995). Evidence that 
the FK506-binding immunophilin heat shock protein 56 is required for trafficking of the 
glucocorticoid receptor from the cytoplasm to the nucleus. Molecular Endocrinology, 9(11), 
1549-60. 
Czar, M. J., Owens-Grillo, J. K., Yem, A. W., Leach, K. L., Deibel, M. R., Welsh, M. J., Pratt, 
W. B. (1994). The hsp56 immunophilin component of untransformed steroid receptor 
complexes is localized both to microtubules in the cytoplasm and to the same nonrandom 
regions within the nucleus as the steroid receptor. Molecular Endocrinology, 8(12), 1731-41. 
Dahlman-Wright, K., Siltala-Roos, H., Carlstedt-Duke, J., & Gustafsson, J. A. (1990). 
Protein-protein interactions facilitate DNA binding by the glucocorticoid receptor DNA-
binding domain. Journal of Biological Chemistry, 265(23), 14030-5. 
Davies, L., Karthikeyan, N., Lynch, J. T., Sial, E., Gkourtsa, A., Demonacos, C., Krstic-
Demonacos, M. (2008). Cross talk of signaling pathways in the regulation of the 
glucocorticoid receptor function. Molecular Endocrinology, 22(6), 1331-44. 
137 
 
Davies, T. H., Ning, Y., & Sanchez, E. R. (2005). Differential control of Glucocorticoid 
Receptor hormone-binding function by tetratricopeptide repeat (TPR) proteins and the 
immunosuppressive ligand FK506. Biochemistry, 44(6), 2030- 38. 
Davies, T. H., Ning, Y., & Sánchez, E. R. (2002). A new first step in activation of steroid 
receptors: hormone-induced switching of FKBP51 and FKBP52 immunophilins. Journal of 
Biological Chemistry, 277(7), 4597-600. 
Denny, W. B., Valentine, D. L., Reynolds, P. D., Smith, D. F., & Scammell, J. G. (2000). 
Squirrel monkey immunophilin FKBP51 is a potent inhibitor of glucocorticoid receptor 
binding. Endocrinology, 141(11), 4107-13. 
Derijk, R. H., & de Kloet, E. R. (2008). Corticosteroid receptor polymorphisms: determinants 
of vulnerability and resilience. European Journal of Pharmacology, 583(2-3), 303-11. 
Dewint, P., Gossye, V., De Bosscher, K., Vanden Berghe, W., Van Beneden, K., Deforce, 
D., Van Calenbergh, S., Müller-Ladner, U., Vander Cruyssen, B., Verbruggen, G., 
Haegeman, G., Elewaut, D. (2008). A plant-derived ligand favoring monomeric glucocorticoid 
receptor conformation with impaired transactivation potential attenuates collagen-induced 
arthritis. Journal of Immunology, 180(4), 2608-15. 
 
Diefenderfer, D. L., Osyczka, A. M., Garino, J. P., & Leboy, P. S. (2003). Regulation of BMP-
induced transcription in cultured human bone marrow stromal cells. The Journal of Bone and 
Joint Surgery. American volume, 85-A Suppl, 19-28. 
Duma, D., Jewell, C. M., & Cidlowski, J. A. (2006). Multiple glucocorticoid receptor isoforms 
and mechanisms of post-translational modification. Journal of Steroid Biochemistry and 
Molecular Biology, 102(1-5), 11-21. 
Echeverría, P. C., Mazaira, G., Erlejman, A., Gomez-Sanchez, C., Piwien Pilipuk, G., 
Galigniana, M. D. (2009). Nuclear import of the glucocorticoid receptor-hsp90 complex 
through the nuclear pore complex is mediated by its interaction with Nup62 and importin 
beta. Molecular and Cellular Biology, 29(17), 4788-97. 
Eddleston, J., Herschbach, J., Wagelie-Steffen, A. L., Christiansen, S. C., & Zuraw, B. L. 
(2007). The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced 
leucine zipper in epithelial cells. Journal of Allergy and Clinical Immunology, 119(1), 115-22. 
Elbi, C., Walker, D. A., Lewis, M., Romero, G., Sullivan, W. P., Toft, D. O., Hager, G. L., 
DeFranco, D. B. (2004). A novel in situ assay for the identification and characterization of 
soluble nuclear mobility factors. Science's STKE: signal transduction knowledge 
environment, 2004 (238), pl10. 
 
Fang, L., Ricketson, D., Getubig, L., & Darimont, B. (2006). Unliganded and hormone-bound 
glucocorticoid receptors interact with distinct hydrophobic sites in the Hsp90 C-terminal 
domain. Proceedings of the National Academy of Sciences of the United States of America, 
103(49), 18487-92. 
Faus, H., & Haendler, B. (2006). Post-translational modifications of steroid receptors. 
Biomedicine & Pharmacotherapy, 60(9), 520-8. 
138 
 
Faus, H., & Haendler, B. (2008). Androgen receptor acetylation sites differentially regulate 
gene control. Journal of Cellular Biochemistry, 104(2), 511-24. 
Fletcher, T. M., Xiao, N., Mautino, G., Baumann, C. T., Wolford, R., Warren, B. S., Hager, G. 
L. (2002). ATP-dependent mobilization of the glucocorticoid receptor during chromatin 
remodeling. Molecular and Cellular Biology, 22(10), 3255-63. 
Freedman, N. D., & Yamamoto, K. R. (2004). Importin 7 and importin alpha/importin beta are 
nuclear import receptors for the glucocorticoid receptor. Molecular Biology of the Cell, 15(5), 
2276-86. 
Freeman, B. C., & Yamamoto, K. R. (2002). Disassembly of transcriptional regulatory 
complexes by molecular chaperones. Science, 296(5576), 2232-5. 
Frego, L., & Davidson, W. (2006). Conformational changes of the glucocorticoid receptor 
ligand binding domain induced by ligand and cofactor binding, and the location of cofactor 
binding sites determined by hydrogen/deuterium exchange mass spectrometry. Protein 
Science: a publication of the Protein Society, 15(4), 722-30. 
Fryer, C. J., Kinyamu, H. K., Rogatsky, I., Garabedian, M. J., & Archer, T. K. (2000). 
Selective activation of the glucocorticoid receptor by steroid antagonists in human breast 
cancer and osteosarcoma cells. Journal of Biological Chemistry, 275(23), 17771-7. 
Fu, M., Liu, M., Sauve, A. A., Jiao, X., Zhang, X., Wu, X., Powell, M. J., Yang, T., Gu, W., 
Avantaggiati, M. L., Pattabiraman, N., Pestell, T. G., Wang, F., Quong, A. A., Wang, C., 
Pestell, R. G. (2006). Hormonal control of androgen receptor function through SIRT1. 
Molecular and Cellular Biology, 26(21), 8122-35. 
 
Fu, M., Rao, M., Wu, K., Wang, C., Zhang, X., Hessien, M., Yeung, Y., Gioeli, D.,Weber, M. 
J., Pestell, R. G. (2004). The androgen receptor acetylation site regulates cAMP and AKT 
but not ERK-induced activity. Journal of Biological Chemistry, 279(28), 29436-49. 
Fu, M., Wang, C., Reutens, A. T., Wang, J., Angeletti, R. H., Siconolfi-Baez, L., Ogryzko, V., 
Avantaggiati, M. L., Pestell, R. G. (2000). p300 and p300/cAMP-response element-binding 
protein-associated factor acetylate the androgen receptor at sites governing hormone-
dependent transactivation. Journal of Biological Chemistry, 275(27), 20853-60. 
Fu, M., Wang, C., Wang, J., Zhang, X., Sakamaki, T., Yeung, Y. G., Chang, C., Hopp, T., 
Fuqua, S., Jaffray, E., Hay, R., Palvimo, J., Jänne, O., Pestell, R. G. (2002). Androgen 
receptor acetylation governs trans activation and MEKK1-induced apoptosis without 
affecting in vitro sumoylation and trans-repression function. Molecular and Cellular Biology, 
22(10), 3373-88. 
Fu, M., Rao, M., Wang, J., Di Vizio, D., Wang, C., Zhang, X., Sakamaki, T., Albanese, C., 
Balk, S., Chang, C., Fan, S., Rosen, E., Palvimo, J., Jänne, O., Muratoglu, S., Avantaggiati, 
M., Pestell, R. G. (2003). Acetylation of androgen receptor enhances coactivator binding and 
promotes prostate cancer cell growth. Molecular and Cellular Biology, 23(23), 8563-75. 
Galigniana, M. D., Erlejman, A. G., Monte, M., Gomez-Sanchez, C., & Piwien-Pilipuk, G. 
(2010). The hsp90*FKBP52 complex links the mineralocorticoid receptor to motor proteins 
139 
 
and persists bound to the receptor in early nuclear events. Molecular and Cellular Biology. 
30(5): 1285- 98. 
Galigniana, M. D., Harrell, J. M., Murphy, P. J., Chinkers, M., Radanyi, C., Renoir, J., Zhang, 
M., Pratt, W. B., (2002). Binding of hsp90-associated immunophilins to cytoplasmic dynein: 
direct binding and in vivo evidence that the peptidylprolyl isomerase domain is a dynein 
interaction domain. Biochemistry, 41(46), 13602-10. 
 
Galliher-Beckley, A. J., Williams, J. G., Collins, J. B., & Cidlowski, J. A. (2008). Glycogen 
synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid 
receptor redirects gene expression profiles. Molecular and Cellular Biology, 28(24), 7309-22. 
Gallo, L. I., Ghini, A. A., Piwien Pilipuk, G., & Galigniana, M. D. (2007). Differential 
recruitment of tetratricopeptide repeat domain immunophilins to the mineralocorticoid 
receptor influences both heat-shock protein 90-dependent retrotransport and hormone-
dependent transcriptional activity. Biochemistry, 46(49), 14044-57. 
Garside, H., Stevens, A., Farrow, S., Normand, C., Houle, B., Berry, A., Maschera, B., Ray, 
D. (2004). Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric 
effects on the glucocorticoid receptor DNA binding domain. Journal of Biological Chemistry, 
279(48), 50050-9. 
 
Gaughan, L., Logan, I. R., Cook, S., Neal, D. E., & Robson, C. N. (2002). Tip60 and histone 
deacetylase 1 regulate androgen receptor activity through changes to the acetylation status 
of the receptor. Journal of Biological Chemistry, 277(29), 25904-13. 
Gehring, U., Segnitz, B., Foellmer, B., & Francke, U. (1985). Assignment of the human gene 
for the glucocorticoid receptor to chromosome 5. Proceedings of the National Academy of 
Sciences of the United States of America, 82(11), 3751-5. 
George, A. A., Schiltz, R. L., & Hager, G. L. (2009). Dynamic access of the glucocorticoid 
receptor to response elements in chromatin. The International Journal of Biochemistry & Cell 
Biology, 41(1), 214-24. 
Glickman, M. H., & Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: 
destruction for the sake of construction. Physiological Reviews, 82(2), 373-428. 
Glozak, M. A., Sengupta, N., Zhang, X., & Seto, E. (2005). Acetylation and deacetylation of 
non-histone proteins. Gene, 363, 15-23. 
Goel, A., & Janknecht, R. (2004). Concerted activation of ETS protein ER81 by p160 
coactivators, the acetyltransferase p300 and the receptor tyrosine kinase HER2/Neu. 
Journal of Biological Chemistry, 279(15), 14909-16. 
Grad, I., & Picard, D. (2007). The glucocorticoid responses are shaped by molecular 
chaperones. Molecular and Cellular Endocrinology, 275(1-2), 2-12. 
Grad, J. M., Dai, J. L., Wu, S., & Burnstein, K. L. (1999). Multiple androgen response 
elements and a Myc consensus site in the androgen receptor (AR) coding region are 
involved in androgen-mediated up-regulation of AR messenger RNA. Molecular 
Endocrinology, 13(11), 1896-911. 
140 
 
Grenier, J., Trousson, A., Chauchereau, A., Cartaud, J., Schumacher, M., Massaad, C. 
(2006). Differential recruitment of p160 coactivators by glucocorticoid receptor between 
Schwann cells and astrocytes. Molecular Endocrinology, 20(2), 254-67. 
Gross, K. L., & Cidlowski, J. A. (2008). Tissue-specific glucocorticoid action: a family affair. 
Trends in Endocrinology and Metabolism: TEM, 19(9), 331-9. 
Harrell, J. M., Murphy, P. J., Morishima, Y., Chen, H., Mansfield, J. F., Galigniana, M. D., 
Pratt, W. B. (2004). Evidence for glucocorticoid receptor transport on microtubules by 
dynein. Journal of Biological Chemistry, 279(52), 54647-54. 
Hayashi, R., Wada, H., Ito, K., & Adcock, I. M. (2004). Effects of glucocorticoids on gene 
transcription. European Journal of Pharmacology, 500(1-3), 51-62.  
Heitzer, M. D., Wolf, I. M., Sanchez, E. R., Witchel, S. F., & DeFranco, D. B. (2007). 
Glucocorticoid receptor physiology. Reviews in Endocrine & Metabolic Disorders, 8(4), 321-
30. 
Hoeck, W., Rusconi, S., & Groner, B. (1989). Down-regulation and phosphorylation of 
glucocorticoid receptors in cultured cells. Investigations with a monospecific antiserum 
against a bacterially expressed receptor fragment. Journal of Biological Chemistry, 264(24), 
14396-402. 
Horwitz, K. B., Jackson, T. A., Bain, D. L., Richer, J. K., Takimoto, G. S., Tung, L., (1996). 
Nuclear receptor coactivators and corepressors. Molecular Endocrinology, 10(10), 1167-77. 
Hultman, M. L., Krasnoperova, N. V., Li, S., Du, S., Xia, C., Dietz, J. D., Lala, D. S., Welsch, 
D. J., Hu, X. (2005). The ligand-dependent interaction of mineralocorticoid receptor with 
coactivator and corepressor peptides suggests multiple activation mechanisms. Molecular 
Endocrinology, 19(6), 1460-73. 
 
Igarashi-Migitaka, J., Takeshita, A., Koibuchi, N., Yamada, S., Ohtani-Kaneko, R., Hirata, K., 
(2005). Differential expression of p160 steroid receptor coactivators in the rat testis and 
epididymis. European Journal of Endocrinology, 153(4), 595-604. 
Ismaili, N., & Garabedian, M. J. (2004). Modulation of glucocorticoid receptor function via 
phosphorylation. Annals of the New York Academy of Sciences, 1024, 86-101. 
Ito, K. (2007). Impact of post-translational modifications of proteins on the inflammatory 
process. Biochemical Society Transactions, 35(Pt 2), 281-3. 
Ito, K., Yamamura, S., Essilfie-Quaye, S., Cosio, B., Ito, M., Barnes, P. J., Adcock, I. (2006). 
Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-
kappaB suppression. The Journal of Experimental Medicine, 203(1), 7-13. 
Kaffman, A., & O'Shea, E. K. (1999). Regulation of nuclear localization: a key to a door. 
Annual review of Cell and Developmental Biology, 15, 291-339. 
Kang, Z., Jänne, O. A., & Palvimo, J. J. (2004). Coregulator recruitment and histone 
modifications in transcriptional regulation by the androgen receptor. Molecular 
Endocrinology, 18(11), 2633-48. 
141 
 
Kassel, O., & Herrlich, P. (2007). Crosstalk between the glucocorticoid receptor and other 
transcription factors: molecular aspects. Molecular and Cellular Endocrinology, 275(1-2), 13-
29. 
Kassel, O., Sancono, A., Krätzschmar, J., Kreft, B., Stassen, M., Cato, A. C. (2001). 
Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of 
MKP-1. The EMBO Journal, 20(24), 7108-16. 
Katzenellenbogen, J. A., O'Malley, B. W., & Katzenellenbogen, B. S. (1996). Tripartite 
steroid hormone receptor pharmacology: interaction with multiple effector sites as a basis for 
the cell- and promoter-specific action of these hormones. Molecular Endocrinology, 10(2), 
119-31. 
Kauppi, B., Jakob, C., Färnegårdh, M., Yang, J., Ahola, H., Alarcon, M., Calles, K., 
Engström, O., Harlan, J., Muchmore, S., Ramqvist, A., Thorell, S., Ohman, L., Greer, J., 
Gustafsson, J., Carlstedt-Duke, J., Carlquist, M. (2003). The three-dimensional structures of 
antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-
486 induces a transconformation that leads to active antagonism. Journal of Biological 
Chemistry, 278(25), 22748-54. 
 
Kim, M. Y., Woo, E. M., Chong, Y. T., Homenko, D. R., & Kraus, W. L. (2006). Acetylation of 
estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid 
binding and transactivation activities of the receptor. Molecular Endocrinology, 20(7), 1479-
93. 
Kino, T., Manoli, I., Kelkar, S., Wang, Y., Su, Y. A., Chrousos, G. P. (2009). Glucocorticoid 
receptor (GR) beta has intrinsic, GRalpha-independent transcriptional activity. Biochemical 
and Biophysical Research Communications, 381(4), 671-5. 
Kino, T., Su, Y. A., & Chrousos, G. P. (2009). Human glucocorticoid receptor isoform beta: 
recent understanding of its potential implications in physiology and pathophysiology. Cellular 
and Molecular Life Sciences : CMLS, 66(21), 3435-48. 
Kinyamu, H. K., Chen, J., & Archer, T. K. (2005). Linking the ubiquitin-proteasome pathway 
to chromatin remodeling/modification by nuclear receptors. Journal of Molecular 
Endocrinology, 34(2), 281-97. 
Kotitschke, A., Sadie-Van Gijsen, H., Avenant, C., Fernandes, S., & Hapgood, J. P. (2009). 
Genomic and nongenomic cross talk between the gonadotropin-releasing hormone receptor 
and glucocorticoid receptor signaling pathways. Molecular Endocrinology, 23(11), 1726-45. 
Kotitschke, A. (2009) Genomic and non-genomic cross talk between the gonadotropin-
releasing hormone receptor and glucocorticoid receptor signalling pathways. PhD thesis, 
Department of Molecular and Cell Biology, University of Cape Town, Cape Town, South 
Africa. 
Kroe, R. R., Baker, M. A., Brown, M. P., Farrow, N. A., Gautschi, E., Hopkins, J. L., 
LaFrance, R. R., Kronkaitis, A., Freeman, D., Thomson, D., Nabozny, G., Grygon, C., 
Labadia, M. E. (2007). Agonist versus antagonist induce distinct thermodynamic modes of 




Kumar, R., & Thompson, E. B. (2005). Gene regulation by the glucocorticoid receptor: 
structure: function relationship. Journal of Steroid Biochemistry and Molecular Biology, 94(5), 
383-94. 
Kumar, R., Baskakov, I. V., Srinivasan, G., Bolen, D. W., Lee, J. C., Thompson, E. B. (1999). 
Interdomain signaling in a two-domain fragment of the human glucocorticoid receptor. 
Journal of Biological Chemistry, 274(35), 24737-41. 
Le Drean, Y., Mincheneau, N., Le Goff, P., & Michel, D. (2002). Potentiation of glucocorticoid 
receptor transcriptional activity by sumoylation. Endocrinology, 143(9), 3482-9. 
Leclerc, N., Noh, T., Khokhar, A., Smith, E., & Frenkel, B. (2005). Glucocorticoids inhibit 
osteocalcin transcription in osteoblasts by suppressing Egr2/Krox20-binding enhancer. 
Arthritis and Rheumatism, 52(3), 929-39. 
Lee, Y., Koh, S. S., Zhang, X., Cheng, X., & Stallcup, M. R. (2002). Synergy among nuclear 
receptor coactivators: selective requirement for protein methyltransferase and 
acetyltransferase activities. Molecular and Cellular Biology, 22(11), 3621-32. 
Leeman, M. F., Curran, S., & Murray, G. I. (2002). The structure, regulation, and function of 
human matrix metalloproteinase-13. Critical Reviews in Biochemistry and Molecular Biology, 
37(3), 149-66. 
Lefstin, J. A., Thomas, J. R., & Yamamoto, K. R. (1994). Influence of a steroid receptor 
DNA-binding domain on transcriptional regulatory functions. Genes & Development, 8(23), 
2842-56. 
Lewis-Tuffin, L. J., Jewell, C. M., Bienstock, R. J., Collins, J. B., & Cidlowski, J. A. (2007). 
Human glucocorticoid receptor beta binds RU-486 and is transcriptionally active. Molecular 
and Cellular Biology, 27(6), 2266-82. 
Li, L., Leung, D. Y., Hall, C. F., & Goleva, E. (2006). Divergent expression and function of 
glucocorticoid receptor beta in human monocytes and T cells. Journal of Leukocyte Biology, 
79(4), 818-27. 
Li, X., Wong, J., Tsai, S. Y., Tsai, M., & O'Malley, B. W. (2003). Progesterone and 
glucocorticoid receptors recruit distinct coactivator complexes and promote distinct patterns 
of local chromatin modification. Molecular and Cellular Biology, 23(11), 3763-73. 
Lightman, S. L., Wiles, C. C., Atkinson, H. C., Henley, D. E., Russell, G. M., Leendertz, J. A., 
McKenna, M., Spiga, F., Wood, S., Conway-Campbell, B. L. (2008). The significance of 
glucocorticoid pulsatility. European Journal of Pharmacology, 583(2-3), 255-62. 
 
Liu, W., Wang, J., Sauter, N. K., & Pearce, D. (1995). Steroid receptor heterodimerization 
demonstrated in vitro and in vivo. Proceedings of the National Academy of Sciences of the 
United States of America, 92(26), 12480-4. 
Lu, N. Z., & Cidlowski, J. A. (2006). Glucocorticoid receptor isoforms generate transcription 
specificity. Trends in Cell Biology, 16(6), 301-7. 
143 
 
Lu, N. Z., Wardell, S. E., Burnstein, K. L., Defranco, D., Fuller, P. J., Giguere, V., Hochberg, 
R., McKay, L., Renoir, J., Weigel, N., Wilson, E., McDonnell, D., Cidlowski, J. (2006). 
International Union of Pharmacology. LXV. The pharmacology and classification of the 
nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen 
receptors. Pharmacological Reviews, 58(4), 782-97. 
 
Luisi, B. F., Xu, W. X., Otwinowski, Z., Freedman, L. P., Yamamoto, K. R., Sigler, P. B.  
(1991). Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. 
Nature, 352(6335), 497-505. 
Ma, H., Shang, Y., Lee, D. Y., & Stallcup, M. R. (2003). Study of nuclear receptor-induced 
transcription complex assembly and histone modification by chromatin immunoprecipitation 
assays. Methods in Enzymology, 364, 284-96. 
Maya-Núñez, G., & Conn, P. M. (2003). Transcriptional regulation of the GnRH receptor 
gene by glucocorticoids. Molecular and Cellular Endocrinology, 200(1-2), 89-98.  
McNally, J. G., Müller, W. G., Walker, D., Wolford, R., & Hager, G. L. (2000). The 
glucocorticoid receptor: rapid exchange with regulatory sites in living cells. Science, 
287(5456), 1262-5. 
Meijer, O. C., Steenbergen, P. J., & De Kloet, E. R. (2000). Differential expression and 
regional distribution of steroid receptor coactivators SRC-1 and SRC-2 in brain and pituitary. 
Endocrinology, 141(6), 2192-9.  
Meijsing, S. H., Pufall, M. A., So, A. Y., Bates, D. L., Chen, L., Yamamoto, K. R. (2009). DNA 
binding site sequence directs glucocorticoid receptor structure and activity. Science, 
324(5925), 407-10. 
Mendel, D. B., Bodwell, J. E., Gametchu, B., Harrison, R. W., & Munck, A. (1986). 
Molybdate-stabilized nonactivated glucocorticoid-receptor complexes contain a 90-kDa non-
steroid-binding phosphoprotein that is lost on activation. Journal of Biological Chemistry, 
261(8), 3758-63. 
Meneses De Leon, J., Balsiger, H., Iwai, A., Trepel, J., Lee, S., Kim, Y., Neckers, L.M., Cox, 
M. B. (2009). Characterization and targeting of a putative FKBP52 interaction surface on the 
Androgen Receptor hormone binding domain. In Endo '09 (pp. P2-21). 
 
Meyer, T., Gustafsson, J. A., & Carlstedt-Duke, J. (1997). Glucocorticoid-dependent 
transcriptional repression of the osteocalcin gene by competitive binding at the TATA box. 
DNA and Cell Biology, 16(8), 919-27. 
Mikuni, S., Pack, C., Tamura, M., & Kinjo, M. (2007). Diffusion analysis of glucocorticoid 
receptor and antagonist effect in living cell nucleus. Experimental and Molecular Pathology, 
82(2), 163-8. 
Miner, J. N., Ardecky, B., Benbatoul, K., Griffiths, K., Larson, C. J., Mais, D. E., Marschke, 
K., Rosen, J., Vajda, E., Zhi, L., Negro-Vilar, A. (2007). Antiinflammatory glucocorticoid 
receptor ligand with reduced side effects exhibits an altered protein-protein interaction 
144 
 
profile. Proceedings of the National Academy of Sciences of the United States of America, 
104(49), 19244-9. 
 
Miyata, Y., Chambraud, B., Radanyi, C., Leclerc, J., Lebeau, M. C., Renoir, J. M., Shirai, R., 
Catelli, M. G., Yahara, I., Baulieu, E. E. (1997). Phosphorylation of the immunosuppressant 
FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of 
FKBP52. Proceedings of the National Academy of Sciences of the United States of America, 
94(26), 14500-5. 
 
Murphy, B. A., Vick, M. M., Sessions, D. R., Cook, R. F., & Fitzgerald, B. P. (2007). Acute 
systemic inflammation transiently synchronizes clock gene expression in equine peripheral 
blood. Brain, Behavior, and Immunity, 21(4), 467-76. 
Nader, N., Chrousos, G. P., & Kino, T. (2009). Circadian rhythm transcription factor CLOCK 
regulates the transcriptional activity of the glucocorticoid receptor by acetylating its hinge 
region lysine cluster: potential physiological implications. The FASEB Journal, 23(5), 1572-
83. 
Newton, R. (2000). Molecular mechanisms of glucocorticoid action: what is important? 
Thorax, 55(7), 603-13. 
Newton, R., & Holden, N. S. (2007). Separating transrepression and transactivation: a 
distressing divorce for the glucocorticoid receptor? Molecular Pharmacology, 72(4), 799-809. 
Nicolaides, N. C., Galata, Z., Kino, T., Chrousos, G. P., & Charmandari, E. (2010). The 
human glucocorticoid receptor: Molecular basis of biologic function. Steroids, 75(1). 
Nissen, R. M., & Yamamoto, K. R. (2000). The glucocorticoid receptor inhibits NFkappaB by 
interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. 
Genes & Development, 14(18), 2314-29. 
Oakley, R. H., & Cidlowski, J. A. (1993). Homologous down regulation of the glucocorticoid 
receptor: the molecular machinery. Critical Reviews in Eukaryotic Gene Expression, 3(2), 
63-88. 
Oakley, R. H., Jewell, C. M., Yudt, M. R., Bofetiado, D. M., & Cidlowski, J. A. (1999). The 
dominant negative activity of the human glucocorticoid receptor beta isoform. Specificity and 
mechanisms of action. Journal of Biological Chemistry, 274(39), 27857-66. 
Pacifici, R. (1996). Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. 
Journal of Bone and Mineral Research, 11(8), 1043-51. 
Papadimitriou, A., & Priftis, K. N. (2009). Regulation of the hypothalamic-pituitary-adrenal 
axis. Neuroimmunomodulation, 16(5), 265-71. 
Pariante, C. M., Pearce, B. D., Pisell, T. L., Su, C., & Miller, A. H. (2001). The steroid 
receptor antagonists RU40555 and RU486 activate glucocorticoid receptor translocation and 




Paul-Clark, M. J., Roviezzo, F., Flower, R. J., Cirino, G., Soldato, P. D., Adcock, I. M.,  
(2003). Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel 
steroid ligands. Journal of Immunology, 171(6), 3245-52. 
Peeters, B. W., Ruigt, G. S., Craighead, M., & Kitchener, P. (2008). Differential effects of the 
new glucocorticoid receptor antagonist ORG 34517 and RU486 (mifepristone) on 
glucocorticoid receptor nuclear translocation in the AtT20 cell line. Annals of the New York 
Academy of Sciences, 1148, 536-41. 
Perrot-Applanat, M., Cibert, C., Géraud, G., Renoir, J. M., & Baulieu, E. E. (1995). The 59 
kDa FK506-binding protein, a 90 kDa heat shock protein binding immunophilin (FKBP59-
HBI), is associated with the nucleus, the cytoskeleton and mitotic apparatus. Journal of Cell 
Science, 108(5), 2037-51. 
Peterson, T. J., Karmakar, S., Pace, M. C., Gao, T., & Smith, C. L. (2007). The silencing 
mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for 
full estrogen receptor alpha transcriptional activity. Molecular and Cellular Biology, 27(17). 
Petrie, K., Guidez, F., Howell, L., Healy, L., Waxman, S., Greaves, M., Zelent, A. (2003). The 
histone deacetylase 9 gene encodes multiple protein isoforms. Journal of Biological 
Chemistry, 278(18), 16059-72. 
Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-
PCR. Nucleic Acids Research, 29(9), e45. 
Picard, D., & Yamamoto, K. R. (1987). Two signals mediate hormone-dependent nuclear 
localization of the glucocorticoid receptor. The EMBO Journal, 6(11), 3333-40. 
Poukka, H., Karvonen, U., Janne, O. A., & Palvimo, J. J. (2000). Covalent modification of the 
androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proceedings of the National 
Academy of Sciences of the United States of America, 97(26), 14145-50. 
Pratt, W. B. (1987). Transformation of glucocorticoid and progesterone receptors to the 
DNA-binding state. Journal of Cellular Biochemistry, 35(1), 51-68. 
Pratt, W. B., & Toft, D. O. (1997). Steroid receptor interactions with heat shock protein and 
immunophilin chaperones. Endocrine Reviews, 18(3), 306-60. 
Pratt, W. B., Galigniana, M. D., Harrell, J. M., & DeFranco, D. B. (2004). Role of hsp90 and 
the hsp90-binding immunophilins in signalling protein movement. Cellular Signalling, 16(8), 
857-72. 
Privalsky, M. L. (2004). The role of corepressors in transcriptional regulation by nuclear 
hormone receptors. Annual review of physiology, 66, 315-60. 
Rani, C. S., Elango, N., Wang, S., Kobayashi, K., & Strong, R. (2009). Identification of an 
activator protein-1-like sequence as the glucocorticoid response element in the rat tyrosine 
hydroxylase gene. Molecular Pharmacology, 75(3), 589-98. 
Ratajczak, T., Ward, B. K., Cluning, C., & Allan, R. K. (2009). Cyclophilin 40: an Hsp90-
cochaperone associated with apo-steroid receptors. International Journal of Biochemistry & 
Cell Biology, 41(8-9), 1652-5. 
146 
 
Revollo, J. R., & Cidlowski, J. A. (2009). Mechanisms generating diversity in glucocorticoid 
receptor signaling. Annals of the New York Academy of Sciences, 1179, 167-78. 
Reynolds, P. D., Ruan, Y., Smith, D. F., & Scammell, J. G. (1999). Glucocorticoid resistance 
in the squirrel monkey is associated with overexpression of the immunophilin FKBP51. The 
Journal of Clinical Endocrinology and Metabolism, 84(2), 663-9. 
Riggs, D. L., Cox, M. B., Tardif, H. L., Hessling, M., Buchner, J., Smith, D. F. (2007). 
Noncatalytic role of the FKBP52 peptidyl-prolyl isomerase domain in the regulation of steroid 
hormone signaling. Molecular and Cellular Biology, 27(24), 8658-69. 
Riggs, D. L., Roberts, P. J., Chirillo, S. C., Cheung-Flynn, J., Prapapanich, V., Ratajczak, T., 
Gaber, R., Picard, D., Smith, D. (2003). The Hsp90-binding peptidylprolyl isomerase 
FKBP52 potentiates glucocorticoid signaling in vivo. The EMBO journal, 22(5), 1158-67. 
 
Robertson, S., Allie-Reid, F., Vanden Berghe, W., Visser, K., Binder, A., Africander, D., 
Vismer, M., De Bosscher, K., Hapgood, J., Haegeman, G., Louw, A. (2009). Abrogation of 
glucocorticoid receptor dimerization correlates with dissociated glucocorticoid behavior of 
compound A. Journal of Biological Chemistry. In press. 
 
Rogatsky, I., & Ivashkiv, L. B. (2006). Glucocorticoid modulation of cytokine signaling. Tissue 
Antigens, 68(1), 1-12. 
Rogatsky, I., Luecke, H. F., Leitman, D. C., & Yamamoto, K. R. (2002). Alternate surfaces of 
transcriptional coregulator GRIP1 function in different glucocorticoid receptor activation and 
repression contexts. Proceedings of the National Academy of Sciences of the United States 
of America, 99(26), 16701-6. 
Rogatsky, I., Trowbridge, J. M., & Garabedian, M. J. (1997). Glucocorticoid receptor-
mediated cell cycle arrest is achieved through distinct cell-specific transcriptional regulatory 
mechanisms. Molecular and Cellular Biology, 17(6), 3181-93. 
Rogatsky, I., Zarember, K. A., & Yamamoto, K. R. (2001). Factor recruitment and 
TIF2/GRIP1 corepressor activity at a collagenase-3 response element that mediates 
regulation by phorbol esters and hormones. The EMBO Journal, 20(21), 6071-83. 
Ronacher, K., Hadley, K., Avenant, C., Stubsrud, E., Simons, S. S., Louw, A., Hapgood, J.  
(2009). Ligand-selective transactivation and transrepression via the glucocorticoid receptor: 
role of cofactor interaction. Molecular and Cellular Endocrinology, 299(2), 219-31. 
Rosen, J., & Miner, J. N. (2005). The search for safer glucocorticoid receptor ligands. 
Endocrine reviews, 26(3), 452-64.  
Rosenfeld, M. G., & Glass, C. K. (2001). Coregulator codes of transcriptional regulation by 
nuclear receptors. Journal of Biological Chemistry, 276(40), 36865-8. 
Russcher, H., van Den Akker, E. L., Smit, P., van Rossum, E. F., Brinkmann, A. O., de Jong, 
F. H., Lamberts, S., Koper, J. (2005). Two polymorphisms in the glucocorticoid receptor 
gene directly affect glucocorticoid-regulated gene expression. The Journal of Clinical 




Sambrook, J., Fritsch, E., & Maniatis, T. (1989). Molecular Cloning, a laboratory manual (2nd 
edition.). Cold Springs Harbour Laboratory Press. 
Savory, J. G., Hsu, B., Laquian, I. R., Giffin, W., Reich, T., Haché, R. J., Lefebvre, Y. (1999). 
Discrimination between NL1- and NL2-mediated nuclear localization of the glucocorticoid 
receptor. Molecular and Cellular Biology, 19(2), 1025-37. 
Savory, J. G., Préfontaine, G. G., Lamprecht, C., Liao, M., Walther, R. F., Lefebvre, Y. A., 
Haché, R. (2001). Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid 
receptor heterodimers form in the cytoplasm through alternative dimerization interfaces. 
Molecular and Cellular Biology, 21(3), 781-93. 
Schaaf, M. J., & Cidlowski, J. A. (2003). Molecular determinants of glucocorticoid receptor 
mobility in living cells: the importance of ligand affinity. Molecular and Cellular Biology, 23(6), 
1922-34. 
Schaaf, M. J., Lewis-Tuffin, L. J., & Cidlowski, J. A. (2005). Ligand-selective targeting of the 
glucocorticoid receptor to nuclear subdomains is associated with decreased receptor 
mobility. Molecular Endocrinology, 19(6), 1501-15. 
Schmidt, T. J., & Meyer, A. S. (1994). Autoregulation of corticosteroid receptors. How, when, 
where, and why? Receptor, 4(4), 229-57. 
Schoneveld, O. J., Gaemers, I. C., & Lamers, W. H. (2004). Mechanisms of glucocorticoid 
signalling. Biochimica et Biophysica Acta, 1680(2), 114-28. 
Schäcke, H., Rehwinkel, H., & Asadullah, K. (2005). Dissociated glucocorticoid receptor 
ligands: compounds with an improved therapeutic index. Current Opinion in Investigational 
Drugs, 6(5), 503-7. 
Seckl, J. R., & Walker, B. R. (2001). Minireview: 11beta-hydroxysteroid dehydrogenase type 
1- a tissue-specific amplifier of glucocorticoid action. Endocrinology, 142(4), 1371-6. 
Shiota, M., Yokomizo, A., Masubuchi, D., Tada, Y., Inokuchi, J., Eto, M., Uchiumi, T., 
Fujimoto, N., Naito, S., (2009). Tip60 promotes prostate cancer cell proliferation by 
translocation of androgen receptor into the nucleus. The Prostate. 
Silverstein, A. M., Galigniana, M. D., Kanelakis, K. C., Radanyi, C., Renoir, J. M., Pratt, W. 
B. (1999). Different regions of the immunophilin FKBP52 determine its association with the 
glucocorticoid receptor, hsp90, and cytoplasmic dynein. Journal of Biological Chemistry, 
274(52), 36980-6. 
Simmonds, R. E., & Foxwell, B. M. (2008). Signalling, inflammation and arthritis: NF-kappaB 
and its relevance to arthritis and inflammation. Rheumatology, 47(5), 584-90. 
Simons, S. S. (2003). The importance of being varied in steroid receptor transactivation. 
Trends in Pharmacological Science, 24(5), 253-259. 
Slayden, O. D., & Brenner, R. M. (2004). Hormonal regulation and localization of estrogen, 
progestin and androgen receptors in the endometrium of nonhuman primates: effects of 
progesterone receptor antagonists. Archives of Histology and Cytology, 67(5), 393-409. 
148 
 
Smoak, K. A., & Cidlowski, J. A. (2004). Mechanisms of glucocorticoid receptor signaling 
during inflammation. Mechanisms of Ageing and Development, 125(10-11), 697-706. 
Spencer, T. E., Jenster, G., Burcin, M. M., Allis, C. D., Zhou, J., Mizzen, C. A., et al., (1997). 
Steroid receptor coactivator-1 is a histone acetyltransferase. Nature, 389(6647), 194-8. 
Stallcup, M. R., Kim, J. H., Teyssier, C., Lee, Y., Ma, H., Chen, D. (2003). The roles of 
protein-protein interactions and protein methylation in transcriptional activation by nuclear 
receptors and their coactivators. Journal of Steroid Biochemistry and Molecular Biology, 
85(2-5), 139-45. 
Stanbury, R. M., & Graham, E. M. (1998). Systemic corticosteroid therapy--side effects and 
their management. British Journal of Ophthalmology, 82(6), 704-8. 
Stavreva, D. A., Müller, W. G., Hager, G. L., Smith, C. L., & McNally, J. G. (2004). Rapid 
glucocorticoid receptor exchange at a promoter is coupled to transcription and regulated by 
chaperones and proteasomes. Molecular and Cellular Biology, 24(7), 2682-97. 
Stoecklin, E., Wissler, M., Moriggl, R., & Groner, B. (1997). Specific DNA binding of Stat5, 
but not of glucocorticoid receptor, is required for their functional cooperation in the regulation 
of gene transcription. Molecular and Cellular Biology, 17(11), 6708-16. 
Strömstedt, P. E., Poellinger, L., Gustafsson, J. A., & Carlstedt-Duke, J. (1991). The 
glucocorticoid receptor binds to a sequence overlapping the TATA box of the human 
osteocalcin promoter: a potential mechanism for negative regulation. Molecular and Cellular 
Biology, 11(6), 3379-83. 
Stubsrud, E. (2005) An investigation of the role of phosphorylation of Ser211 of the 
glucocorticoid receptor in ligand-specific transcriptional regulation. M.Sc. thesis. Department 
of Biochemistry, University of Stellenbosch, Stellenbosch, South Africa. 
Sui, X., Bramlett, K. S., Jorge, M. C., Swanson, D. A., von Eschenbach, A. C., Jenster, G. 
(1999). Specific androgen receptor activation by an artificial coactivator. Journal of Biological 
Chemistry, 274(14), 9449-54. 
Tai, P. K., Maeda, Y., Nakao, K., Wakim, N. G., Duhring, J. L., Faber, L. E. (1986). A 59-
kilodalton protein associated with progestin, estrogen, androgen, and glucocorticoid 
receptors. Biochemistry, 25(18), 5269-75. 
Tao, T., Lan, J., Lukacs, G. L., Haché, R. J., & Kaplan, F. (2006). Importin 13 regulates 
nuclear import of the glucocorticoid receptor in airway epithelial cells. American Journal of 
Respiratory Cell and Molecular Biology, 35(6), 668-80. 
Tao, Y., Xu, Y., Xu, H. E., & Simons, S. S. (2008). Mutations of glucocorticoid receptor 
differentially affect AF2 domain activity in a steroid-selective manner to alter the potency and 
efficacy of gene induction and repression. Biochemistry, 47(29), 7648-62. 
Thomas, M., Dadgar, N., Aphale, A., Harrell, J. M., Kunkel, R., Pratt, W. B. (2004). Androgen 
receptor acetylation site mutations cause trafficking defects, misfolding, and aggregation 
similar to expanded glutamine tracts. Journal of Biological Chemistry, 279(9), 8389-95. 
149 
 
Tian, S., Poukka, H., Palvimo, J. J., & Jänne, O. A. (2002). Small ubiquitin-related modifier-1 
(SUMO-1) modification of the glucocorticoid receptor. The Biochemical Journal, 367(Pt 3), 
907-11. 
Torpy, D. J., & Ho, J. T. (2007). Corticosteroid-binding globulin gene polymorphisms: clinical 
implications and links to idiopathic chronic fatigue disorders. Clinical Endocrinology, 67(2), 
161-7. 
Trousson, A., Grenier, J., Fonte, C., Massaad-Massade, L., Schumacher, M., Massaad, C. 
(2007). Recruitment of the p160 coactivators by the glucocorticoid receptor: dependence on 
the promoter context and cell type but not hypoxic conditions. Journal of Steroid 
Biochemistry and Molecular Biology, 104(3-5), 305-11. 
Tsai, S. Y., Carlstedt-Duke, J., Weigel, N. L., Dahlman, K., Gustafsson, J. A., Tsai, M. J., 
O’Malley, B. (1988). Molecular interactions of steroid hormone receptor with its enhancer 
element: evidence for receptor dimer formation. Cell, 55(2), 361-9. 
Tuckermann, J. P., Reichardt, H. M., Arribas, R., Richter, K. H., Schütz, G., Angel, P. (1999). 
The DNA binding-independent function of the glucocorticoid receptor mediates repression of 
AP-1-dependent genes in skin. Journal of Cell Biology, 147(7), 1365-70. 
Turner, J. D., Schote, A. B., Macedo, J. A., Pelascini, L. P., & Muller, C. P. (2006). Tissue 
specific glucocorticoid receptor expression, a role for alternative first exon usage? 
Biochemical Pharmacology, 72(11), 1529-37. 
Van den Wyngaert, I., de Vries, W., Kremer, A., Neefs, J., Verhasselt, P., Luyten, W. H., 
Kass, S. (2000). Cloning and characterization of human histone deacetylase 8. FEBS letters, 
478(1-2), 77-83. 
Vanderbilt, J. N., Miesfeld, R., Maler, B. A., & Yamamoto, K. R. (1987). Intracellular receptor 
concentration limits glucocorticoid-dependent enhancer activity. Molecular Endocrinology, 
1(1), 68-74. 
van Steensel, B., Brink, M., van Der Meulen, K., van Binnendijk, E. P., Wansink, D. G., de 
Jong, L., et al., (1995). Localization of the glucocorticoid receptor in discrete clusters in the 
cell nucleus. Journal of Cell Science, 108  Pt 9, 3003-11. 
Vesely, P. W., Staber, P. B., Hoefler, G., & Kenner, L. (2009). Translational regulation 
mechanisms of AP-1 proteins. Mutation Research, 682(1), 7-12. 
Vicent, G. P., Pecci, A., Ghini, A., Piwien-Pilipuk, G., & Galigniana, M. D. (2002). Differences 
in nuclear retention characteristics of agonist-activated glucocorticoid receptor may 
determine specific responses. Experimental Cell Research, 276(2), 142-54. 
Wallace, A. D., & Cidlowski, J. A. (2001). Proteasome-mediated glucocorticoid receptor 
degradation restricts transcriptional signaling by glucocorticoids. Journal of Biological 
Chemistry, 276(46), 42714-21. 
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, 
M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., Fuqua, S. A., Lopez, G. N., Kushner, P. 
J., Pestell, R. G. (2001). Direct acetylation of the estrogen receptor alpha hinge region by 
150 
 
p300 regulates transactivation and hormone sensitivity. Journal of Biological Chemistry, 
276(21), 18375-83. 
Wang, D., & Simons, S. S. (2005). Corepressor binding to progesterone and glucocorticoid 
receptors involves the activation function-1 domain and is inhibited by molybdate. Molecular 
Endocrinology, 19(6), 1483-500. 
Wang, Z., Chen, W., Kono, E., Dang, T., & Garabedian, M. J. (2007a). Modulation of 
glucocorticoid receptor phosphorylation and transcriptional activity by a C-terminal-
associated protein phosphatase. Molecular Endocrinology, 21(3), 625-34. 
Wang, D., Wang, Q., Awasthi, S., & Simons, S. S. (2007b). Amino-terminal domain of TIF2 
is involved in competing for corepressor binding to glucocorticoid and progesterone 
receptors. Biochemistry, 46(27), 8036-49. 
Wang, J., Derynck, M. K., Nonaka, D. F., Khodabakhsh, D. B., Haqq, C., Yamamoto, K. R. 
(2004). Chromatin immunoprecipitation (ChIP) scanning identifies primary glucocorticoid 
receptor target genes. Proceedings of the National Academy of Sciences of the United 
States of America, 101(44), 15603-8. 
Wang, J., Shah, N., Pantoja, C., Meijsing, S. H., Ho, J. D., Scanlan, T. S., Yamamoto, K. R. 
(2006). Novel arylpyrazole compounds selectively modulate glucocorticoid receptor 
regulatory activity. Genes & Development, 20(6), 689-99. 
Wang, Q., Blackford, J. A., Song, L., Huang, Y., Cho, S., Simons, S. S. (2004). Equilibrium 
interactions of corepressors and coactivators with agonist and antagonist complexes of 
glucocorticoid receptors. Molecular Endocrinology, 18(6), 1376-95. 
Wang, Z., Frederick, J., & Garabedian, M. J. (2002). Deciphering the phosphorylation "code" 
of the glucocorticoid receptor in vivo. Journal of Biological Chemistry, 277(29), 26573-80. 
Webster, J. C., Jewell, C. M., Bodwell, J. E., Munck, A., Sar, M., Cidlowski, J. A. (1997). 
Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the 
receptor protein. Journal of Biological Chemistry, 272(14), 9287-93. 
Weigel, N. L., & Moore, N. L. (2007). Steroid receptor phosphorylation: a key modulator of 
multiple receptor functions. Molecular Endocrinology, 21(10), 2311-9. 
Wochnik, G. M., Rüegg, J., Abel, G. A., Schmidt, U., Holsboer, F., Rein, T. (2005). FK506-
binding proteins 51 and 52 differentially regulate dynein interaction and nuclear translocation 
of the glucocorticoid receptor in mammalian cells. Journal of Biological Chemistry, 280(6), 
4609-16. 
Wolf, I. M., Periyasamy, S., Hinds, T., Yong, W., Shou, W., Sanchez, E. R. (2009). Targeted 
ablation reveals a novel role of FKBP52 in gene-specific regulation of glucocorticoid receptor 
transcriptional activity. Journal of Steroid Biochemistry and Molecular Biology, 113(1-2), 36-
45. 
Xu, J., & Li, Q. (2003). Review of the in vivo functions of the p160 steroid receptor 
coactivator family. Molecular Endocrinology, 17(9), 1681-92. 
151 
 
Xu, J., Wu, R., & O'Malley, B. W. (2009). Normal and cancer-related functions of the p160 
steroid receptor co-activator (SRC) family. Nature reviews. Cancer, 9(9), 615-30.  
Young, J. C., Obermann, W. M., & Hartl, F. U. (1998). Specific binding of tetratricopeptide 
repeat proteins to the C-terminal 12-kDa domain of hsp90. Journal of Biological Chemistry, 
273(29), 18007-10. 
Yu, G. Q., Chen, S. y., Wang, J., Liu, W., & Pearce, D. (1997). Androgen and glucocorticoid 
receptor heterodimer formation. A possible mechanism for mutual inhibition of transcriptional 
activity. Journal of Biological Chemistry, 272(22), 14087-92. 
Yudt, M. R., & Cidlowski, J. A. (2001). Molecular identification and characterization of a and 
b forms of the glucocorticoid receptor. Molecular Endocrinology, 15(7), 1093-103. 
Zhang, H., Yi, X., Sun, X., Yin, N., Shi, B., Wu, H., Wang, D., Wu, G., Shang, Y. (2004). 
Differential gene regulation by the SRC family of coactivators. Genes & Development, 
18(14), 1753-65. 
 
Zhang, Y., Leung, D. Y., Nordeen, S. K., & Goleva, E. (2009). Estrogen inhibits 
glucocorticoid action via protein phosphatase 5 (PP5)-mediated glucocorticoid receptor 
dephosphorylation. Journal of Biological Chemistry, 284(36), 24542-52. 
Zhao, Q., Pang, J., Favata, M. F., & Trzaskos, J. M. (2003). Receptor density dictates the 
behavior of a subset of steroid ligands in glucocorticoid receptor-mediated transrepression. 
International Immunopharmacology, 3(13-14), 1803-17. 
Zhou, J., & Cidlowski, J. A. (2005). The human glucocorticoid receptor: one gene, multiple 




Appendix A : GR ligands 
 
Chemical structures of the GR ligands used in this study are shown in figure A.1.  
 
 
Fig. A1. Chemical structures of GR ligands used in this thesis 
 
Receptor theory dictates that ligand binding to GR must obey the basic laws of 
thermodynamics. In a given pool of receptor and ligand, a certain proportion of 
receptor will be occupied by ligand. This proportion depends on the rate of 
association (Kon) and dissociation (Koff) of the ligand-receptor complex. At 
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equilibrium, the rate of complex formation and dissociation are equal, and the ratio of 
Koff/Kon is the equilibrium dissociation constant (KD) of a given ligand, which gives an 
indication of the concentration of ligand which will saturate 50% of the available 
receptors.  
 
The fractional occupancy of receptors refers to the proportion of total receptors 
which are occupied at a given concentration of ligand. 
 
 
By substituting in the equation for KD, 
 
 
We find that 
  
 
Thus, the fractional occupancy of the GR by a given ligand can be calculated if the 
KD is known. KD values may be found in the literature, or determined experimentally 
using competitive binding assays, in which cells are incubated with a single 
concentration of a radiolabelled ligand, and increasing concentrations of the 
unlabelled ligand of interest. The concentration of ligand which displaces 50% of the 
radiolabelled ligand is known as the IC50 for that ligand. At equilibrium, the rate of 
and the ratio of Koff/Kon for the unlabelled competing ligand is the equilibrium inhibitor 
dissociation constant (Ki) of that ligand, which gives an indication of the 
concentration of ligand which would saturate 50% of the available receptors in the 




The relative fractional occupancy of different ligands can then be determined using 
 x 100% 
 
Table A1. IC50 concentrations, Ki values and relative fractional occupancies of 
GR ligands resulting in GR occupancy of at least 96.5% (Ronacher et al., 2009) 
 
Cells with grey fill indicate the fractional occupancy of GR at the final 
concentration used in experiments. 
 
Calculation of the relative fractional occupancies of the different ligands as shown in 
table A1, is based on binding and dose response analysis performed by previous 
members of the Hapgood lab. It was important to control for the different GR binding 
affinities of the ligands in the panel, rather than using a single concentration for all 
ligands. This is because, if the concentration selected was too low, differential 
saturation of GR would occur, and prevent analysis of ligand-specific effects. 
Similarly, if the selected concentration were too high, spurious non-specific effects 
could be elicited, as have been observed in the Hapgood lab upon treatment of 




For use as a MR-specific agonist (figure 4.1A) ald was used at 10nM, at which 
concentration, it would saturate 100% of MR present, but only about 6% of GR 
present, since the Kd of Ald for the MR is 0.15 nM (Dr D. Africander, PhD thesis), 





Appendix B: Dilutions and diluents of primary and secondary antibodies used 
in Western blot 
 






















1:5000 5% non-fat milk 
powder in TBST 
AR 1:10000 TBST Anti-mouse 
HRP 
1:10000 10% non-fat milk 
powder in TBST 
FKBP52 1:1000 TBST Anti-goat 
HRP 
1:5000 5% non-fat milk 
powder in TBST 




1:5000 5% non-fat milk 
powder in TBST 
GR 
(endogenous 
GR in U2OS) 
1:1000 TBST Anti-rabbit 
HRP 
1:5000 5% non-fat milk 
powder in TBST 
GR 
(overexpressed 
in COS-7 cells) 
1:5000 TBST Anti-rabbit 
HRP 
1:5000 5% non-fat milk 
powder in TBST 
GR-Phospho 
S211 




1:5000 5% non-fat milk 
powder in TBST 
GR-Phospho 
S226 




1:5000 5% non-fat milk 
powder in TBST 




1:10000 5% non-fat milk 
powder in TBST 




1:5000 5% non-fat milk 
powder in TBST 




1:5000 5% non-fat milk 
powder in TBST 




1:5000 5% non-fat milk 
powder in TBST 
β-actin 1:2000 TBST Anti-rabbit 
HRP 
1:10000 5% non-fat milk 
powder in TBST 
β-tubulin 1:5000 TBST Anti-mouse 
HRP 
1:20000 10% non-fat milk 
powder in TBST 
 
TBST: 50 mM Tris, 150 mM NaCl, 0.1% (v/v) Tween.   
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Figure C.1. K494/495A hGR and K494/495Q HAhGR exhibit less 
nuclear translocation that WT GR after 16 h of dex treatment. COS-7 
cells were plated and transfected with WT hGR and K494/495A hGR (A) 





treated with vehicle (EtOH) or 1 µM dex for 16 h before being fixed and 
immunostained as described in materials and methods, chapter 3. Results 











Figure C.3. FKBP52 levels do not change following 1 h treatment 
with 1 µM dex. COS-7 cells were plated and transfected with WT HAhGR 
or K494/495Q HAhGR as described in materials and methods for ChIP. 
Cells were treated for 1 h with 1 µM dex before whole cell lysates were 




Appendix D: Supplementary results pertaining to Chapter 4 
 
 
Figure D.1. Steroid receptor-specific agonists give a transcriptional 
response on pTAT-GRE-E1b-luc in the presence of the receptor of 
interest. U2OS cells were transfected with pCMV -galactosidase 
reporter and the GR responsive luciferase reporter construct pTAT-GRE-
E1b-luc as well as plasmids encoding either the GR, AR, MR or PR-B. 
Cells were treated with vehicle (EtOH) or 1 µM dex, 1 µM mib, 10 nM Ald 
or 1 µM R5020, respectively for 24 h. Luciferase activity of cell lysates 
was monitored and normalised to β-galactosidase activity for each well to 
control for transfection efficiency. Histogram shows results of a single 








Figure D.2. Transrepression of NFκB and AP-1 promoters in U2OS 
cells is greater in the presence of exogenous HAhGR. U2OS cells 
were transfected with pCMV -galactosidase reporter and (A) NFκB-Luc 
or (B) AP-1-Luc reporter constructs. Cells were treated with vehicle 
(EtOH) or 1 µM dex in the presence of 20 ng/ml PMA for 24 h. Luciferase 
activity of cell lysates was monitored and normalised to β-galactosidase 
activity for each well to control for transfection efficiency. Histogram 
shows pooled results of two independent experiments each performed in 












 Figure D.3. Graphs of correlation analyses. Correlation analyses of 
transactivation, S211 phosphorylation, and nuclear localisation were 
performed in GraphPad Prism using two-tailed Pearson correlations, as 
described in materials and methods and shown in table 4.1.  
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Appendix E: Optimisation of experimental techniques 
 
E.1. Quantitative Real Time PCR 
 
Analysis of the relative expression level of a gene was performed using two-step 
quantitative real-time PCR in a Corbett Rotorgene thermal cycler. Following isolation 
of RNA, the two-step protocol entails reverse transcription of the RNA to cDNA, and 
subsequent analysis by PCR. Performing reverse transcription and PCR in separate 
reactions (rather than in the PCR reaction, as in a one-step protocol) facilitates 
trouble-shooting of these steps independently. 
 
Since RNA is a relatively unstable molecule, every sample was analysed by agarose 
gel electrophoresis prior to the reverse transcription. Agarose gel electrophoresis 
gave an indication of the integrity of the RNA sample, which was evaluated on the 
extent of smearing, and the ratio of the intensity of 18S:28S bands which should 
ideally be 1:2. A representative RNA gel is shown in figure E.1.1. Furthermore, 
absorbance analysis was used to indicate the purity of the RNA sample. Pure RNA 
has a 260:280 ratio greater than or equal to 2.0 (Sambrook et al., 1989), therefore 
samples with a 260:280 ratio below 1.9 were not used due to the presence of 




Figure E.1.1. Representative RNA agarose gel. 500 ng of RNA isolated 
from U2OS cells was analysed on a formaldehyde agarose gel. The 18S 
and 28S RNA bands are indicated by arrows. 
 
Initial real time PCR experiments were found to be unreproducible, and in order to 
troubleshoot the cause of the variability, a single RNA sample was used for several 
parallel cDNA synthesis experiments, and each cDNA sample was analysed in 
duplicate PCR reactions. As shown in figure E.1.2, there was little variation between 
duplicate PCR samples, however variability was observed between the amount of 
PCR product detected from amplification of the cDNA samples reverse transcribed in 
parallel. This indicated that the likely cause of the variability was introduced during 




Figure E.1.2. Evaluation of parallel cDNA syntheses and PCR 
reactions. A single RNA sample was reverse transcribed in four parallel 
reactions (cDNA 1- 4). Each cDNA sample was subsequently amplified in 
parallel, in duplicate PCR reactions. The crossing point (Cp) of each 
reaction above threshold is plotted ± the range of the duplicate PCR 
reactions. The histogram shows results of a single experiment. 
 
In order to eliminate this problem, several different cDNA synthesis kits from three 
different manufacturers, were compared in three parallel reactions on a single RNA 
sample. Each cDNA sample was subsequently amplified by PCR using primer sets 
for GILZ and GAPDH. The relative abundance of the GILZ transcript was calculated 
for each sample, as shown in figure E.1.3. A high degree of variability was detected 





Figure E.1.3. Comparison of different cDNA synthesis kits. Parallel 
cDNA synthesis reactions were performed on a single RNA sample in 
triplicate, using three different kits designated R, P and C. The relative 
abundance of the GILZ transcript was subsequently analysed in each 
sample by duplicate quantitative real time PCR reactions in parallel. The 
average Cp of duplicate PCR samples amplified with GILZ primers was 
normalised to the average Cp of duplicate PCR samples analysed with 
GAPDH primers to give the relative expression of GILZ in each cDNA 
sample, which was plotted. 
 
In order to compare the extent of transrepression elicited by different ligands 
via the GR, the extent of transrepression elicited by dex was compared under 
different conditions, in order to determine which condition would yield optimal 
transrepression. Important parameters include the type and concentration of 
pro-inflammatory compound used for induction and the time of treatment with 
GC and pro-inflammatory compound. Preliminary time course experiments 
performed in the stably transfected U2OS.HAhGR cell line indicated that 
maximal transrepression of the IL8 gene occurred at 2 h of treatment, as shown 




Figure E.1.4. Time course of transrepression of IL8 gene in 
U2OS.HAhGR cells. U2OS.HAhGR cells were plated in 12 well plates at 
a density of 1 x 105 cells per well. Cells were treated with 50ng/ml PMA 
and 100 nM dex simultaneously for 2 h, after which the relative 
abundance of the IL8 transcript was quantified, and plotted relative to 
vehicle treated cells.  
 
Having determined that a 2 h treatment resulted in a high level of 
transrepression, this was further investigated in WT U2OS cells, and a 
comparison between simultaneous and staggered PMA and dex treatment was 
conducted. On both the IL8 and COL3 genes, it appeared that simultaneous 
treatment gave a higher degree of transrepression than when PMA treatment 
was delayed by 30 min, as shown in figure E.1.5. Simultaneous treatment with 
PMA and GC was thus used in subsequent experiments. Although the extent of 
transrepression observed in this experiment is greater than that shown in figure 
4.6, for both IL8 and COL3, this graph shows the result of a single experiment. 
Variability between experiments was such that the mean transrepression from 




Figure E.1.5. Comparison of treatment conditions on IL8 and COL3 
transrepression in U2OS cells. U2OS cells were treated with PMA and 
100 nM dex as indicated, and the relative abundance of IL8 and COL3 
transcripts was measured by realtime PCR as indicated in materials and 
methods.  
 
Transrepression of the TNFα gene was subsequently investigated, and a 
comparison was made between induction by PMA and TNFα, and 
simultaneous versus staggered treatment. In this instance, slightly better 
transrepression was observed upon TNFα stimulation 30 min after GC 
treatment of cells, as shown in figure E.1.6. This condition was therefore used 
for subsequent analysis of TNFα transrepression by different ligands in U2OS 
cells. Although the extent of transrepression observed in this experiment is 
greater than that shown in figure 4.6 for TNFα, this graph shows the result of a 
single experiment in duplicate for addition of TNFα 30 min after dex treatment. 
Variability between experiments was such that the mean transrepression from 





Figure E.1.6. Comparison of treatment conditions for 
transrepression of TNFα. U2OS cells were treated with PMA or TNFα 
and vehicle or 100 nM dex as indicated, and the relative abundance of 
TNFα transcripts was measured by realtime PCR as indicated in materials 
and methods. Pooled results of one to three experiments, each performed 
in duplicate, are shown. 
 
E.2. ChIP Assay 
 
The ChIP assay is a multistep assay in which proteins are cross-linked to DNA (Ma, 
et al., 2003). The DNA is subsequently fragmented by sonication, prior to 
immunoprecipitation. After reversal of the crosslinks, the immunoprecipitated DNA is 
purified, and analysed by PCR. Sonication is a crucial step in this assay, as it not 
only facilitates the rupture of the crosslinked cells, but also determines the average 
size of the DNA fragments. This can determine the success of the assay, as 
fragments that are too large will be retarded in the immunoprecipitation step, and 
fragments that are too small may be lost during DNA cleanup, or not successfully 
amplified during the PCR step. The recommended average size of DNA fragments is 
between 300 bp and 800 bp (Ma et al., 2003). To this end, the sonication step was 
optimised to yield DNA fragments of an appropriate size. Since the crosslinked 
chromatin also contains heat-labile proteins, the sonication must be performed in 
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short bursts, with an intermittent rest period on ice, to prevent heating. The time 
required for “on” and “off” periods, as well as the number of cycles, and the power 
setting of the sonicator must all be optimised for the particular sonicator to be used. 
A representative gel of different sonication conditions is shown in figure E.2.1. The 
selected sonication parameters for initial ChIP optimisation experiments in U2OS 
cells were those in the third lane, which gave slightly larger fragments (average size 






Figure E.2.1. Optimisation of sonication conditions using probe. 
U2OS cells were plated, crosslinked, and scraped as indicated in 
materials and methods for a ChIP assay. Cells were sonicated under 
different conditions as indicated using a Misonix Sonicator 3000 with 
microtip, before crosslinks were reversed overnight. DNA was purified 
using QiaQuick columns, and approximately 1 µg was analysed by 




For subsequent ChIP experiments in COS-7 cells, a Bioruptor (Diagneode, Belgium) 
was available. This is a water-bath based sonicator which allows simultaneous 
sonication of up to six samples. This is advantageous as it increases reproducibility 
of sonication between samples. Furthermore, sonication occurs in sealed tubes, 
which prevents cross-contamination of samples. The manufacturer’s recommended 
sonication parameters for mammalian cells including COS cells was 10 cycles of 30s 
on, and 30s rest on ice. When these parameters were used, they were found to yield 
fragments between 300 bp and 500 bp, as shown in figure E.2.2. 
 
Figure E.2.2. Sonication in Bioruptor. COS-7 cells were plated, 
crosslinked, and scraped as indicated in materials and methods for a 
ChIP assay. Cells were sonicated in a Bioruptor before crosslinks were 
reversed overnight. DNA was purified using QiaQuick columns, and 
approximately 1µg was analysed by agarose gel electrophoresis.  
 
ChIP is a powerful tool for elucidating interactions between transcription factors and 
DNA in intact cells. Cellular proteins are crosslinked by incubation with 
formaldehyde, which reduces the occurrence of false-positive results caused by 
interaction of proteins following lysis. ChIP analysis was performed to investigate 
whether promoter occupancy at the endogenous GILZ promoter by activated GR 
correlated with transactivational efficacy and nuclear localisation. Accordingly, ChIP 
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technique was extensively optimised, but failed to yield reproducible GR recruitment 
to the GILZ promoter in U2OS cells. Since the ChIP assay is a complicated multi-
step assay, there are numerous steps at which the assay can be compromised, and 
trouble-shooting is an arduous and time-consuming, not to mention expensive 
exercise. After several attempts proved fruitless, it was decided to try the ChIP assay 
in another cell line, to check if the experimental procedure was working. A549 cells 
were selected, since recruitment of endogenous GR to the GILZ promoter has been 
reported in these cells (Wang et al., 2004). 
As shown in figure E.2.3A, ChIP in A549 cells yielded an approximately 7-fold 
increase in GR recruitment to the GILZ promoter upon dex treatment. This is in line 
with reported values of 8-10 fold recruitment reported in these cells by Wang et al. 
(2004), using different primers that fall within approximately the same region of the 
GILZ promoter.  Pooled results of three independent ChIP experiments in U2OS 
show a large amount of error, and fail to show a significant difference in GR 
recruitment between EtOH and dex.  
 
Endogenously expressed levels of GR in A549, COS-1 and U2OS cells (figure 
E.2.3B) were subsequently examined. There is a clear difference in the amount of 
GR expressed by the three cell lines, with A549 levels being the highest. This may 
indicate that the relatively low GR levels in U2OS account for the weak recruitment 
of GR to the GILZ promoter observed in the ChIP assay, and that the ChIP assay 





Figure E.2.3. GR ChIP assay is not reproducible in U2OS cells (A) 
ChIP assay was performed in parallel in A549 and U2OS cells, to 
measure recruitment of endogenous GR to the GILZ promoter. One 
experiment is shown for A549, while pooled results of three independent 
experiments are presented for U2OS, presented as mean +/- SEM (B) 
Relative levels of GR are shown in A549, COS-1 and U2OS cells, as 




Co-immunoprecipitation is a useful technique for evaluation of protein-protein 
interactions. Cells are lysed, and the protein of interest is immunoprecipitated, 
followed by elution from beads, and analysis of the eluate by Western blot to detect 
the presence of a specific interacting protein. As a positive control for the 
experimental technique, co-immunoprecipitation was used to detect ligand-specific 
interactions between overexpressed GR and GRIP-1 in COS-1 cells, as shown in 
figure E.3.1. However, co-immunoprecipitation of endogenous proteins in U2OS was 





Figure E.3.1. Co-immunoprecipitation of overexpressed HAhGR and 
HA-GRIP1 for COS-1 cells. COS-1 cells were transfected with 3 µg each 
of HAhGR and HA-GRIP1 in 10cm plates, and treated for 1 h with 100 nM 
dex or vehicle (EtOH). Cells were then lysed and incubated with an anti-
GR antibody and protein A/G agarose beads overnight. Beads were then 
washed and immunoprecipitated proteins were analysed for total GR and 
HA-GRIP1 by Western blotting. 
 
The interaction between GR and immunophilins was subsequently investigated by 
co-immunoprecipitation. The interaction between GR and immunophilins in the 
Hsp90 heterocomplex is quite unstable, and particular conditions are required to 
maintain this association during immunoprecipitation (Davies et al., 2002; Echeverría 
et al., 2009). Several reports have been published demonstrating a ligand-selective 
switch in immunophilin association of the GR, using different techniques (Davies et 
al., 2002; Echeverría et al., 2009) and this has been shown to occur in A549 cells 
(Croxtall et al., 2003). However, experiments in the present authors hands failed to 
show a ligand-dependent change in the levels of GR:FKBP52 association in A549 
cells, as shown in figure E.3.2. The two protocols used (Davies et al., 2002; Croxtall 
et al., 2003) differ considerably in treatment time and temperature of the cells, the 
lysis procedure, and the quantity of input material. It is possible that some 
unpredictable difference in conditions or experimental protocol prevented successful 





Figure E.3.2. Co-immunoprecipitation of GR and immunophilins. (A) 
A549 cells were plated, treated with EtOH or dex and subjected to 
immunoprecipitation with an anti-FKBP52 antibody, according to a 
published protocol (Davies et al., 2002). After immunoprecipitation, the 
supernatant was harvested, and analysed by Western blot, alongside the 
eluate from the beads, and input samples harvested prior to 
immunoprecipitation. The Western blot was probed for FKBP52 and GR. 
(B) A549 were plated, treated with EtOH or dex, and immunoprecipitated 
according to a published protocol (Croxtall et al., 2003). 
Immunoprecipitation was performed using antibodies towards GR, 
FKBP51, or FKBP52, and protein A/G agarose beads. Eluted proteins 






E.4. RNA interference (RNAi) 
 
Transfection of short interfering RNA (siRNA) causes knockdown of specific mRNA 
transcripts, allowing analysis of the role of a particular protein by examining the 
effect of reduced protein levels. siRNA strands cause activation of the RNA-induced 
silencing complex (RISC), which allows sequence recognition and mRNA 
degradation. The experimental protocol requires careful optimisation to allow 
maximal knockdown, with minimal off-target effects, and cell death. Where available, 
pre-validated siRNA sequences from commercial vendors can save a lot of time. 
These are often supplied with a transfection reagent. In this case HiPerfect 
transfection reagent and pre-validated siRNA sequences (GR5, GR6, and non-
silencing control, NSC) were purchased from Qiagen. The optimal concentration of 
HiPerfect was determined by comparing the success of knockdown at high and low 
concentrations within the recommended range, as shown in figure E.4.1. GR5, GR6 
and a combination of 5 and 6 all gave efficient knockdown of GR at both low and 
high concentrations of HiPerfect transfection reagent. However, at high 
concentrations of transfection reagent, a high level of cell death was apparent on 
microscopic examination (data not shown). This is also evident from the reduced 
levels of β-tubulin observed upon Western blotting (figure E.4.1, right hand panel). 
Based on this experiment, it was decided to continue optimisation using a low 




Figure E.4.1. Comparison of different siRNA sequences and different 
concentrations of transfection reagent. U2OS cells were plated in 6 
well plates and left untreated (UT) or transfected with 100 nM GR siRNA 
or NSC, using 7 µl (low) or 21 µl (high) of HiPerfect transfection reagent 
per well, or transfection reagent only (TRO). Cells were incubated for 48 h 
before harvesting and analysis of GR  and β-tubulin protein expression 
levels by Western blotting using GR and β-tubulin specific antibodies, as 
listed in materials and methods. 
 
Having determined a suitable concentration of transfection reagent, it was necessary 
to determine the lowest effective concentration of siRNA. This was established by 
transfecting different concentrations of GR siRNA and monitoring GR expression 
levels relative to β-tubulin, as shown in figure E.4.2. GR levels were reduced at all 
concentrations of GR6 siRNA transfected. In this Western blot the GR antibody 
detected two bands, with the lower band most likely representing degradation 
products of GR. Although GR levels appeared similar in cells transfected with 10 nM 
and 1 nM GR6 siRNA, the lower GR band was slightly stronger in the cell transfected 
with 1 nM GR6 than 10 nM, indicating possible degradation of GR in this sample. 
Therefore, it was decided that 10 nM of GR6 siRNA would be suitable for 
subsequent knockdown experiments. 
 
Figure E.4.2. Dose response of siRNA transfection in U2OS cells. 
U2OS cells were transfected with serial dilutions of siRNA GR6, as 
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indicated, using 7 µl of transfection reagent per well. Cells were incubated 
for 48 h before analysis of GR and β-tubulin levels by Western blotting. 
 
In order to determine the optimal time for knockdown of GR expression, a time 
course analysis was performed, with transfected cells being harvested over a 
period of five days. As shown in figure E.4.3., successful knockdown was 
observed at every time point examined. A time point of 48 h post-transfection 
was selected as a suitable time for analysis of knockdown effects in 
subsequent experiments.  
 
Figure E.4.3. Time course analysis of GR expression knockdown by 
NSC and GR6 transfection in U2OS cells. U2OS cells were plated and 
transfected with 10 nM of GR6 siRNA or NSC siRNA, and incubated for 
the indicated times before proteins were harvested. Expression levels of 
GR relative to β-tubulin were analysed by Western blot.  
 
As shown in figure 4.1A, only GR, and not AR, MR or PR gave a ligand-dependant 
transcriptional response in a reporter assay. Since SRs have previously been 
reported to regulate each others’ expression (reviewed in Schmidt & Meyer, 1994; 
Slayden & Brenner, 2004) the effect of GR knockdown on the activity of AR, MR and 
PR was examined using reporter assays and receptor-specific ligands. Expression of 
the luciferase reporter gene was normalised to expression of a co-transfected β-
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galactosidase plasmid to normalise for transfection efficiency. As shown in figure 
E.4.4, knockdown of GR reduced the dex-mediated response as expected. However, 
GR knockdown did not affect the response to mibolerone (mib), aldosterone (ald) or 




Figure E.4.4. Effect of transfection of NSC or GR6 on response to 
receptor-specific ligands in U2OS cells. U2OS cells were transfected 
with NSC or GR6 siRNA, the HRE-luciferase reporter plasmid pTAT-GRE-
E1b-Luc and pCMV-β galactosidase as a transfection control. After 24 h 
cells were treated as indicated for a further 24 h, before cells were lysed 
and luciferase activity was measured, and normalised to β-galactosidase 
activity. The graph shows pooled results of two independent experiments 
performed in triplicate.  
 
E.5. Effect of stable and transient overexpression of GR in U2OS cells 
 
Stable transformation of U2OS cells with HAhGR to create the U2OS.HAhGR cell 
line was performed by Dr Ronacher, a previous member of the Hapgood lab. Stably 
transfected colonies were selected by G418 screening. After selection of several 
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colonies, these clones were propagated in the presence of G418, and lysates were 
harvested over several weeks to analyse GR expression levels over time. This was 
observed to decrease over time, as shown by Western blotting (figure E.5.1). 
Although it has previously been shown that U2OS cells express endogenous GR 
which is detectable by Western blotting (figure 4.1B) levels of GR in U2OS cells 
appear low here, probably due to variation in Western blotting conditions used, 




Figure E.5.1. Changes in stably transfected GR expression levels 
over time. Lysates of transiently transfected COS-1 cells were analysed 
by Western blot in parallel with lysates of stable transfected U2OS.hGR 
cells harvested at passage 6 and passage 20. Western blots were probed 
with antibodies towards GR and β-actin. 
 
The decrease in GR expression over time may have been due to hypermethylation 
of the exogenous promoter, with no apparent effect on the expression of genes 
required for G418 resistance. Several attempts were made to prevent loss of HAhGR 
expression, including varying antibiotic concentration, testing different clones, and 
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carefully monitoring levels at every passage to discern whether certain clones may 
exhibit reliably stable expression for at least a few passages. However, it was 
ultimately decided that HAhGR expression of the stably transfected cells was too 
unpredictable for a study in which GR expression levels could have such a 
significant impact. 
 
Having ascertained that stably transfected U2OS-HAhGR cells would not be a 
suitable model system for the present study, the effect of transient GR 
overexpression was examined in U2OS cells. As shown in Appendix D, figure D2, 
significant dex-mediated transrepression was observed on AP-1 and NFκB reporters 
in the presence of overexpressed GR. In contrast WT U2OS cells, expressing 
endogenous GR exhibited significant dex-mediated transrepression on the AP-1 
promoter, but not the NFκB promoter. Since endogenous GR in U2OS cells caused 
significant repression in a promoter-specific fashion, it was decided to use this model 
system for further investigation. Use of untransfected U2OS cells presented the 
additional advantage of even GR distribution in all cells, as opposed to transiently 
transfected cells, in which only a small percentage of cells would express high levels 
of the transfected construct. Unfortunately, the lack of reproducibility of the ChIP 
assay in U2OS, which is likely attributable to low endogenous GR levels, was only 
identified after the initial experiments on transactivation and transrepression were 
completed.  
